[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"PHASE SCIENTIFIC INTERNATIONAL LIMITED\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":398},{"warningLetters":4,"total":397},[5,32,57,78,100,121,141,157,178,199,216,234,251,271,290,302,319,340,358,376],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},98,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-27T04:00:00Z\">05\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmathen-international-sa-723680-05272026\">Pharmathen International S.A.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-80\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. John Pius Nason\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pharmathen International S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>44 Kifissias Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>15125\u003C\u002Fspan> \u003Cspan>Marousi Attica\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greece\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-80\u003C\u002Fp>\u003Cp>May 27, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Nason:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pharmathen International S.A., FEI 3009961173, at Industrial Park, Sapes Rodopi Prefecture, Block No 5 Rodopi, Evrou, Greece, from November 10 to 21, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your December 15, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003Cbr>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The airflow visualization studies (i.e., smoke studies) you performed for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic vial filling line you use to fill sterile powder drug products for the U.S. market did not demonstrate unidirectional airflow. This processing line is housed in an \u003Cstrong>(b)(4)\u003C\u002Fstrong> Restricted Access Barrier System (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS).\u003C\u002Fp>\u003Cp>For example, during the simulation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> installation, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> remained \u003Cstrong>(b)(4)\u003C\u002Fstrong> for an extended time. The airflow was observed exiting the filling line area, bouncing off the operator’s chest, and reentering the filling line.\u003C\u002Fp>\u003Cp>This problematic airflow pattern in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>RABS creates significant potential for microbial contamination.\u003C\u002Fp>\u003Cp>Notably, our investigators also observed multiples instances of inappropriate aseptic behavior. For example, when removing empty fallen vials, the operator blocked first air, and exposed vials were not discarded. In addition, your smoke studies failed to sufficiently evaluate removal of fallen vials as well as other critical aseptic manipulations.\u003C\u002Fp>\u003Cp>Our inspection also found multiple instances of gram-negative microbes in ISO 5 air samples. It is highly atypical to find gram-negative microbes in an aseptic processing room environment. In one such instance, you attributed the probable cause of gram-negative microbial contamination to room disinfection practices and \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. It is essential that you thoroughly investigate the recurring identification of gram-negative microbes in your aseptic processing environment to determine the root causes and fully remediate with appropriate actions.\u003C\u002Fp>\u003Cp>Your firm also does not document non-routine interventions in the batch record, nor does it document whether vials are removed due to an intervention.\u003C\u002Fp>\u003Cp>The ISO 5 (Grade A) area is critical because sterile products are exposed during aseptic production and therefore are vulnerable to contamination if operations are not well designed and diligently controlled. Your aseptic processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of operations, can promote influx of contamination into the critical processing area in which sterile drugs are exposed.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the systematic deficiencies we identified through our inspection including deficient airflow visualization and operator interventions. Your risk assessment for the affected products includes recommendations to implement additional training, update procedures, and perform a gap assessment related to aseptic manufacturing processes.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your response does not sufficiently address the inadequate oversight of operators, nor the scope and extent of the poor aseptic practices. It also does not determine their root cause and potential impact on sterile drug products. Your risk assessment does not sufficiently evaluate the inspectional deficiencies and support the needed remediation of the overall aseptic processing operation including, but not limited to, the smoke study program. Smoke studies will be essential to substantively assess whether your remediated operation enables robust unidirectional airflow in the ISO 5 (Grade A) area and is capable of maintaining continuous protection of sterile drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A review of past smoke studies by qualified independent consultants with a thorough and comprehensive review of deficiencies in the air flow visualization program and your aseptic processing operations. After you remediate your aseptic operation, provide a summary of updated smoke studies that visualize airflow and critically evaluate unidirectional airflow.\u003C\u002Fli>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o Suitable cleanroom classifications, appropriate differential pressure limits, and alarm limits, Equipment placement and suitability including ergonomics for each human interaction and sufficient cleanroom space\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Reduction or elimination of aseptic manipulations\u003Cbr>o Facility layout\u003Cbr>o Personnel flow and material flow throughout all rooms used to conduct and support sterile operations\u003Cbr>o Cleaning and disinfection (e.g., use of sterile agents) program\u003Cbr>o Specific corrective action and preventive action (CAPA) recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>A comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient including, but not limited to, completeness of batch record entries. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not adequately investigate out-of-specification (OOS) and out-of-limit (OOL) results. Your investigations of sterility failures and significant environmental monitoring excursions lacked adequate scientific rationale to support root causes and implementation of effective CAPA.\u003C\u002Fp>\u003Cp>Your firm did not implement effective CAPA to reduce recurrence of severe contamination hazards including, but not limited to, operator error that had contributed significantly to recurring sterility and media-fill failures over the past five years.\u003C\u002Fp>\u003Cp>For example, your investigation did not include in-depth analysis of the conditions that create the circumstances for human error. It is imperative that you conduct in-depth, root-cause analysis to identify effective CAPA including design remediations.\u003C\u002Fp>\u003Cp>Your firm also failed to investigate failures to meet in-process acceptance criteria for visible particulates. You lacked an adequate investigation for the failure of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection sterile drug product to meet your visible particulate rejection limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of vials. Also, our inspection found a very high visual inspection rejection rate for multiple batches. For example, you rejected approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of vials during visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the importance of conducting robust sterility failure investigations that include comprehensive root cause analyses and effective CAPA implementation. In particular, you indicate that investigations have not sufficiently addressed the underlying factors contributing to human error in manufacturing operations. However, your proposed CAPAs lack sufficient detail and a description of how effectiveness of these actions will be evaluated.\u003C\u002Fp>\u003Cp>Your response also acknowledges the importance of maintaining a robust visual inspection program that includes routine particle identification and thorough deviation investigations to ensure effective CAPA. You commit to comprehensively evaluating your visual inspection program, assessing the manufacturing process, and identification of particles. You also plan to implement alternative methods to enhance visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection. Your response is inadequate. You did not provide sufficient detail on how your remediation plans will prevent foreign particle contamination.\u003C\u002Fp>\u003Cp>It is important that visible particulate contamination is appropriately evaluated. When categorizing visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible insanitary or microbial contamination. Sterile manufacturing operations should be designed to prevent foreign contaminants, and such contamination should trigger a thorough investigation and appropriate CAPA.\u003C\u002Fp>\u003Cp>For more information about handling out-of-specification and failing results, and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision. While this guidance addresses chemistry laboratory analyses, many of its principles are also relevant to investigating out-of-specification microbiological results and out-of-trend results.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure that your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results, for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS-result investigation system with a CAPA plan that includes, but is not limited to:\u003Cbr>o QU oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system that includes, but is not limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program wherever needed, ensures final QU decision authority, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>An independent third-party review of the adequacy of your CAPA in response to each of your sterility failures, media-fill failures, and microbial deviation investigations over the last five years. Address the need for sterile facility and process redesign, wherever needed.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your aseptic processing operation was inadequately designed to prevent contamination of your sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Significantly, your room pressurization and facility monitoring systems were fundamentally flawed. As a consequence, your aseptic processing operation was inadequately designed to prevent contamination of your sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\u003Cp>Our inspection found the pressure differentials in the aseptic manufacturing rooms were inadequate. For example, the aseptic filling rooms had lower pressure than the adjacent rooms. This can result in contaminants readily migrating from lower-classified areas into the higher-classified areas where critical manufacturing operations occur.\u003C\u002Fp>\u003Cp>Furthermore, you failed to routinely record basic facility monitoring data, including differential pressure, temperature, and humidity. Your monitoring devices displayed real-time data only and lack data storage capability. As a result, parameter excursions that occur when operators are not actively monitoring pressures went undocumented. You also had no alarm history or recorded data.\u003C\u002Fp>\u003Cp>Reliable aseptic processes are designed to minimize exposure of sterile articles to potential contamination hazards including, but not limited to, variation in environmental conditions. A suitable facility monitoring system, with appropriate alarms and data retention, is critical to maintain appropriate environmental control throughout all your cleanrooms. You should appropriately investigate all deviations from established limits to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination in your aseptic production operations. For example, differential pressure is a critical facility monitoring parameter. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness.\u003C\u002Fp>\u003Cp>We acknowledge that you suspended manufacturing in November 2025.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that your legacy facility design and control strategy allowed an inappropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong> to persist. You also acknowledge that this was compounded by your outdated monitoring systems that lack continuous data capture, alarm retention, and trending. You commit to establishing facility \u003Cstrong>(b)(4)\u003C\u002Fstrong> from areas of higher air cleanliness to lower areas. Also, you acknowledged that your aseptic manufacturing facility should have a system in place to continuously monitor, store, report, and trend historical pressure differential, temperature and humidity data, including alarm events.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide CAPA details on how you plan to implement appropriate cleanroom facility \u003Cstrong>(b)(4)\u003C\u002Fstrong> from areas of higher air cleanliness to those of lower classification. Also, you did not perform a timely risk assessment to evaluate the impact of inadequate pressure differentials in your classified manufacturing areas.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan and timeline to establish appropriate facility \u003Cstrong>(b)(4)\u003C\u002Fstrong> between cleanrooms. In addition, discuss whether you intend to install a new air handling system or you are modifying the existing system, and address how you will ensure its suitability for aseptic manufacturing.\u003C\u002Fli>\u003Cli>Your CAPA plan for the installation and validation of a compliant Facility Monitoring System.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment with assistance from an independent qualified consultant. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to document at the time of performance required laboratory control mechanisms and to record and justify any deviations from required laboratory control mechanisms (21 CFR 211.160(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your control over microbiological laboratory records was inadequate. Our investigators found that microbial plates (for sterility, environmental monitoring, and water samples) in incubators lacked appropriate documentation. For example, you did not have raw data and information related to sample preparation and the batch\u002Fsample identification number available for review. You also did not document the associated data and information contemporaneously.\u003C\u002Fp>\u003Cp>We also noticed that critical CGMP documentation forms used to document test results printed from your IQVIA software (e.g., sterility test report) are not adequately controlled.\u003C\u002Fp>\u003Cp>Proper document control and data management is foundational to CGMP to ensure the availability and integrity of data. Data should be attributable, legible, contemporaneously recorded, original or a true copy, and accurate (ALCOA) to ensure complete and accurate records.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that raw data was not documented contemporaneously and the need to improve your documentation practices based on a thorough root cause analysis and CAPA plan. You indicate that you reviewed all in-process microbiological worksheets for missing sterility testing documentation and identified 14 additional batches with missing sterility documentation. Based on these findings, you have invalidated the sterility tests of all 16 batches. You also commit to engaging an independent third-party consultant to review the integrity of data by conducting a complete review of all batch release records and a sample of other CGMP records using statistical methods.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your response is limited to discarding sterility tests you conducted during our inspection and that were found to have inadequate CGMP documentation. You did not holistically assess microbiological laboratory practices to determine the full scope of the impact on microbiological test reliability. Additionally, your proposal for a third-party data integrity review using a statistical sampling method is inadequate, as the degree of retrospective review is not sufficient given the significance of the questionable practices documented during the inspection.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Include an assessment of all test methods and procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and have been appropriately validated to determine whether they are fit for purpose. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers.\u003C\u002Fp>\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>o A comprehensive retrospective evaluation of the nature of testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits for at least two years to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated by an independent quality assurance function, along with expertise from outside entities whenever needed.\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA held a teleconference with you recommending you consider removing any batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection and \u003Cstrong>(b)(4)\u003C\u002Fstrong> suspension currently in distribution from the U.S. market and address the quality issues with the sponsors of these drugs.\u003C\u002Fp>\u003Cp>On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you communicated your commitment to cease manufacturing and distribution of all drugs for U.S. market for indefinite time until all CAPAs are completed and assessed by an external consultant. You also informed the agency that you had recommended the sponsors initiate voluntary recalls of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection and \u003Cstrong>(b)(4)\u003C\u002Fstrong> suspension in current distribution in U.S. market.\u003C\u002Fp>\u003Cp>On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your drugs sponsors, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, issued voluntary recalls of \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection and \u003Cstrong>(b)(4)\u003C\u002Fstrong> suspension respectively due to lack of assurance of sterility. You also commit to not distributing batches that remain within your control.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all U.S. products at this facility, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection,\u003Cstrong>(b)(4)\u003C\u002Fstrong> suspension, \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection, \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection \u003Cstrong>(b)(4)\u003C\u002Fstrong> capsule drugs. In response to this letter, clarify whether you intend to resume manufacturing any drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any sterile manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming those manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 23, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Pharmathen International S.A., FEI 3009961173, at Industrial Park, Sapes Rodopi Prefecture, Block No 5 Rodopi, Evrou, Greece, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009961173 and ATTN: Rafael E. Arroyo.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-80\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. John Pius Nason\n\nRecipient Title\n\nGroup CEO\n\nPharmathen International S.A.\n\n44 Kifissias Ave.\n\n15125 Marousi Attica\n\nGreece\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-80\nMay 27, 2026\nDear Mr. Nason:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pharmathen International S.A., FEI 3009961173, at Industrial Park, Sapes Rodopi Prefecture, Block No 5 Rodopi, Evrou, Greece, from November 10 to 21, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your December 15, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nThe airflow visualization studies (i.e., smoke studies) you performed for the (b)(4) aseptic vial filling line you use to fill sterile powder drug products for the U.S. market did not demonstrate unidirectional airflow. This processing line is housed in an (b)(4) Restricted Access Barrier System ((b)(4)RABS).\nFor example, during the simulation of the (b)(4) installation, the (b)(4) remained (b)(4) for an extended time. The airflow was observed exiting the filling line area, bouncing off the operator’s chest, and reentering the filling line.\nThis problematic airflow pattern in your (b)(4)RABS creates significant potential for microbial contamination.\nNotably, our investigators also observed multiples instances of inappropriate aseptic behavior. For example, when removing empty fallen vials, the operator blocked first air, and exposed vials were not discarded. In addition, your smoke studies failed to sufficiently evaluate removal of fallen vials as well as other critical aseptic manipulations.\nOur inspection also found multiple instances of gram-negative microbes in ISO 5 air samples. It is highly atypical to find gram-negative microbes in an aseptic processing room environment. In one such instance, you attributed the probable cause of gram-negative microbial contamination to room disinfection practices and (b)(4) contamination. It is essential that you thoroughly investigate the recurring identification of gram-negative microbes in your aseptic processing environment to determine the root causes and fully remediate with appropriate actions.\nYour firm also does not document non-routine interventions in the batch record, nor does it document whether vials are removed due to an intervention.\nThe ISO 5 (Grade A) area is critical because sterile products are exposed during aseptic production and therefore are vulnerable to contamination if operations are not well designed and diligently controlled. Your aseptic processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of operations, can promote influx of contamination into the critical processing area in which sterile drugs are exposed.\nIn your response, you acknowledge the systematic deficiencies we identified through our inspection including deficient airflow visualization and operator interventions. Your risk assessment for the affected products includes recommendations to implement additional training, update procedures, and perform a gap assessment related to aseptic manufacturing processes.\nYour response is inadequate. Your response does not sufficiently address the inadequate oversight of operators, nor the scope and extent of the poor aseptic practices. It also does not determine their root cause and potential impact on sterile drug products. Your risk assessment does not sufficiently evaluate the inspectional deficiencies and support the needed remediation of the overall aseptic processing operation including, but not limited to, the smoke study program. Smoke studies will be essential to substantively assess whether your remediated operation enables robust unidirectional airflow in the ISO 5 (Grade A) area and is capable of maintaining continuous protection of sterile drug products.\nIn response to this letter, provide the following:\nA review of past smoke studies by qualified independent consultants with a thorough and comprehensive review of deficiencies in the air flow visualization program and your aseptic processing operations. After you remediate your aseptic operation, provide a summary of updated smoke studies that visualize airflow and critically evaluate unidirectional airflow.\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\no Suitable cleanroom classifications, appropriate differential pressure limits, and alarm limits, Equipment placement and suitability including ergonomics for each human interaction and sufficient cleanroom space\no Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no Reduction or elimination of aseptic manipulations\no Facility layout\no Personnel flow and material flow throughout all rooms used to conduct and support sterile operations\no Cleaning and disinfection (e.g., use of sterile agents) program\no Specific corrective action and preventive action (CAPA) recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nA comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient including, but not limited to, completeness of batch record entries. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm did not adequately investigate out-of-specification (OOS) and out-of-limit (OOL) results. Your investigations of sterility failures and significant environmental monitoring excursions lacked adequate scientific rationale to support root causes and implementation of effective CAPA.\nYour firm did not implement effective CAPA to reduce recurrence of severe contamination hazards including, but not limited to, operator error that had contributed significantly to recurring sterility and media-fill failures over the past five years.\nFor example, your investigation did not include in-depth analysis of the conditions that create the circumstances for human error. It is imperative that you conduct in-depth, root-cause analysis to identify effective CAPA including design remediations.\nYour firm also failed to investigate failures to meet in-process acceptance criteria for visible particulates. You lacked an adequate investigation for the failure of your (b)(4) injection sterile drug product to meet your visible particulate rejection limit of (b)(4)% of vials. Also, our inspection found a very high visual inspection rejection rate for multiple batches. For example, you rejected approximately (b)(4)% of vials during visual inspection of (b)(4) batch (b)(4).\nIn your response, you acknowledge the importance of conducting robust sterility failure investigations that include comprehensive root cause analyses and effective CAPA implementation. In particular, you indicate that investigations have not sufficiently addressed the underlying factors contributing to human error in manufacturing operations. However, your proposed CAPAs lack sufficient detail and a description of how effectiveness of these actions will be evaluated.\nYour response also acknowledges the importance of maintaining a robust visual inspection program that includes routine particle identification and thorough deviation investigations to ensure effective CAPA. You commit to comprehensively evaluating your visual inspection program, assessing the manufacturing process, and identification of particles. You also plan to implement alternative methods to enhance visual inspection of (b)(4) Injection. Your response is inadequate. You did not provide sufficient detail on how your remediation plans will prevent foreign particle contamination.\nIt is important that visible particulate contamination is appropriately evaluated. When categorizing visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible insanitary or microbial contamination. Sterile manufacturing operations should be designed to prevent foreign contaminants, and such contamination should trigger a thorough investigation and appropriate CAPA.\nFor more information about handling out-of-specification and failing results, and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Finvestigating-out-specification-oos-test-results-pharmaceutical-production-level-2-revision. While this guidance addresses chemistry laboratory analyses, many of its principles are also relevant to investigating out-of-specification microbiological results and out-of-trend results.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure that your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results, for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS-result investigation system with a CAPA plan that includes, but is not limited to:\no QU oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system that includes, but is not limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program wherever needed, ensures final QU decision authority, and is fully supported by executive management.\nAn independent third-party review of the adequacy of your CAPA in response to each of your sterility failures, media-fill failures, and microbial deviation investigations over the last five years. Address the need for sterile facility and process redesign, wherever needed.\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n3. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\nYour aseptic processing operation was inadequately designed to prevent contamination of your sterile (b)(4) drug products. Significantly, your room pressurization and facility monitoring systems were fundamentally flawed. As a consequence, your aseptic processing operation was inadequately designed to prevent contamination of your sterile (b)(4) drug products.\nOur inspection found the pressure differentials in the aseptic manufacturing rooms were inadequate. For example, the aseptic filling rooms had lower pressure than the adjacent rooms. This can result in contaminants readily migrating from lower-classified areas into the higher-classified areas where critical manufacturing operations occur.\nFurthermore, you failed to routinely record basic facility monitoring data, including differential pressure, temperature, and humidity. Your monitoring devices displayed real-time data only and lack data storage capability. As a result, parameter excursions that occur when operators are not actively monitoring pressures went undocumented. You also had no alarm history or recorded data.\nReliable aseptic processes are designed to minimize exposure of sterile articles to potential contamination hazards including, but not limited to, variation in environmental conditions. A suitable facility monitoring system, with appropriate alarms and data retention, is critical to maintain appropriate environmental control throughout all your cleanrooms. You should appropriately investigate all deviations from established limits to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination in your aseptic production operations. For example, differential pressure is a critical facility monitoring parameter. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness.\nWe acknowledge that you suspended manufacturing in November 2025.\nIn your response, you acknowledge that your legacy facility design and control strategy allowed an inappropriate (b)(4) to persist. You also acknowledge that this was compounded by your outdated monitoring systems that lack continuous data capture, alarm retention, and trending. You commit to establishing facility (b)(4) from areas of higher air cleanliness to lower areas. Also, you acknowledged that your aseptic manufacturing facility should have a system in place to continuously monitor, store, report, and trend historical pressure differential, temperature and humidity data, including alarm events.\nYour response is inadequate. You do not provide CAPA details on how you plan to implement appropriate cleanroom facility (b)(4) from areas of higher air cleanliness to those of lower classification. Also, you did not perform a timely risk assessment to evaluate the impact of inadequate pressure differentials in your classified manufacturing areas.\nIn response to this letter, provide:\nYour CAPA plan and timeline to establish appropriate facility (b)(4) between cleanrooms. In addition, discuss whether you intend to install a new air handling system or you are modifying the existing system, and address how you will ensure its suitability for aseptic manufacturing.\nYour CAPA plan for the installation and validation of a compliant Facility Monitoring System.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment with assistance from an independent qualified consultant. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n4. Your firm failed to document at the time of performance required laboratory control mechanisms and to record and justify any deviations from required laboratory control mechanisms (21 CFR 211.160(a)).\nYour control over microbiological laboratory records was inadequate. Our investigators found that microbial plates (for sterility, environmental monitoring, and water samples) in incubators lacked appropriate documentation. For example, you did not have raw data and information related to sample preparation and the batch\u002Fsample identification number available for review. You also did not document the associated data and information contemporaneously.\nWe also noticed that critical CGMP documentation forms used to document test results printed from your IQVIA software (e.g., sterility test report) are not adequately controlled.\nProper document control and data management is foundational to CGMP to ensure the availability and integrity of data. Data should be attributable, legible, contemporaneously recorded, original or a true copy, and accurate (ALCOA) to ensure complete and accurate records.\nIn your response, you acknowledge that raw data was not documented contemporaneously and the need to improve your documentation practices based on a thorough root cause analysis and CAPA plan. You indicate that you reviewed all in-process microbiological worksheets for missing sterility testing documentation and identified 14 additional batches with missing sterility documentation. Based on these findings, you have invalidated the sterility tests of all 16 batches. You also commit to engaging an independent third-party consultant to review the integrity of data by conducting a complete review of all batch release records and a sample of other CGMP records using statistical methods.\nYour response is inadequate. Your response is limited to discarding sterility tests you conducted during our inspection and that were found to have inadequate CGMP documentation. You did not holistically assess microbiological laboratory practices to determine the full scope of the impact on microbiological test reliability. Additionally, your proposal for a third-party data integrity review using a statistical sampling method is inadequate, as the degree of retrospective review is not sufficient given the significance of the questionable practices documented during the inspection.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Include an assessment of all test methods and procedures used by your firm to ensure they have appropriate instructions, method suitability criteria, and have been appropriately validated to determine whether they are fit for purpose. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate (ALCOA) records throughout your operation.\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdata-integrity-and-compliance-drug-cgmp-questions-and-answers.\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\no A comprehensive retrospective evaluation of the nature of testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits for at least two years to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated by an independent quality assurance function, along with expertise from outside entities whenever needed.\no A status report for any of the above activities already underway or completed.\nDrug Recall\nOn (b)(4), FDA held a teleconference with you recommending you consider removing any batches of (b)(4) injection and (b)(4) suspension currently in distribution from the U.S. market and address the quality issues with the sponsors of these drugs.\nOn (b)(4), you communicated your commitment to cease manufacturing and distribution of all drugs for U.S. market for indefinite time until all CAPAs are completed and assessed by an external consultant. You also informed the agency that you had recommended the sponsors initiate voluntary recalls of (b)(4) injection and (b)(4) suspension in current distribution in U.S. market.\nOn (b)(4), your drugs sponsors, (b)(4), issued voluntary recalls of (b)(4) injection and (b)(4) suspension respectively due to lack of assurance of sterility. You also commit to not distributing batches that remain within your control.\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all U.S. products at this facility, including (b)(4) injection,(b)(4) suspension, (b)(4) injection, (b)(4) injection (b)(4) capsule drugs. In response to this letter, clarify whether you intend to resume manufacturing any drugs for the U.S. market at this facility in the future.\nIf you plan to resume any sterile manufacturing operations regulated under the FD&C Act, notify this office before resuming those manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 23, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Pharmathen International S.A., FEI 3009961173, at Industrial Park, Sapes Rodopi Prefecture, Block No 5 Rodopi, Evrou, Greece, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009961173 and ATTN: Rafael E. Arroyo.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Pharmathen International S.A.","pharmathen-international-sa-723680-05272026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmathen-international-sa-723680-05272026","2026-10-26T08:09:41.509981+00:00","Warning Letter","Issued","2026-06-16","723680","Drugs","Mr. John Pius Nason","2026-08-19T04:36:24.773+00:00","Via Email Return Receipt Requested","320-26-80","2026-05-27",{"id":33,"raw":34,"subject":39,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":38,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":56,"medical_device_id":19,"response_letter_date":19},3350,[35,36,37,38,39,13,40,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-07T04:00:00Z\">05\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsema-international-inc-614691-05072021\">Sema International Inc.\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsema-international-inc-614691-05272022\">\u003Ctime datetime=\"2022-06-07T04:00:00Z\">06\u002F07\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anan Barbarawi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Sema International Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1636 Gervais Ave Ste 15\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maplewood\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:shop@semavape.com\"> shop@semavape.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sema.international@gmail.com\"> sema.international@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 7, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Anan Barbarawi:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fsemavape.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fsemavape.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Vapotech Strawberry and Vapotech Mango Xtreme.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 500 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101594, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Sema International Inc\u003Cbr>\n1703 Cope Ave E Unit G\u003Cbr>\nMaplewood, MN 55109\u003C\u002Fp>\n\n\u003Cp>1&amp;1 IONOS SE\u003Cbr>\nabuse@ionos.com\u003C\u002Fp>\n\n\u003Cp>1&amp;1 IONOS Inc.\u003Cbr>\nabuse@1and1.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nAnan Barbarawi\n\nSema International Inc.\n\n1636 Gervais Ave Ste 15\n\nMaplewood, MN 55109\n\nUnited States\n\nshop@semavape.com\n\nsema.international@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 7, 2021\n\nWARNING LETTER\n\nDear Anan Barbarawi:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fsemavape.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fsemavape.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Vapotech Strawberry and Vapotech Mango Xtreme.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 500 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101594, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nSema International Inc\n\n1703 Cope Ave E Unit G\n\nMaplewood, MN 55109\n\n1&1 IONOS SE\n\nabuse@ionos.com\n\n1&1 IONOS Inc.\n\nabuse@1and1.com","Sema International Inc.","sema-international-inc-614691-05072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsema-international-inc-614691-05072021","2026-10-26T08:09:55.397579+00:00","Closed Out","2021-05-18","614691","Tobacco","2022-06-07","Anan Barbarawi","2026-08-20T03:08:22.095+00:00","VIA UPS and Electronic Mail","2021-05-07",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":19,"letter_url":70,"updated_at":71,"action_type":22,"case_status":23,"posted_date":72,"marcs_cms_no":73,"product_type":26,"closeout_date":19,"issuing_office":63,"recipient_name":74,"body_fetched_at":75,"delivery_method":76,"recipient_title":19,"reference_number":19,"action_taken_date":77,"medical_device_id":19,"response_letter_date":19},1956,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2023-08-08T13:20:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-04T04:00:00Z\">08\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgtp-international-corp-664367-08042023\">GTP International Corp\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vu Tran\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GTP International Corp\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3677 W. Emporium Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mesquite\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75150\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-32\u003C\u002Fp>\n\n\u003Cp>August 4, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tran:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products including \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hand Sanitizer. On August 16, 2022, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. A second email request was sent on August 31, 2022. FDA attempted to contact your firm by phone on October 24, 2022, and left a voice message requesting a response by October 31, 2022. The Agency sent a follow-up written request for such records and other information via certified return-receipt mail that was delivered to the physical address provided in your registration file on November 22, 2022. These requests went unanswered. On August 1, 2023, we contacted you by phone, during which you did not acknowledge FDA’s previous attempts to contact you, but agreed to respond to our request for records and other information by August 2, 2023. However, you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request for records and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>Respond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\u003C\u002Fp>\n\n\u003Cp>The Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Continued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\u003C\u002Fp>\n\n\u003Cp>You may provide additional information for our consideration as we continue to assess your activities and practices.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3012495223 and ATTN: Joel Hustedt.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Since declaration of the COVID-19 public health emergency, a number of hand sanitizer products have been recalled due to quality issues including from substitution with other drug substances, impurities at unacceptable levels, and subpotency. The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing, to assess the overall quality of the drugs registered as manufactured by these firms. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 PHE. Additionally, on December 31, 2021, these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Vu Tran\n\nRecipient Title\n\nPresident\n\nGTP International Corp\n\n3677 W. Emporium Circle\n\nMesquite, TX 75150\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-32\n\nAugust 4, 2023\n\nDear Mr. Tran:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products including (b)(4) Hand Sanitizer. On August 16, 2022, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. A second email request was sent on August 31, 2022. FDA attempted to contact your firm by phone on October 24, 2022, and left a voice message requesting a response by October 31, 2022. The Agency sent a follow-up written request for such records and other information via certified return-receipt mail that was delivered to the physical address provided in your registration file on November 22, 2022. These requests went unanswered. On August 1, 2023, we contacted you by phone, during which you did not acknowledge FDA’s previous attempts to contact you, but agreed to respond to our request for records and other information by August 2, 2023. However, you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request for records and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nBecause your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts,1 we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nRespond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\n\nThe Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\n\nContinued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYou may provide additional information for our consideration as we continue to assess your activities and practices.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3012495223 and ATTN: Joel Hustedt.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\n_____________________\n\n1 Since declaration of the COVID-19 public health emergency, a number of hand sanitizer products have been recalled due to quality issues including from substitution with other drug substances, impurities at unacceptable levels, and subpotency. The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing, to assess the overall quality of the drugs registered as manufactured by these firms. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 PHE. Additionally, on December 31, 2021, these guidances were withdrawn, and firms were required to cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.","GTP International Corp","gtp-international-corp-664367-08042023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgtp-international-corp-664367-08042023","2026-10-26T08:08:51.056789+00:00","2023-08-08","664367","Mr. Vu Tran","2026-08-20T00:48:38.897+00:00","VIA UPS","2023-08-04",{"id":79,"raw":80,"subject":85,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":90,"fei_number":19,"letter_url":91,"updated_at":92,"action_type":22,"case_status":23,"posted_date":93,"marcs_cms_no":94,"product_type":95,"closeout_date":19,"issuing_office":84,"recipient_name":96,"body_fetched_at":97,"delivery_method":98,"recipient_title":19,"reference_number":19,"action_taken_date":99,"medical_device_id":19,"response_letter_date":19},2709,[81,82,83,84,85,13,13,13],"\u003Ctime datetime=\"2022-05-03T13:20:00Z\">05\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-24T05:00:00Z\">02\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmya-international-inc-619877-02242022\">MYA International, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations –West Division 5","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Michael (NMI) Martins\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MYA International, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3517 Main St Ste 304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chula Vista\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91911-0800\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations –West Division 5\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 24, 2022\u003C\u002Fp>\n\n\u003Cp>WL # 619877\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Martins:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your facility MYA International, Inc., located at 3517 Main St Ste 304, Chula Vista, CA, on 8\u002F30\u002F2021-9\u002F3\u002F2021, 9\u002F8\u002F2021, and 9\u002F10\u002F2021. Based on the inspection and our subsequent review of product labeling collected during the inspection, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find copies of the Act and related regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u002FMisbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Food and Drug Administration (FDA) reviewed your product labels for Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper following this inspection. The claims on your product labeling establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims on your product labeling in your 2021 MYA International Catalog that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>HYGLY and Diapro-Z products:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The catalog in Spanish states:\u003C\u002Fp>\n\n\u003Cp>Under the category “AUXILIAR EN PROBLEMAS DE DIABETES”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Poderosa combinación de dos fórmulas diseñadas para ayudar a estabilizar los problemas de niveles de glucosa en la sangre y ayudar a mantener una regulación de su metabolismo reduciendo así la necesidad de insulina y ayudando a regular los niveles de azúcar en la sangre . . .”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Which translates in English to:\u003Cbr>\nUnder the category “Diabetes Problems Assistant”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Powerful combination of two formulas designed to help stabilize blood glucose problems and help maintain regulation of your metabolism thereby reducing the need for insulin and helping to regulate blood sugar levels . . .”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Bioampixilina product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The product name “ampixilina” in Spanish translates to “ampicillin” in English. (Ampicillin is an antibiotic used to treat infections.)\u003C\u002Fp>\n\n\u003Cp>The product label image in the catalog states “Natural Antibiotic Qualities.”\u003C\u002Fp>\n\n\u003Cp>The catalog in Spanish states:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[A]yuda con las infecciones como influenza, anginas, gripe, y afecciones del sistema respiratorio. Este suplemento con cualidades antibióticas naturales de amplio espectrum [sic] es efectivo contra muchos procesos bacterianos.”\u003C\u002Fli>\n\t\u003Cli>“Ayuda en infecciones como:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Influenza\u003Cbr>\no Anginas\u003Cbr>\no Gripe\u003Cbr>\no Afecciones del sistema respiratorio”\u003C\u002Fp>\n\n\u003Cp>Which translates in English to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Helps with infections such as influenza…tonsillitis, flu, and respiratory system conditions. This supplement with natural antibiotic qualities of wide spectrum [sic] is effective against many bacterial processes.”\u003C\u002Fli>\n\t\u003Cli>“Helps in infections like:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Influenza\u003Cbr>\no Anginas\u003Cbr>\no Flu\u003Cbr>\no Diseases of the respiratory system”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Penalin product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The catalog in Spanish states:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Penalin es un producto directo del extracto de ajo. El ajo se llama espantaenfermedades.... Estudios señalan que el ajo combate el colesterol … reduce la presión sanguínea, es antiinflamatorio, evita resfriados, mejora el asma.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Which translates in English to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"Penalin is a direct product of garlic extract. Garlic is known to ward off diseases .... Studies show that garlic fights cholesterol ... lowers blood pressure, is anti-inflammatory, prevents colds, improves asthma.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Colloidal Silver product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The catalog in Spanish states:\u003Cbr>\nUnder the category “AUXILIAR EN PROBLEMAS DE CANCER Y TUMORES”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Es un poderoso auxiliar … que inactiva las enzimas de todas las células bacterianas, hongos, y virus que están usando para su metabolismo del oxígeno causando entonces su sofocación en 6 minutos o menos. Ayuda en: parásitos, herpes, fatiga crónica, en la piel ayuda en el acné, heridas abiertas, pie de atleta, conjuntivitis o irritaciones.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Which translates in English to:\u003Cbr>\nUnder the category “Assistant in Cancer and Tumors Problems”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“It is a powerful helper...that inactivates the enzymes of all bacterial cells, fungi, and viruses that are using oxygen for their metabolism, causing them to suffocate in 6 minutes or less. Helps in: parasites, herpes, chronic fatigue, on the skin helps with acne, open wounds, athlete’s foot, conjunctivitis or irritations.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Tea (Tea Cellular) product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The catalog in Spanish states:\u003Cbr>\nUnder the category “AUXILIAR EN PROBLEMAS DE CANCER Y TUMORES”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Combinación de extractos de plantas purificadoras que ayudan a identificar, reunir y eliminar toxinas del cuerpo. Es de gran ayuda en el control de: cáncer, artritis, diabetes, alergias, infecciones, problemas circulatorios, … disminuye el dolor, la inflamación, y rigidez de las articulaciones.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Which translates in English to:\u003Cbr>\nUnder the category “Assistant in Cancer and Tumors Problems”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"This combination of purifying plant extracts helps identify, gather, and eliminate toxins from the body. It is of great help in the control of: cancer, arthritis, diabetes, allergies, infections, circulatory problems ...reduces pain, inflammation, and joint stiffness\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Quiebra Piedras product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The catalog in Spanish states:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“La actividad antiespasmódica de los alcaloides de Chancapiedra demostró ligera relajación muscular específica para el tracto urinario y biliar, por lo que los investigadores atribuyeron facilidades para la expulsión de cálculos de vejiga y riñón.\u003C\u002Fli>\n\t\u003Cli>PRINCIPALES USOS: … elimina las obstrucciones, erradica los cálculos, reduce las inflamaciones, . . . desintoxica el hígado, … reduce el nivel de azúcar en la sangre, reduce la presión sanguínea y el colesterol.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Which translates in English to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The antispasmodic activity of the stone crushing alkaloids showed slight muscle relaxation specific to the urinary tract and bile duct, for which the researchers attributed facilities an ease in the expulsion of bladder and kidney stones.\u003C\u002Fli>\n\t\u003Cli>“MAIN USES: … eliminate obstructions, eradicate stones, reduce inflammation, … detoxify the liver, … reduces blood sugar levels, reduces blood pressure and cholesterol.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Shark Cartilage product:\u003C\u002Fem>\u003Cbr>\nThe catalog in Spanish states:\u003Cbr>\nUnder the category “AUXILIAR EN PROBLEMAS DE CANCER Y TUMORES”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Posee cualidades auxiliares como antiinflamatorias, analgésicas …. Estas propiedades lo convierten en un aliado del tratamiento contra el cáncer. Contiene sustancias … que ayudan padecimientos como el lupus y psoriasis.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Which translates in English to:\u003Cbr>\nUnder the category “Assistant in Cancer and Tumors Problems”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Has auxiliary qualities as an anti-inflammatory, analgesic …. These properties make it an ally of the treatment of cancer. Contains substances … that help ailments such as lupus and psoriasis.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Helper product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The catalog in Spanish states:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Es un suplemento excepcional para niños que sufren de desórdenes o hiperactividad, esquizofrenia, bi-polaridad, depresión, problemas de memoria tipo Parkinson. También auxilia contra … insomnio ….”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Which translates in English to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“It is an exceptional supplement for children who suffer from disorders or hyperactivity, schizophrenia, bipolarity, depression, Parkinson's-like memory problems. It also helps against … insomnia ….”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper fail to bear adequate directions for their intended use and, therefore, the products misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement cGMP Violations:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Additionally, even if your Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper were not unapproved new drugs and misbranded drugs, these products would be adulterated dietary supplements under section 402(g)(1) of the Act.\u003C\u002Fp>\n\n\u003Cp>The violations include the following:\u003C\u002Fp>\n\n\u003Cp>1. For each dietary supplement that you manufacture, you failed to establish specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you did not establish specification for identity, purity, strength, and composition of your dietary supplement products.\u003C\u002Fp>\n\n\u003Cp>Once you establish finished product specifications, you must verify, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, and composition [21 CFR 111.75(c)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated September 24, 2021, and have determined that your response fails to correct the deficiency identified during the inspection. In your response you stated that you “will develop a Finished Product Evaluation Form (FPEF) to include product specifications” for each finished product. As an example, you provided an FPEF for the product Impo-Frigi. The FPEF you provided fails to satisfy the requirements for finished product specifications because this form indicates that the strength and composition of the ingredients Maca Root, Ginseng Siberian, Damiana Leaf, Saw Palmetto, Valerian Root, and Ginkgo Biloba in the dietary supplements will all be determined by input only. Input is not a scientifically valid method to determine strength at the finished product stage.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish component specifications for each component that you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b). Specifically, you did not establish component specifications that are necessary to ensure that specifications for the identity, purity, strength, composition and limits on contamination of the dietary supplements manufactured using the components are met. For example, you have not established such component specifications for:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The Echinacea purpurea, Golden Seal, Bee Porpolis 70%, and Parsley Leaf used to manufacture your finished dietary supplement product Bioampixilina.\u003C\u002Fli>\n\t\u003Cli>The Burdock Root Powder, Sheep Sorrel, Slippery Elm Bark, Watercress, Rhubarb Root, and Cinnamon Chips\u002FPowder in your finished dietary supplement product Tea.\u003C\u002Fli>\n\t\u003Cli>The Magnesium Chloride in your finished dietary supplement product Magnesium.\u003C\u002Fli>\n\t\u003Cli>The Slippery Elm, Psyllium Husk, Fennel Seed, Licorice Root, Rhubarb Root, and Calcium Citrate in your finished dietary supplement product Intestinal Cleanser Part A.\u003C\u002Fli>\n\t\u003Cli>The Maca Root, Ginseng Siberian Root, L-Arginine, Niacinamide, Damiana Leaf, Saw Palmetto Fruit, Valerian Officinalis Root Powder, and Gingko Biloba in your finished dietary supplement product Impo-Frigi.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). You must also ensure that the tests and examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records of the specifications established, as required by 21 CFR 111.95(b)(1).\u003C\u002Fp>\n\n\u003Cp>In addition, under 21 CFR 111.75(a)(2), you must either conduct appropriate tests or examinations or rely on a certificate of analysis (COA) from the supplier of the component that you receive, provided that the COA meets specific requirements. To the extent you receive dietary ingredients from suppliers from which you rely on a COA, you may only rely on a COA if the following conditions are met: (A) you first qualify the supplier by establishing the reliability of the supplier's COA through confirmation of the results of the supplier's tests or examinations; (B) the COA includes a description of the test or examination method(s) used, limits of the test or examinations, and actual results of the tests or examinations; (C) you maintain documentation of how you qualified the supplier; (D) you periodically reconfirm the supplier's COA; and (E) your quality control personnel review and approve the documentation setting forth the basis for qualification (and re-qualification) of any supplier. We note that it does not appear that you have not qualified any suppliers by confirming the reliability of the COA.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your September 24, 2021 response and have determined that your response fails to correct the deficiency identified during the inspection. The documents that you purport to be component specifications, including those you provided for Echinacea&nbsp;purpurea, do not demonstrate that you have established specifications to ensure that specifications for the identity, purity, and strength of the dietary supplements manufactured using the components are met. For example, the document only states “Passed ID” for the identity specification for Echinacea, and the identity specification is not provided.\u003C\u002Fp>\n\n\u003Cp>3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, as required by 21 CFR 111.255(a), and for your products in which you did prepare BPRs, your BPRs failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, you informed us during the investigation that you do not have BPRs for your Colloidal Silver product, and the executed BPRs you provided to our investigator for Bioampixilina 500mg capsules, lot number 0721315; Tea (Tea Cellular or Cat’s Claw Tea), lot number 0821421; Magnesium Liquid, lot number 821429; Intestinal Cleanser Part A, lot number 0821520; and Impro-Frigi, lot number 0821536, were incomplete as several sections, including sections related to production, were left blank, unsigned, or undated.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your September 24, 2021 response, and we have determined that it fails to correct the deficiency identified during the inspection. You stated that you have discontinued the product 670 Sodirite and that you will create a batch record for the 454 Colloidal Silver product. You also responded that for the incomplete batch production records, you would be updating the current versions to include written procedures and documentation for all key processing operations including double signature during key process steps, weights and lot numbers of components, label evaluation and control, blending specifications, in-process checks-on-weights and physical defects, yield reconciliation, major equipment and processing line identification, and quality review and release. However, your batch record templates already have locations\u002Fblank spaces on the forms to monitor processes such as entering weights and lot numbers of components, perform label evaluation and control, record blending specifications, reconcile yield, identify major equipment and processing lines, and sign and date for quality review and release. Your forms have most of the batch production record structure in place; however, it is necessary to determine that the staff is now entering\u002Fhandwriting the information on these forms to complete the batch records. Your response also did not include any examples of BPRs created or revised and fully completed by your staff for review, which documentation could help demonstrate that the proposed corrective action has been implemented.\u003C\u002Fp>\n\n\u003Cp>4. You failed to identify all processing lines and major equipment used during manufacturing to indicate their contents, including the name of the dietary supplement and the specific batch or lot number and, when necessary, the phase of manufacturing, as required by 21 CFR 111.365(k). Specifically, during the inspection, the investigator noticed that the capsule filling machine contained an unidentified brown powder inside the hopper and did not have any identification to indicate what contents were inside the hopper, or the name and lot number of the dietary supplement being encapsulated.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your September 24, 2021 response, and we have determined that it fails to correct the deficiency identified during the inspection. In your response, you stated that you are planning on developing a procedure for manufacturing control that will include the identification of equipment, status, and identification tag for lines used in manufacturing. You stated that you plan to create line, usage, maintenance and cleaning logs for each line, and provided blank examples of an identification tag and log page. However, you did not provide supporting documentation that you have implemented these corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Magnesium, Intestinal Cleaner Part A, and Impo-Frigi products are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101. In addition, even if your Tea, Penalin, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Quiebra Piedras, and Helper products were not unapproved new and misbranded drugs, these products would be misbranded under section 403 of the Act because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Penalin, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Quiebra Piedras, and Helper products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761) may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>2. Your Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Penalin, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Quiebra Piedras, and Helper products are misbranded with the meaning of section 403(f) of the Act [21 U.S.C. § 343(f)] because your product labels contain information in two languages but does not repeat all the required label information (including the nutrition information) in both languages. In accordance with 21 CFR 101.15(c), if a product label contains any representation in a foreign language or foreign characters, all words, statements, and other information required by or under authority of the Act to appear on the label must appear in the foreign language.\u003C\u002Fp>\n\n\u003Cp>3. Your Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Bioampixilina, Helper, and Quiebra Piedras products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] because the presentation of the nutrition information on the labeling does not comply with 21 CFR 101.36 and 101.9. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, and Helper product labels declare several dietary ingredients but fail to express the amount of (b)(2)-dietary ingredients using the units of measurement given in 21 CFR 101.9(c) as required by 21 CFR 101.36(b)(2)(ii)(B) or the amount of (b)(3)-dietary ingredients using a metric measure as required by 21 CFR 101.36(b)(3)(ii)(A). Furthermore, your Helper product label fails to use the allowed abbreviation for micrograms for vitamin B12 listed in 21 CFR 101.9(d)(7)(i).\u003C\u002Fp>\n\n\u003Cp>b. Your Magnesium product label declares “magnesium chloride” as a dietary ingredient. The quantitative amounts by weight shall represent the weight of the dietary ingredient rather than the weight of the source of the dietary ingredient (e.g., the weight of magnesium rather than that of magnesium chloride) [101.36(b)(2)(ii)]. The source of the dietary ingredient must be declared either within the Supplement Facts (for example, \"magnesium (as magnesium chloride)\") or in the ingredients statement [21 CFR 101.36(d)]. Furthermore, the %DV must be based on the quantitative amount of magnesium and not on the magnesium chloride.\u003C\u002Fp>\n\n\u003Cp>c. Your Intestinal Cleaner Part A product label fails to declare calories, total carbohydrate, dietary fiber, and iron. The (b)(2)-dietary ingredients total calories, total fat, saturated fat, trans fat, cholesterol, sodium, total carbohydrate, dietary fiber, total sugars, added sugars, protein, vitamin D, calcium, iron, and potassium shall be declared when they are present in a dietary supplement in quantitative amounts by weight that exceed the amount that can be declared as zero in nutrition labeling of foods in accordance with 21 CFR 101.9(c), as required by 21 CFR 101.36(b)(2)(i). Furthermore, the label bears an incorrect %DV for calcium based on the quantitative amount declared per serving.\u003C\u002Fp>\n\n\u003Cp>d. Your Tea, Intestinal Cleanser Part A, Bioampixilina, and Diapro-Z product labels declare a proprietary blend but fail to indent the dietary ingredients under the term \"Proprietary Blend\" or other appropriately descriptive term or fanciful name. Furthermore, the labels fail to place the quantitative amount by weight specified for the proprietary blend on the same line to the right of that term, as required by 21 CFR 101.36(c)(2) and (3).\u003C\u002Fp>\n\n\u003Cp>e. Your Impo-Frigi product label declares the (b)(2)-dietary ingredient niacin but fails to state the source of the niacin and the %DV, as required by 21 CFR 101.36(d) and 21 CFR 101.36(b)(2)(iii) respectively. Furthermore, the (b)(2)-ingredients must be listed first followed by a heavy bar and then (b)(3)-dietary ingredients, as required by 21 CFR 101.36(e)(6).\u003C\u002Fp>\n\n\u003Cp>f. Your Helper and Hygly product labels fail to declare the (b)(2)-dietary ingredients and (b)(3)-dietary ingredients in the order and format prescribed in 21 CFR 101.36. The (b)(2)-dietary ingredients must be listed first in the order prescribed in 21 CFR 101.36(b)(2)(i) followed by a heavy bar and then (b)(3)-dietary ingredients.\u003C\u002Fp>\n\n\u003Cp>g. Your Helper product label declares riboflavin as vitamin B2 and thiamin as vitamin B1. While these alternative names are acceptable synonyms for the listed vitamins, in accordance with 21 CFR 101.36(b)(2)(i)(B)(2), the synonym must parenthetically follow the name of the dietary ingredient. Furthermore, the label declares niacinamide and vitamin B5 which are not the nomenclature specified in 21 CFR 101.9 or 101.36(b)(2)(i)(B) for niacin or pantothenic acid, respectively. Additionally, the label fails to correctly list the %DV for each (b)(2)-dietary ingredient in accordance with 21 CFR 101.36(b)(2)(iii) and 21 CFR 101.9(c) and fails to indicate a Daily Value has not been established for the (b)(3)-dietary ingredient bee pollen, as required by 21 CFR 101.36(b)(3)(iv). Lastly, the label fails to declare the source of the vitamins. The source of each dietary ingredient must be designated on the label in accordance with 21 CFR 101.36(d).\u003C\u002Fp>\n\n\u003Cp>h. Your Bioampixilina product label fails to set the title “Supplement Facts” in a type size larger than all other print size in the nutrition label, as required by 21 CFR 101.36(e)(1). Furthermore, your Bioampixilina, Penalin, Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Helper, and Quiebra Piedras product labels fail to present the nutrition information using the bolding, heavy bars, and other format requirements outlined in 21 CFR 101.36(e).\u003C\u002Fp>\n\n\u003Cp>i. Your Bioampixilina product label fails to present the quantitative amounts of the dietary ingredients under the heading “Amount Per Serving” or “Amount Per 2 Capsules” as required by 21 CFR 101.36(b)(2)(i)(A). Furthermore, your Penalin, Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Helper, and Quiebra Piedras product labels use the term “Each Serving,” but this is not an acceptable name for the heading “Amount Per Serving.”\u003C\u002Fp>\n\n\u003Cp>4. Your Hygly, Diapro-Z, Quiebra Piedras, and Penalin products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. For example,\u003Cbr>\na. Your Hygly and Diapro-Z product labels declare “Prostate Powder” which is not the common or usual name of an ingredient.\u003Cbr>\nb. Your Penalin product is manufactured into capsules, but the product label fails to list each of the ingredients used to form the capsules.\u003Cbr>\nc. Your Quiebra Piedras product label declares chanca piedra, but the standardized common name listed in the reference Herbs of Commerce is phyllanthus. Furthermore, the correct Latin binomial name is Phyllanthus niruri.\u003Cbr>\nd. Your Helper product label declares Paba, but this is not the common or usual name for para-aminobenzoic acid.\u003C\u002Fp>\n\n\u003Cp>5. Your Magnesium, Tea, Intestinal Cleanser Part A, and Colloidal Silver products are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to correctly declare the net quantity of contents on the principal display panel as required by 21 CFR 101.7. The label fails to express the net quantity of contents in terms of avoirdupois measure (gallon, pint, etc.) with any remainder in terms of ounces or common or decimal fractions of the measure, followed by the metric units as required by 1453(a) of the Fair Packaging and Labeling Act [15 U.S.C. § 1453(a)].\u003C\u002Fp>\n\n\u003Cp>6. Your Tea, Impo-Frigi, Diapro-Z, and Bioampixilina products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\u003C\u002Fp>\n\n\u003Cp>7. Your Magnesium, Tea, Colloidal Silver, Shark Cartilage, and Intestinal Cleanser Part A products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the label fails to declare the serving size as required by 21 CFR 101.36(b)(1)(i). Serving size must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams). Furthermore, serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Shark Cartilage product’s suggested dose is 2 capsules, but the serving size lists 1 capsule. The serving size listed should be 2 capsules and quantitative amounts of dietary ingredients should be adjusted accordingly.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We offer the following comments:\u003C\u002Fp>\n\n\u003Cp>1. Your full street address is not declared on the several of the product labels as required by 21 CFR 101.5(d); however, the street address may be omitted if it is shown in a current city directory or telephone directory.\u003C\u002Fp>\n\n\u003Cp>2. Your Magnesium product label’s information panel includes nutrition information intermingled with information considered intervening material [21 CFR 101.2(e)]. Examples of intervening material include lot number and expiration date.\u003C\u002Fp>\n\n\u003Cp>3. Your Magnesium, Colloidal Silver, Shark Cartilage, and Quiebra Piedras products list the “Other ingredients” in the (b)(3)-dietary ingredient section within the Supplement Facts label. The “Ingredients” or “Other Ingredients” must be listed outside and immediately following the Supplement Facts label as required by 21 CFR 101.4(g).\u003C\u002Fp>\n\n\u003Cp>4. Your Tea product label misspells the dietary ingredient watercress, your Shark Cartilage product label misspells the dietary ingredient chondroitin sulfate, and your Impo-Frigi product label misspells the dietary ingredient \u003Cem>Ginkgo biloba\u003C\u002Fem>. Furthermore, the lower-case letter “g” appears to be partially truncated in the dietary ingredients Ginseng and L-Arginine on your Impo-Frigi label.\u003C\u002Fp>\n\n\u003Cp>5. Some of the text on your Diapro-Z product label’s Supplement Facts is illegible.\u003C\u002Fp>\n\n\u003Cp>6. Your Bioampixilina product label’s statement of identity must be in a size reasonably related to the most prominent printed matter on the principal display panel [21 CFR 101.3(d)].\u003C\u002Fp>\n\n\u003Cp>7. Your Penalin product label bears the statement “Special Garlic Preparation.” 21 CFR 101 does not allow for such a statement within the Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>8. Your Bioampixilina product label’s servings per container should be “15” and not “15 capsules.”\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild Irvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number CMS#619877 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Kimberly Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or 949-608-2967.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Michael (NMI) Martins\n\nRecipient Title\n\nCEO\u002FOwner\n\nMYA International, Inc.\n\n3517 Main St Ste 304\n\nChula Vista, CA 91911-0800\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations –West Division 5\n\nUnited States\n\nWARNING LETTER\n\nFebruary 24, 2022\n\nWL # 619877\n\nDear Dr. Martins:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your facility MYA International, Inc., located at 3517 Main St Ste 304, Chula Vista, CA, on 8\u002F30\u002F2021-9\u002F3\u002F2021, 9\u002F8\u002F2021, and 9\u002F10\u002F2021. Based on the inspection and our subsequent review of product labeling collected during the inspection, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find copies of the Act and related regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs\u002FMisbranded Drugs\n\nThe Food and Drug Administration (FDA) reviewed your product labels for Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper following this inspection. The claims on your product labeling establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the claims on your product labeling in your 2021 MYA International Catalog that provide evidence that your products are intended for use as drugs include:\n\nHYGLY and Diapro-Z products:\n\nThe catalog in Spanish states:\n\nUnder the category “AUXILIAR EN PROBLEMAS DE DIABETES”\n\n“Poderosa combinación de dos fórmulas diseñadas para ayudar a estabilizar los problemas de niveles de glucosa en la sangre y ayudar a mantener una regulación de su metabolismo reduciendo así la necesidad de insulina y ayudando a regular los niveles de azúcar en la sangre . . .”\n\nWhich translates in English to:\n\nUnder the category “Diabetes Problems Assistant”:\n\n“Powerful combination of two formulas designed to help stabilize blood glucose problems and help maintain regulation of your metabolism thereby reducing the need for insulin and helping to regulate blood sugar levels . . .”\n\nBioampixilina product:\n\nThe product name “ampixilina” in Spanish translates to “ampicillin” in English. (Ampicillin is an antibiotic used to treat infections.)\n\nThe product label image in the catalog states “Natural Antibiotic Qualities.”\n\nThe catalog in Spanish states:\n\n“[A]yuda con las infecciones como influenza, anginas, gripe, y afecciones del sistema respiratorio. Este suplemento con cualidades antibióticas naturales de amplio espectrum [sic] es efectivo contra muchos procesos bacterianos.”\n\n“Ayuda en infecciones como:\n\no Influenza\n\no Anginas\n\no Gripe\n\no Afecciones del sistema respiratorio”\n\nWhich translates in English to:\n\n“Helps with infections such as influenza…tonsillitis, flu, and respiratory system conditions. This supplement with natural antibiotic qualities of wide spectrum [sic] is effective against many bacterial processes.”\n\n“Helps in infections like:\n\no Influenza\n\no Anginas\n\no Flu\n\no Diseases of the respiratory system”\n\nPenalin product:\n\nThe catalog in Spanish states:\n\n“Penalin es un producto directo del extracto de ajo. El ajo se llama espantaenfermedades.... Estudios señalan que el ajo combate el colesterol … reduce la presión sanguínea, es antiinflamatorio, evita resfriados, mejora el asma.”\n\nWhich translates in English to:\n\n\"Penalin is a direct product of garlic extract. Garlic is known to ward off diseases .... Studies show that garlic fights cholesterol ... lowers blood pressure, is anti-inflammatory, prevents colds, improves asthma.”\n\nColloidal Silver product:\n\nThe catalog in Spanish states:\n\nUnder the category “AUXILIAR EN PROBLEMAS DE CANCER Y TUMORES”:\n\n“Es un poderoso auxiliar … que inactiva las enzimas de todas las células bacterianas, hongos, y virus que están usando para su metabolismo del oxígeno causando entonces su sofocación en 6 minutos o menos. Ayuda en: parásitos, herpes, fatiga crónica, en la piel ayuda en el acné, heridas abiertas, pie de atleta, conjuntivitis o irritaciones.”\n\nWhich translates in English to:\n\nUnder the category “Assistant in Cancer and Tumors Problems”:\n\n“It is a powerful helper...that inactivates the enzymes of all bacterial cells, fungi, and viruses that are using oxygen for their metabolism, causing them to suffocate in 6 minutes or less. Helps in: parasites, herpes, chronic fatigue, on the skin helps with acne, open wounds, athlete’s foot, conjunctivitis or irritations.”\n\nTea (Tea Cellular) product:\n\nThe catalog in Spanish states:\n\nUnder the category “AUXILIAR EN PROBLEMAS DE CANCER Y TUMORES”:\n\n“Combinación de extractos de plantas purificadoras que ayudan a identificar, reunir y eliminar toxinas del cuerpo. Es de gran ayuda en el control de: cáncer, artritis, diabetes, alergias, infecciones, problemas circulatorios, … disminuye el dolor, la inflamación, y rigidez de las articulaciones.”\n\nWhich translates in English to:\n\nUnder the category “Assistant in Cancer and Tumors Problems”:\n\n\"This combination of purifying plant extracts helps identify, gather, and eliminate toxins from the body. It is of great help in the control of: cancer, arthritis, diabetes, allergies, infections, circulatory problems ...reduces pain, inflammation, and joint stiffness\"\n\nQuiebra Piedras product:\n\nThe catalog in Spanish states:\n\n“La actividad antiespasmódica de los alcaloides de Chancapiedra demostró ligera relajación muscular específica para el tracto urinario y biliar, por lo que los investigadores atribuyeron facilidades para la expulsión de cálculos de vejiga y riñón.\n\nPRINCIPALES USOS: … elimina las obstrucciones, erradica los cálculos, reduce las inflamaciones, . . . desintoxica el hígado, … reduce el nivel de azúcar en la sangre, reduce la presión sanguínea y el colesterol.”\n\nWhich translates in English to:\n\n“The antispasmodic activity of the stone crushing alkaloids showed slight muscle relaxation specific to the urinary tract and bile duct, for which the researchers attributed facilities an ease in the expulsion of bladder and kidney stones.\n\n“MAIN USES: … eliminate obstructions, eradicate stones, reduce inflammation, … detoxify the liver, … reduces blood sugar levels, reduces blood pressure and cholesterol.”\n\nShark Cartilage product:\n\nThe catalog in Spanish states:\n\nUnder the category “AUXILIAR EN PROBLEMAS DE CANCER Y TUMORES”:\n\n“Posee cualidades auxiliares como antiinflamatorias, analgésicas …. Estas propiedades lo convierten en un aliado del tratamiento contra el cáncer. Contiene sustancias … que ayudan padecimientos como el lupus y psoriasis.”\n\nWhich translates in English to:\n\nUnder the category “Assistant in Cancer and Tumors Problems”:\n\n“Has auxiliary qualities as an anti-inflammatory, analgesic …. These properties make it an ally of the treatment of cancer. Contains substances … that help ailments such as lupus and psoriasis.\n\nHelper product:\n\nThe catalog in Spanish states:\n\n“Es un suplemento excepcional para niños que sufren de desórdenes o hiperactividad, esquizofrenia, bi-polaridad, depresión, problemas de memoria tipo Parkinson. También auxilia contra … insomnio ….”\n\nWhich translates in English to:\n\n“It is an exceptional supplement for children who suffer from disorders or hyperactivity, schizophrenia, bipolarity, depression, Parkinson's-like memory problems. It also helps against … insomnia ….”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper fail to bear adequate directions for their intended use and, therefore, the products misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nDietary Supplement cGMP Violations:\n\nThe inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. Additionally, even if your Hygly, Diapro-Z, Bioampixilina, Penalin, Colloidal Silver, Tea (Tea Cellular), Quiebra Piedras, Shark Cartilage, and Helper were not unapproved new drugs and misbranded drugs, these products would be adulterated dietary supplements under section 402(g)(1) of the Act.\n\nThe violations include the following:\n\n1. For each dietary supplement that you manufacture, you failed to establish specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you did not establish specification for identity, purity, strength, and composition of your dietary supplement products.\n\nOnce you establish finished product specifications, you must verify, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, and composition [21 CFR 111.75(c)].\n\nWe have reviewed your response dated September 24, 2021, and have determined that your response fails to correct the deficiency identified during the inspection. In your response you stated that you “will develop a Finished Product Evaluation Form (FPEF) to include product specifications” for each finished product. As an example, you provided an FPEF for the product Impo-Frigi. The FPEF you provided fails to satisfy the requirements for finished product specifications because this form indicates that the strength and composition of the ingredients Maca Root, Ginseng Siberian, Damiana Leaf, Saw Palmetto, Valerian Root, and Ginkgo Biloba in the dietary supplements will all be determined by input only. Input is not a scientifically valid method to determine strength at the finished product stage.\n\n2. You failed to establish component specifications for each component that you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b). Specifically, you did not establish component specifications that are necessary to ensure that specifications for the identity, purity, strength, composition and limits on contamination of the dietary supplements manufactured using the components are met. For example, you have not established such component specifications for:\n\nThe Echinacea purpurea, Golden Seal, Bee Porpolis 70%, and Parsley Leaf used to manufacture your finished dietary supplement product Bioampixilina.\n\nThe Burdock Root Powder, Sheep Sorrel, Slippery Elm Bark, Watercress, Rhubarb Root, and Cinnamon Chips\u002FPowder in your finished dietary supplement product Tea.\n\nThe Magnesium Chloride in your finished dietary supplement product Magnesium.\n\nThe Slippery Elm, Psyllium Husk, Fennel Seed, Licorice Root, Rhubarb Root, and Calcium Citrate in your finished dietary supplement product Intestinal Cleanser Part A.\n\nThe Maca Root, Ginseng Siberian Root, L-Arginine, Niacinamide, Damiana Leaf, Saw Palmetto Fruit, Valerian Officinalis Root Powder, and Gingko Biloba in your finished dietary supplement product Impo-Frigi.\n\nBefore using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). You must also ensure that the tests and examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records of the specifications established, as required by 21 CFR 111.95(b)(1).\n\nIn addition, under 21 CFR 111.75(a)(2), you must either conduct appropriate tests or examinations or rely on a certificate of analysis (COA) from the supplier of the component that you receive, provided that the COA meets specific requirements. To the extent you receive dietary ingredients from suppliers from which you rely on a COA, you may only rely on a COA if the following conditions are met: (A) you first qualify the supplier by establishing the reliability of the supplier's COA through confirmation of the results of the supplier's tests or examinations; (B) the COA includes a description of the test or examination method(s) used, limits of the test or examinations, and actual results of the tests or examinations; (C) you maintain documentation of how you qualified the supplier; (D) you periodically reconfirm the supplier's COA; and (E) your quality control personnel review and approve the documentation setting forth the basis for qualification (and re-qualification) of any supplier. We note that it does not appear that you have not qualified any suppliers by confirming the reliability of the COA.\n\nWe have reviewed your September 24, 2021 response and have determined that your response fails to correct the deficiency identified during the inspection. The documents that you purport to be component specifications, including those you provided for Echinacea purpurea, do not demonstrate that you have established specifications to ensure that specifications for the identity, purity, and strength of the dietary supplements manufactured using the components are met. For example, the document only states “Passed ID” for the identity specification for Echinacea, and the identity specification is not provided.\n\n3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, as required by 21 CFR 111.255(a), and for your products in which you did prepare BPRs, your BPRs failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, you informed us during the investigation that you do not have BPRs for your Colloidal Silver product, and the executed BPRs you provided to our investigator for Bioampixilina 500mg capsules, lot number 0721315; Tea (Tea Cellular or Cat’s Claw Tea), lot number 0821421; Magnesium Liquid, lot number 821429; Intestinal Cleanser Part A, lot number 0821520; and Impro-Frigi, lot number 0821536, were incomplete as several sections, including sections related to production, were left blank, unsigned, or undated.\n\nWe have reviewed your September 24, 2021 response, and we have determined that it fails to correct the deficiency identified during the inspection. You stated that you have discontinued the product 670 Sodirite and that you will create a batch record for the 454 Colloidal Silver product. You also responded that for the incomplete batch production records, you would be updating the current versions to include written procedures and documentation for all key processing operations including double signature during key process steps, weights and lot numbers of components, label evaluation and control, blending specifications, in-process checks-on-weights and physical defects, yield reconciliation, major equipment and processing line identification, and quality review and release. However, your batch record templates already have locations\u002Fblank spaces on the forms to monitor processes such as entering weights and lot numbers of components, perform label evaluation and control, record blending specifications, reconcile yield, identify major equipment and processing lines, and sign and date for quality review and release. Your forms have most of the batch production record structure in place; however, it is necessary to determine that the staff is now entering\u002Fhandwriting the information on these forms to complete the batch records. Your response also did not include any examples of BPRs created or revised and fully completed by your staff for review, which documentation could help demonstrate that the proposed corrective action has been implemented.\n\n4. You failed to identify all processing lines and major equipment used during manufacturing to indicate their contents, including the name of the dietary supplement and the specific batch or lot number and, when necessary, the phase of manufacturing, as required by 21 CFR 111.365(k). Specifically, during the inspection, the investigator noticed that the capsule filling machine contained an unidentified brown powder inside the hopper and did not have any identification to indicate what contents were inside the hopper, or the name and lot number of the dietary supplement being encapsulated.\n\nWe have reviewed your September 24, 2021 response, and we have determined that it fails to correct the deficiency identified during the inspection. In your response, you stated that you are planning on developing a procedure for manufacturing control that will include the identification of equipment, status, and identification tag for lines used in manufacturing. You stated that you plan to create line, usage, maintenance and cleaning logs for each line, and provided blank examples of an identification tag and log page. However, you did not provide supporting documentation that you have implemented these corrective actions.\n\nMisbranded Dietary Supplements\n\nYour Magnesium, Intestinal Cleaner Part A, and Impo-Frigi products are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101. In addition, even if your Tea, Penalin, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Quiebra Piedras, and Helper products were not unapproved new and misbranded drugs, these products would be misbranded under section 403 of the Act because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Penalin, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Quiebra Piedras, and Helper products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761) may receive a report of a serious adverse event with such dietary supplement.\n\n2. Your Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Penalin, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Quiebra Piedras, and Helper products are misbranded with the meaning of section 403(f) of the Act [21 U.S.C. § 343(f)] because your product labels contain information in two languages but does not repeat all the required label information (including the nutrition information) in both languages. In accordance with 21 CFR 101.15(c), if a product label contains any representation in a foreign language or foreign characters, all words, statements, and other information required by or under authority of the Act to appear on the label must appear in the foreign language.\n\n3. Your Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Bioampixilina, Helper, and Quiebra Piedras products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] because the presentation of the nutrition information on the labeling does not comply with 21 CFR 101.36 and 101.9. For example:\n\na. Your Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, and Helper product labels declare several dietary ingredients but fail to express the amount of (b)(2)-dietary ingredients using the units of measurement given in 21 CFR 101.9(c) as required by 21 CFR 101.36(b)(2)(ii)(B) or the amount of (b)(3)-dietary ingredients using a metric measure as required by 21 CFR 101.36(b)(3)(ii)(A). Furthermore, your Helper product label fails to use the allowed abbreviation for micrograms for vitamin B12 listed in 21 CFR 101.9(d)(7)(i).\n\nb. Your Magnesium product label declares “magnesium chloride” as a dietary ingredient. The quantitative amounts by weight shall represent the weight of the dietary ingredient rather than the weight of the source of the dietary ingredient (e.g., the weight of magnesium rather than that of magnesium chloride) [101.36(b)(2)(ii)]. The source of the dietary ingredient must be declared either within the Supplement Facts (for example, \"magnesium (as magnesium chloride)\") or in the ingredients statement [21 CFR 101.36(d)]. Furthermore, the %DV must be based on the quantitative amount of magnesium and not on the magnesium chloride.\n\nc. Your Intestinal Cleaner Part A product label fails to declare calories, total carbohydrate, dietary fiber, and iron. The (b)(2)-dietary ingredients total calories, total fat, saturated fat, trans fat, cholesterol, sodium, total carbohydrate, dietary fiber, total sugars, added sugars, protein, vitamin D, calcium, iron, and potassium shall be declared when they are present in a dietary supplement in quantitative amounts by weight that exceed the amount that can be declared as zero in nutrition labeling of foods in accordance with 21 CFR 101.9(c), as required by 21 CFR 101.36(b)(2)(i). Furthermore, the label bears an incorrect %DV for calcium based on the quantitative amount declared per serving.\n\nd. Your Tea, Intestinal Cleanser Part A, Bioampixilina, and Diapro-Z product labels declare a proprietary blend but fail to indent the dietary ingredients under the term \"Proprietary Blend\" or other appropriately descriptive term or fanciful name. Furthermore, the labels fail to place the quantitative amount by weight specified for the proprietary blend on the same line to the right of that term, as required by 21 CFR 101.36(c)(2) and (3).\n\ne. Your Impo-Frigi product label declares the (b)(2)-dietary ingredient niacin but fails to state the source of the niacin and the %DV, as required by 21 CFR 101.36(d) and 21 CFR 101.36(b)(2)(iii) respectively. Furthermore, the (b)(2)-ingredients must be listed first followed by a heavy bar and then (b)(3)-dietary ingredients, as required by 21 CFR 101.36(e)(6).\n\nf. Your Helper and Hygly product labels fail to declare the (b)(2)-dietary ingredients and (b)(3)-dietary ingredients in the order and format prescribed in 21 CFR 101.36. The (b)(2)-dietary ingredients must be listed first in the order prescribed in 21 CFR 101.36(b)(2)(i) followed by a heavy bar and then (b)(3)-dietary ingredients.\n\ng. Your Helper product label declares riboflavin as vitamin B2 and thiamin as vitamin B1. While these alternative names are acceptable synonyms for the listed vitamins, in accordance with 21 CFR 101.36(b)(2)(i)(B)(2), the synonym must parenthetically follow the name of the dietary ingredient. Furthermore, the label declares niacinamide and vitamin B5 which are not the nomenclature specified in 21 CFR 101.9 or 101.36(b)(2)(i)(B) for niacin or pantothenic acid, respectively. Additionally, the label fails to correctly list the %DV for each (b)(2)-dietary ingredient in accordance with 21 CFR 101.36(b)(2)(iii) and 21 CFR 101.9(c) and fails to indicate a Daily Value has not been established for the (b)(3)-dietary ingredient bee pollen, as required by 21 CFR 101.36(b)(3)(iv). Lastly, the label fails to declare the source of the vitamins. The source of each dietary ingredient must be designated on the label in accordance with 21 CFR 101.36(d).\n\nh. Your Bioampixilina product label fails to set the title “Supplement Facts” in a type size larger than all other print size in the nutrition label, as required by 21 CFR 101.36(e)(1). Furthermore, your Bioampixilina, Penalin, Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Helper, and Quiebra Piedras product labels fail to present the nutrition information using the bolding, heavy bars, and other format requirements outlined in 21 CFR 101.36(e).\n\ni. Your Bioampixilina product label fails to present the quantitative amounts of the dietary ingredients under the heading “Amount Per Serving” or “Amount Per 2 Capsules” as required by 21 CFR 101.36(b)(2)(i)(A). Furthermore, your Penalin, Magnesium, Tea, Intestinal Cleaner Part A, Impo-Frigi, Hygly, Diapro-Z, Colloidal Silver, Shark Cartilage, Helper, and Quiebra Piedras product labels use the term “Each Serving,” but this is not an acceptable name for the heading “Amount Per Serving.”\n\n4. Your Hygly, Diapro-Z, Quiebra Piedras, and Penalin products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. For example,\n\na. Your Hygly and Diapro-Z product labels declare “Prostate Powder” which is not the common or usual name of an ingredient.\n\nb. Your Penalin product is manufactured into capsules, but the product label fails to list each of the ingredients used to form the capsules.\n\nc. Your Quiebra Piedras product label declares chanca piedra, but the standardized common name listed in the reference Herbs of Commerce is phyllanthus. Furthermore, the correct Latin binomial name is Phyllanthus niruri.\n\nd. Your Helper product label declares Paba, but this is not the common or usual name for para-aminobenzoic acid.\n\n5. Your Magnesium, Tea, Intestinal Cleanser Part A, and Colloidal Silver products are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to correctly declare the net quantity of contents on the principal display panel as required by 21 CFR 101.7. The label fails to express the net quantity of contents in terms of avoirdupois measure (gallon, pint, etc.) with any remainder in terms of ounces or common or decimal fractions of the measure, followed by the metric units as required by 1453(a) of the Fair Packaging and Labeling Act [15 U.S.C. § 1453(a)].\n\n6. Your Tea, Impo-Frigi, Diapro-Z, and Bioampixilina products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\n\n7. Your Magnesium, Tea, Colloidal Silver, Shark Cartilage, and Intestinal Cleanser Part A products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the label fails to declare the serving size as required by 21 CFR 101.36(b)(1)(i). Serving size must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams). Furthermore, serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Shark Cartilage product’s suggested dose is 2 capsules, but the serving size lists 1 capsule. The serving size listed should be 2 capsules and quantitative amounts of dietary ingredients should be adjusted accordingly.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe offer the following comments:\n\n1. Your full street address is not declared on the several of the product labels as required by 21 CFR 101.5(d); however, the street address may be omitted if it is shown in a current city directory or telephone directory.\n\n2. Your Magnesium product label’s information panel includes nutrition information intermingled with information considered intervening material [21 CFR 101.2(e)]. Examples of intervening material include lot number and expiration date.\n\n3. Your Magnesium, Colloidal Silver, Shark Cartilage, and Quiebra Piedras products list the “Other ingredients” in the (b)(3)-dietary ingredient section within the Supplement Facts label. The “Ingredients” or “Other Ingredients” must be listed outside and immediately following the Supplement Facts label as required by 21 CFR 101.4(g).\n\n4. Your Tea product label misspells the dietary ingredient watercress, your Shark Cartilage product label misspells the dietary ingredient chondroitin sulfate, and your Impo-Frigi product label misspells the dietary ingredient Ginkgo biloba. Furthermore, the lower-case letter “g” appears to be partially truncated in the dietary ingredients Ginseng and L-Arginine on your Impo-Frigi label.\n\n5. Some of the text on your Diapro-Z product label’s Supplement Facts is illegible.\n\n6. Your Bioampixilina product label’s statement of identity must be in a size reasonably related to the most prominent printed matter on the principal display panel [21 CFR 101.3(d)].\n\n7. Your Penalin product label bears the statement “Special Garlic Preparation.” 21 CFR 101 does not allow for such a statement within the Supplement Facts label.\n\n8. Your Bioampixilina product label’s servings per container should be “15” and not “15 capsules.”\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild Irvine, CA 92612\n\nRefer to Unique Identification Number CMS#619877 when replying.\n\nIf you have any questions regarding this letter, please contact Kimberly Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or 949-608-2967.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –West Division 5","MYA International, Inc.","mya-international-inc-619877-02242022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmya-international-inc-619877-02242022","2026-10-26T08:09:29.294583+00:00","2022-05-03","619877","DrugsFood & Beverages","Dr. Michael (NMI) Martins","2026-08-20T01:57:40.142+00:00","United Parcel Service","2022-02-24",{"id":101,"raw":102,"subject":107,"body_html":108,"body_text":109,"firm_name":110,"letter_id":111,"created_at":45,"fei_number":19,"letter_url":112,"updated_at":113,"action_type":22,"case_status":23,"posted_date":114,"marcs_cms_no":115,"product_type":116,"closeout_date":19,"issuing_office":106,"recipient_name":117,"body_fetched_at":118,"delivery_method":119,"recipient_title":19,"reference_number":19,"action_taken_date":120,"medical_device_id":19,"response_letter_date":19},3421,[103,104,105,106,107,13,13,13],"\u003Ctime datetime=\"2021-04-06T13:20:00Z\">04\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-29T04:00:00Z\">03\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fimad-international-llc-613268-03292021\">IMAD International, LLC\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ahmed Ladejobi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IMAD International, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1565 Theriot Ave, Apt 6G\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bronx\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 613268\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 29, 2021\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ladejobi:\u003C\u002Fp>\n\n\u003Cp>On January 14, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection for IMAD International, LLC located at 1565 Theriot Ave, Apt 6G, Bronx, New York 10460. We also conducted an inspection on April 18, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During our most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your honey beans and melon seeds imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;located in&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and your plantain chips imported \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with Section 805 of the FD&amp;C Act. At the conclusion of both the initial FSVP inspection on April 18, 2019 and the follow-up inspection on January 14, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>At the close of the most recent inspection, you stated to the investigator that you are currently working on the FSVP plan with a third-party consultant and it should be completed within the next few weeks. We have not received your response to either Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. For the plantain chips imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Because \u003Cstrong>(b)(4)\u003C\u002Fstrong> appears to be on the CFIA list of firms in good standing, you may be eligible to follow the modified requirements in 21 CFR 1.513 for that product.\u003C\u002Fp>\n\n\u003Cp>2. For the melon seeds and honey beans imported \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not meet your requirements to conduct a hazard analysis in accordance with 21 CFR 1.504(a). During the inspection, you provided a copy \u003Cstrong>(b)(4)\u003C\u002Fstrong> Food Safety Analysis – Hazard Analysis. You may meet your requirement to conduct a hazard analysis, as required by 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of your supplier’s hazard analysis as required by 21 CFR 1.504(d).\u003C\u002Fp>\n\n\u003Cp>3. You must approve your foreign suppliers on the basis of an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505(a), and document your approval, as required by 21 CFR 1.505(b). You did not document your approval of your foreign supplier of melon seeds and honey beans imported \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR 1.505(b).\u003C\u002Fp>\n\n\u003Cp>4. You did not establish and follow written procedures to ensure that you import foods only from foreign suppliers you have approved based on an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505, and document your use of these procedures, as required by 21 CFR 1.506(a)(1).\u003C\u002Fp>\n\n\u003Cp>5. You did not establish and follow written adequate procedures ensuring that foreign supplier verification activities are conducted with respect to the food you import as required by 21 CFR 1.506(b).\u003C\u002Fp>\n\n\u003Cp>6. You did not meet the requirements to conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e)(1). Specifically, you did not conduct and document (or obtain documentation) of one or more supplier verification activities for your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> before importing melon seeds and honey beans periodically thereafter.\u003C\u002Fp>\n\n\u003Cp>The above matters are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import that appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Slater Bartlett, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) slater.bartlett@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Bartlett via email at slater.bartlett@fda.hhs.gov. Please reference CMS # 613268 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dawne Hines\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAhmed Ladejobi\n\nRecipient Title\n\nOwner\n\nIMAD International, LLC\n\n1565 Theriot Ave, Apt 6G\n\nBronx, NY 10460\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nCMS # 613268\n\nMarch 29, 2021\n\nDear Mr. Ladejobi:\n\nOn January 14, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection for IMAD International, LLC located at 1565 Theriot Ave, Apt 6G, Bronx, New York 10460. We also conducted an inspection on April 18, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring our most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your honey beans and melon seeds imported from (b)(4) located in (b)(4) and your plantain chips imported (b)(4). Because of these significant violations, you are not in compliance with Section 805 of the FD&C Act. At the conclusion of both the initial FSVP inspection on April 18, 2019 and the follow-up inspection on January 14, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\n\nAt the close of the most recent inspection, you stated to the investigator that you are currently working on the FSVP plan with a third-party consultant and it should be completed within the next few weeks. We have not received your response to either Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. For the plantain chips imported from your foreign supplier (b)(4), you did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Because (b)(4) appears to be on the CFIA list of firms in good standing, you may be eligible to follow the modified requirements in 21 CFR 1.513 for that product.\n\n2. For the melon seeds and honey beans imported (b)(4), you did not meet your requirements to conduct a hazard analysis in accordance with 21 CFR 1.504(a). During the inspection, you provided a copy (b)(4) Food Safety Analysis – Hazard Analysis. You may meet your requirement to conduct a hazard analysis, as required by 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of your supplier’s hazard analysis as required by 21 CFR 1.504(d).\n\n3. You must approve your foreign suppliers on the basis of an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505(a), and document your approval, as required by 21 CFR 1.505(b). You did not document your approval of your foreign supplier of melon seeds and honey beans imported (b)(4), as required by 21 CFR 1.505(b).\n\n4. You did not establish and follow written procedures to ensure that you import foods only from foreign suppliers you have approved based on an evaluation of the foreign supplier’s performance and the risk posed by the food, conducted in accordance with 21 CFR 1.505, and document your use of these procedures, as required by 21 CFR 1.506(a)(1).\n\n5. You did not establish and follow written adequate procedures ensuring that foreign supplier verification activities are conducted with respect to the food you import as required by 21 CFR 1.506(b).\n\n6. You did not meet the requirements to conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e)(1). Specifically, you did not conduct and document (or obtain documentation) of one or more supplier verification activities for your foreign supplier (b)(4) before importing melon seeds and honey beans periodically thereafter.\n\nThe above matters are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import that appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Slater Bartlett, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) slater.bartlett@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Bartlett via email at slater.bartlett@fda.hhs.gov. Please reference CMS # 613268 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDawne Hines\n\nProgram Division Director\n\nDivision of Northeast Imports","IMAD International, LLC","imad-international-llc-613268-03292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fimad-international-llc-613268-03292021","2026-10-26T08:08:57.611204+00:00","2021-04-06","613268","Food & Beverages","Ahmed Ladejobi","2026-08-20T03:13:36.363+00:00","VIA UNITED PARCEL SERVICE","2021-03-29",{"id":122,"raw":123,"subject":107,"body_html":128,"body_text":129,"firm_name":130,"letter_id":131,"created_at":132,"fei_number":19,"letter_url":133,"updated_at":134,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":136,"product_type":116,"closeout_date":19,"issuing_office":127,"recipient_name":137,"body_fetched_at":138,"delivery_method":139,"recipient_title":19,"reference_number":19,"action_taken_date":140,"medical_device_id":19,"response_letter_date":19},1140,[124,125,126,127,107,13,13,13],"\u003Ctime datetime=\"2024-12-10T14:20:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-05T05:00:00Z\">11\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpurcell-international-680631-11052024\">Purcell International\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Colleen D. Purcell-Kangas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Purcell International\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 Ellinwood Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pleasant Hill\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94523-4703\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 9, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Ms. Purcell-Kangas:\u003C\u002Fp>\u003Cp>On February 28, February 29, and March 6, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Purcell International, 800 Ellinwood Way, Pleasant Hill, CA 94523-4703. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The inspection was initiated in response to a multistate investigation involving elevated levels of lead in apple cinnamon fruit puree pouches (intended for infants as young as six months and the general public), manufactured by your foreign supplier Austrofood S.A.S. (Austrofood) of Ecuador. Apple cinnamon fruit puree pouches were subject to a Class 1 recall, initiated on October 29, 2023. The recall was in response to finished product samples of WanaBana brand ready-to-eat (RTE) apple cinnamon fruit puree packed in\u003Cbr>flexible pouches, collected by North Carolina Department of Health and Human Services (NCDHHS), that were found to contain extremely high concentrations of lead; the recall was expanded to include Schnucks and Weis brand cinnamon apple sauce. You imported the Schnucks and Weis brand Apple Sauce – Apple Cinnamon (cinnamon apple sauce) from your foreign supplier, Austrofood. We placed apple cinnamon fruit puree pouches from your foreign supplier on Import Alert #99-42, “Detention Without P\u003Ca>hysical\u003C\u002Fa> Examination (DWPE) of Foods Due to Heavy Metal (Toxic Element) Contamination,” on Nove\u003Ca>mber 6,\u003C\u002Fa> 2023. You may view this alert at: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_1167.html.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier- verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We received your response to the FDA 483a, on March 29, 2024, describing corrective actions taken and planned by your firm and we address your response below.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulations are as follows:\u003C\u002Fp>\u003Cp>1. Your foreign supplier verification activities did not provide adequate assurance that the hazards requiring a control in the food you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). Specifically, you told our investigator that before the recall, you determined your verification activity for cinnamon apple sauce from Austrofood is \u003Cstrong>(b)(4)\u003C\u002Fstrong> third- party audit (onsite audit), in accordance with 21 CFR 1.506(e)(1)(i). We note that your determination, including the frequency with which the activity must be conducted, was not documented, as required by 21 CFR 1.506(d)(1)(i). Further, records of the onsite audits you provided, conducted before the recall in \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, did not address your supplier’s control of heavy metals, specifically lead, in cinnamon apple sauce. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> audit lists chemical hazard (heavy metals) as one of the hazards assessed by your supplier; however, controls for heavy metals were not addressed in the audit. The October 2023 audit mentions the technical sheet for ground cinnamon was reviewed; however, specifications or hazards associated with ground cinnamon were not addressed in the audit. The October 2023 audit states HACCP plans for fruit and vegetable purees packed in pouches were reviewed; however, the audit does not address whether heavy metals in cinnamon apple sauce was controlled.\u003C\u002Fp>\u003Cp>Additionally, you told our investigator that in past shipments, external laboratory testing was used to verify lead levels in final product. In accordance with 21 CFR 1.506(d)(1)(ii)(B), you may determine sampling and testing of a food is an appropriate verification activity. You provided records of one occurrence of sampling and testing of the finished product of cinnamon apple sauce by a laboratory \u003Cstrong>(b)(4)\u003C\u002Fstrong> contracted by your supplier. The results you provided of the testing conducted in June 2023 of lot “05023:19 \u002F 05023:28” detected less than 0.08 mg\u002Fkg (0.08 ppm) lead. However, after you imported product into the United States, \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampled and tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> cinnamon apple sauce, lot “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and detected 1.44 ppm lead. The products analyzed by \u003Cstrong>(b)(4)\u003C\u002Fstrong> are from the same batch codes of cinnamon apple sauce that were recalled due to elevated levels of lead. The FDA reviewed and supports PDA’s analytical findings.\u003C\u002Fp>\u003Cp>We acknowledge that you told our investigator that the discrepancy in analytical findings informed your plans to perform lab analysis of all lots of food imported from the supplier, including products that do not contain cinnamon, for a period of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, utilizing a third-party laboratory within the United States. We note that your determination of a verification activity, including the frequency with which the activity must be conducted, must be documented, as required by 21 CFR 1.506(d)(1)(i). We will verify your planned corrective actions at the next inspection.\u003C\u002Fp>\u003Cp>As described above, the verification activities you conducted failed to provide assurance that the hazards requiring a control, specifically the chemical hazard of heavy metals in the cinnamon apple sauce products you import, have been significantly minimized or prevented, as required by 21 CFR 1.506(c).\u003C\u002Fp>\u003Cp>Furthermore, per 21 CFR 1.506(e)(3), you must promptly review and assess the results of the verification activities that you conduct and document your review and assessment of the results of the verification activities. If the results do not provide adequate assurances that the hazards requiring a control in the food you obtain from the foreign supplier have been significantly minimized or prevented, you must take appropriate action in accordance with 21 CFR 1.508(a).\u003C\u002Fp>\u003Cp>2. You did not document that you promptly reevaluated a foreign supplier’s performance or the risk posed by a food when you became aware of new information about the foreign supplier’s performance or the risk posed by a food, as required by 21 CFR 1.505(c)(1). Specifically, our inspection found that you did not document that you promptly reevaluated your foreign supplier’s performance or the risk posed by a food when you became aware of the elevated levels of lead detected in the cinnamon apple sauce products you imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. At the inspection you were unable to provide documentation of your reevaluation of Austrofood's performance or the risk posed by the cinnamon apple sauce product you import. You told the FDA investigator that you did not have any documents or updates to your FSVP in response to the lead contamination event.\u003C\u002Fp>\u003Cp>3. You did not promptly investigate to determine whether your FSVP is adequate and, when appropriate, modify your FSVP after you determined that your foreign supplier produced food that is adulterated under section 402 or misbranded under section 403(w) (if applicable) of the Federal Food, Drug, and Cosmetic Act, in accordance with 21 CFR 1.508(b). If you determine that a foreign supplier of food that you import does not produce food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the Federal Food, Drug, and Cosmetic Act, if either is applicable, and the implementing regulations, or produces food that is adulterated under section 402 or misbranded under section 403(w) (if applicable) of the Federal Food, Drug, and Cosmetic Act, you must promptly investigate to determine whether your FSVP is adequate and, when appropriate, modify your FSVP, in accordance with 21 CFR 1.508(b). You must document any investigations, corrective actions, and changes to your FSVP that you undertake. Specifically, during our inspection you were unable to provide documentation of corrective actions and changes to your FSVP for the cinnamon apple sauce product imported from Austrofood after you determined this product from Austrofood was contaminated with lead and product was recalled.\u003C\u002Fp>\u003Cp>Further, on March 5, 2024, you offered for import into the United States apple cinnamon fruit puree product, from the same foreign supplier under a new brand, without having documented corrective actions or changes to your FSVP for this foreign supplier, in accordance with 21 CFR 1.508(b).\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003Cbr>\u003Cbr>You should take prompt action to address the above violations. If you do not promptly address them, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the cinnamon apple sauce imported from your foreign supplier Austrofood. We may place the food you import from the identified foreign supplier on DWPE when you import the product. You can find DWPE information relating to FSVP in Import Alert #99-41, “Detention Without Physical Examination (DWPE) of Human and Animal Foods Imported from Foreign Suppliers by Importers Who Are Not in Compliance with the Requirements of the Foreign Supplier Verification Program (FSVP) Regulation,” at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVPs, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Juliane Jung-Lau, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502, with a copy via electronic mail to WCID@fda.hhs.gov. If you have any questions regarding this letter, you may contact Ms. Jung-Lau via email at Juliane.Jung-Lau@fda.hhs.gov. Please reference CMS # 680631 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>Digitally signed by Lawton W.\u003Cbr>Lawton W. Lum -S Lum -S\u003Cbr>Date: 2024.11.05 15:07:25 -08'00'\u003Cbr>for\u003Cbr>Dr. Kathleen Turner Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nColleen D. Purcell-Kangas\n\nRecipient Title\n\nPresident\n\nPurcell International\n\n800 Ellinwood Way\n\nPleasant Hill, CA 94523-4703\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 9, 2024\nWarning Letter\nDear Ms. Purcell-Kangas:\nOn February 28, February 29, and March 6, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Purcell International, 800 Ellinwood Way, Pleasant Hill, CA 94523-4703. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe inspection was initiated in response to a multistate investigation involving elevated levels of lead in apple cinnamon fruit puree pouches (intended for infants as young as six months and the general public), manufactured by your foreign supplier Austrofood S.A.S. (Austrofood) of Ecuador. Apple cinnamon fruit puree pouches were subject to a Class 1 recall, initiated on October 29, 2023. The recall was in response to finished product samples of WanaBana brand ready-to-eat (RTE) apple cinnamon fruit puree packed in\nflexible pouches, collected by North Carolina Department of Health and Human Services (NCDHHS), that were found to contain extremely high concentrations of lead; the recall was expanded to include Schnucks and Weis brand cinnamon apple sauce. You imported the Schnucks and Weis brand Apple Sauce – Apple Cinnamon (cinnamon apple sauce) from your foreign supplier, Austrofood. We placed apple cinnamon fruit puree pouches from your foreign supplier on Import Alert #99-42, “Detention Without Physical Examination (DWPE) of Foods Due to Heavy Metal (Toxic Element) Contamination,” on November 6, 2023. You may view this alert at: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_1167.html.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier- verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We received your response to the FDA 483a, on March 29, 2024, describing corrective actions taken and planned by your firm and we address your response below.\nYour significant violations of the FSVP regulations are as follows:\n1. Your foreign supplier verification activities did not provide adequate assurance that the hazards requiring a control in the food you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). Specifically, you told our investigator that before the recall, you determined your verification activity for cinnamon apple sauce from Austrofood is (b)(4) third- party audit (onsite audit), in accordance with 21 CFR 1.506(e)(1)(i). We note that your determination, including the frequency with which the activity must be conducted, was not documented, as required by 21 CFR 1.506(d)(1)(i). Further, records of the onsite audits you provided, conducted before the recall in (b)(4) and (b)(4), did not address your supplier’s control of heavy metals, specifically lead, in cinnamon apple sauce. For example, the (b)(4) audit lists chemical hazard (heavy metals) as one of the hazards assessed by your supplier; however, controls for heavy metals were not addressed in the audit. The October 2023 audit mentions the technical sheet for ground cinnamon was reviewed; however, specifications or hazards associated with ground cinnamon were not addressed in the audit. The October 2023 audit states HACCP plans for fruit and vegetable purees packed in pouches were reviewed; however, the audit does not address whether heavy metals in cinnamon apple sauce was controlled.\nAdditionally, you told our investigator that in past shipments, external laboratory testing was used to verify lead levels in final product. In accordance with 21 CFR 1.506(d)(1)(ii)(B), you may determine sampling and testing of a food is an appropriate verification activity. You provided records of one occurrence of sampling and testing of the finished product of cinnamon apple sauce by a laboratory (b)(4) contracted by your supplier. The results you provided of the testing conducted in June 2023 of lot “05023:19 \u002F 05023:28” detected less than 0.08 mg\u002Fkg (0.08 ppm) lead. However, after you imported product into the United States, (b)(4) sampled and tested (b)(4) cinnamon apple sauce, lot “(b)(4)” and detected 1.44 ppm lead. The products analyzed by (b)(4) are from the same batch codes of cinnamon apple sauce that were recalled due to elevated levels of lead. The FDA reviewed and supports PDA’s analytical findings.\nWe acknowledge that you told our investigator that the discrepancy in analytical findings informed your plans to perform lab analysis of all lots of food imported from the supplier, including products that do not contain cinnamon, for a period of (b)(4), utilizing a third-party laboratory within the United States. We note that your determination of a verification activity, including the frequency with which the activity must be conducted, must be documented, as required by 21 CFR 1.506(d)(1)(i). We will verify your planned corrective actions at the next inspection.\nAs described above, the verification activities you conducted failed to provide assurance that the hazards requiring a control, specifically the chemical hazard of heavy metals in the cinnamon apple sauce products you import, have been significantly minimized or prevented, as required by 21 CFR 1.506(c).\nFurthermore, per 21 CFR 1.506(e)(3), you must promptly review and assess the results of the verification activities that you conduct and document your review and assessment of the results of the verification activities. If the results do not provide adequate assurances that the hazards requiring a control in the food you obtain from the foreign supplier have been significantly minimized or prevented, you must take appropriate action in accordance with 21 CFR 1.508(a).\n2. You did not document that you promptly reevaluated a foreign supplier’s performance or the risk posed by a food when you became aware of new information about the foreign supplier’s performance or the risk posed by a food, as required by 21 CFR 1.505(c)(1). Specifically, our inspection found that you did not document that you promptly reevaluated your foreign supplier’s performance or the risk posed by a food when you became aware of the elevated levels of lead detected in the cinnamon apple sauce products you imported from (b)(4). At the inspection you were unable to provide documentation of your reevaluation of Austrofood's performance or the risk posed by the cinnamon apple sauce product you import. You told the FDA investigator that you did not have any documents or updates to your FSVP in response to the lead contamination event.\n3. You did not promptly investigate to determine whether your FSVP is adequate and, when appropriate, modify your FSVP after you determined that your foreign supplier produced food that is adulterated under section 402 or misbranded under section 403(w) (if applicable) of the Federal Food, Drug, and Cosmetic Act, in accordance with 21 CFR 1.508(b). If you determine that a foreign supplier of food that you import does not produce food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the Federal Food, Drug, and Cosmetic Act, if either is applicable, and the implementing regulations, or produces food that is adulterated under section 402 or misbranded under section 403(w) (if applicable) of the Federal Food, Drug, and Cosmetic Act, you must promptly investigate to determine whether your FSVP is adequate and, when appropriate, modify your FSVP, in accordance with 21 CFR 1.508(b). You must document any investigations, corrective actions, and changes to your FSVP that you undertake. Specifically, during our inspection you were unable to provide documentation of corrective actions and changes to your FSVP for the cinnamon apple sauce product imported from Austrofood after you determined this product from Austrofood was contaminated with lead and product was recalled.\nFurther, on March 5, 2024, you offered for import into the United States apple cinnamon fruit puree product, from the same foreign supplier under a new brand, without having documented corrective actions or changes to your FSVP for this foreign supplier, in accordance with 21 CFR 1.508(b).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nYou should take prompt action to address the above violations. If you do not promptly address them, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the cinnamon apple sauce imported from your foreign supplier Austrofood. We may place the food you import from the identified foreign supplier on DWPE when you import the product. You can find DWPE information relating to FSVP in Import Alert #99-41, “Detention Without Physical Examination (DWPE) of Human and Animal Foods Imported from Foreign Suppliers by Importers Who Are Not in Compliance with the Requirements of the Foreign Supplier Verification Program (FSVP) Regulation,” at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVPs, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Juliane Jung-Lau, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502, with a copy via electronic mail to WCID@fda.hhs.gov. If you have any questions regarding this letter, you may contact Ms. Jung-Lau via email at Juliane.Jung-Lau@fda.hhs.gov. Please reference CMS # 680631 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\n\nSincerely,\nDigitally signed by Lawton W.\nLawton W. Lum -S Lum -S\nDate: 2024.11.05 15:07:25 -08'00'\nfor\nDr. Kathleen Turner Program Division Director\nDivision of West Coast Imports","Purcell International","purcell-international-680631-11052024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpurcell-international-680631-11052024","2026-10-26T08:09:45.448468+00:00","2024-12-10","680631","Colleen D. Purcell-Kangas","2026-08-19T17:40:01.769+00:00","Via Express Delivery","2024-11-05",{"id":142,"raw":143,"subject":39,"body_html":147,"body_text":148,"firm_name":149,"letter_id":150,"created_at":45,"fei_number":19,"letter_url":151,"updated_at":152,"action_type":22,"case_status":23,"posted_date":153,"marcs_cms_no":154,"product_type":51,"closeout_date":19,"issuing_office":38,"recipient_name":155,"body_fetched_at":156,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},3407,[144,145,146,38,39,13,13,13],"\u003Ctime datetime=\"2021-04-13T13:20:00Z\">04\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-06T04:00:00Z\">04\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjash-international-inc-613878-04062021\">Jash International, Inc\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Deepti Shah\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Jash International, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>105 Prairie Lake Rd. Ste. A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>East Dundee\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60118\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jashinternation@aol.com\"> jashinternation@aol.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cdiv>\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Deepti Shah,\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our records and determined that Jash International, Inc. is a domestic importer of cigarettes, cigars and pipe tobacco products for the purposes of section 919 of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) (21 U.S.C. § 387s) and subject to user fees in accordance with that provision. Section 919(b)(6) of the FD&amp;C Act (21 U.S.C. § 387s(b)(6)) requires that each domestic importer of certain tobacco products, including cigarettes, cigars and pipe tobacco products, remit payment of its user fee assessment by the last day of the applicable quarter.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to Pay Assessed User Fees\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that all regulated tobacco products imported by Jash International, Inc. are adulterated under section 902(4) of the FD&amp;C Act (21 U.S.C. § 387b(4)) because you have failed to pay user fees assessed to you as required by section 919 of the FD&amp;C Act (21 U.S.C. § 387s). Specifically, based on our records, you import tobacco products into the United States, you import products subject to user fees under section 919 of the FD&amp;C Act, and you were assessed user fees by FDA’s Office of Financial Management (OFM) on the dates indicated below. To date, FDA has not received payment from you for the invoices enumerated in the table below.\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ccaption>&nbsp;\u003C\u002Fcaption>\n\t\u003Cthead>\n\t\t\u003Ctr>\n\t\t\t\u003Cth>Fiscal Quarter(s)\u002FYear of Liability\u003C\u002Fth>\n\t\t\t\u003Cth>Assessment Invoice Date\u003C\u002Fth>\n\t\t\t\u003Cth>Assessment Due Date\u003C\u002Fth>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Fthead>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>1st Quarter 2018\u003C\u002Ftd>\n\t\t\t\u003Ctd>12\u002F1\u002F2017\u003C\u002Ftd>\n\t\t\t\u003Ctd>12\u002F31\u002F2017\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>2nd Quarter 2018\u003C\u002Ftd>\n\t\t\t\u003Ctd>3\u002F1\u002F2018\u003C\u002Ftd>\n\t\t\t\u003Ctd>3\u002F31\u002F2018\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>3rd Quarter 2018\u003C\u002Ftd>\n\t\t\t\u003Ctd>6\u002F1\u002F2018\u003C\u002Ftd>\n\t\t\t\u003Ctd>7\u002F1\u002F2018\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>4th Quarter 2018\u003C\u002Ftd>\n\t\t\t\u003Ctd>9\u002F1\u002F2018\u003C\u002Ftd>\n\t\t\t\u003Ctd>10\u002F1\u002F2018\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>1st, 2nd, and 3rd Quarter 2017\u003C\u002Ftd>\n\t\t\t\u003Ctd>5\u002F31\u002F2020\u003C\u002Ftd>\n\t\t\t\u003Ctd>6\u002F30\u002F2020\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>1st Quarter 2017\u003C\u002Ftd>\n\t\t\t\u003Ctd>5\u002F31\u002F2020\u003C\u002Ftd>\n\t\t\t\u003Ctd>6\u002F30\u002F2020\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>1st Quarter 2017\u003C\u002Ftd>\n\t\t\t\u003Ctd>8\u002F31\u002F2020\u003C\u002Ftd>\n\t\t\t\u003Ctd>9\u002F30\u002F2020\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>Section 919(b)(6) of the FD&amp;C Act (21 U.S.C. § 387s(b)(6)) requires that payments of all assessments must be made by the last day of the applicable quarter. Because you have failed to pay user fees assessed pursuant to section 919 of the FD&amp;C Act by the last day of the applicable quarter, or by the 30th day after final agency action on a resolution of any dispute as to the amount of fees assessed, regulated tobacco products imported by Jash International, Inc. are adulterated under section 902(4) of the FD&amp;C Act (21 U.S.C. § 387b(4)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)), the introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated is a prohibited act.\u003C\u002Fp>\n\n\u003Cp>In addition, compliance with the requirements of the FD&amp;C Act under section 910(a)(2)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(a)(2)(A)(i)) includes payment of assessed user fees as set forth in section 919 of the FD&amp;C Act. Accordingly, FDA is unable to issue an order finding a new tobacco product described in a pending or future substantial equivalence (SE) Report -- other than for products marketed between February 15, 2007 and March 22, 2011, and for which an SE report was submitted by March 22, 2011— to be substantially equivalent to the predicate tobacco product until a firm has paid its assessed fees in their entirety.\u003C\u002Fp>\n\n\u003Cp>Please note that entering a repayment plan for assessed user fees does not render a product compliant with the requirements of the FD&amp;C Act. A firm in arrears, even if on a repayment plan, “fails to pay a user fee assessed to such manufacturer or importer pursuant to section 919 by the date specified in section 919 or by the 30th day after final agency action on a resolution of any dispute as to the amount of such fee,” (section 902(4) of the FD&amp;C Act) and thus its products are adulterated.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions and your plan for maintaining compliance with the FD&amp;C Act. Your response should include:\u003C\u002Fp>\n\n\u003Cp>1. Documentation showing that you have paid or have contacted OFM at \u003Ca>userfees@fda.gov\u003C\u002Fa> for information on how to pay your assessed user fees and set up a plan to pay those fees.\u003C\u002Fp>\n\n\u003Cp>2. Documentation to show the steps you have taken to prevent similar violations from occurring again in the future.\u003C\u002Fp>\n\n\u003Cp>3. If your firm’s planned corrections will occur over time, please include a timetable for implementation of those activities.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, \u003Cstrong>ER2100098\u003C\u002Fstrong>, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>or\u003C\u002Fp>\n\n\u003Cp>ctpcompliance@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Kristina Peters, Office of Compliance and Enforcement, CTP, at \u003Cspan>(301) 796-4083\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or kristina.peters@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc\u003Cbr>\nRhonda A. Anderson\u003Cbr>\n2655 LeJeune Road, Suite 540\u003Cbr>\nCoral Gables, FL 33134\u003Cbr>\nrandersonlaw@gmail.com\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDeepti Shah\n\nJash International, Inc\n\n105 Prairie Lake Rd. Ste. A\n\nEast Dundee, IL 60118\n\nUnited States\n\njashinternation@aol.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Deepti Shah,\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our records and determined that Jash International, Inc. is a domestic importer of cigarettes, cigars and pipe tobacco products for the purposes of section 919 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. § 387s) and subject to user fees in accordance with that provision. Section 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that each domestic importer of certain tobacco products, including cigarettes, cigars and pipe tobacco products, remit payment of its user fee assessment by the last day of the applicable quarter.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nFailure to Pay Assessed User Fees\n\nFDA has determined that all regulated tobacco products imported by Jash International, Inc. are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)) because you have failed to pay user fees assessed to you as required by section 919 of the FD&C Act (21 U.S.C. § 387s). Specifically, based on our records, you import tobacco products into the United States, you import products subject to user fees under section 919 of the FD&C Act, and you were assessed user fees by FDA’s Office of Financial Management (OFM) on the dates indicated below. To date, FDA has not received payment from you for the invoices enumerated in the table below.\n\nFiscal Quarter(s)\u002FYear of Liability\nAssessment Invoice Date\nAssessment Due Date\n\n1st Quarter 2018\n12\u002F1\u002F2017\n12\u002F31\u002F2017\n\n2nd Quarter 2018\n3\u002F1\u002F2018\n3\u002F31\u002F2018\n\n3rd Quarter 2018\n6\u002F1\u002F2018\n7\u002F1\u002F2018\n\n4th Quarter 2018\n9\u002F1\u002F2018\n10\u002F1\u002F2018\n\n1st, 2nd, and 3rd Quarter 2017\n5\u002F31\u002F2020\n6\u002F30\u002F2020\n\n1st Quarter 2017\n5\u002F31\u002F2020\n6\u002F30\u002F2020\n\n1st Quarter 2017\n8\u002F31\u002F2020\n9\u002F30\u002F2020\n\nSection 919(b)(6) of the FD&C Act (21 U.S.C. § 387s(b)(6)) requires that payments of all assessments must be made by the last day of the applicable quarter. Because you have failed to pay user fees assessed pursuant to section 919 of the FD&C Act by the last day of the applicable quarter, or by the 30th day after final agency action on a resolution of any dispute as to the amount of fees assessed, regulated tobacco products imported by Jash International, Inc. are adulterated under section 902(4) of the FD&C Act (21 U.S.C. § 387b(4)).\n\nConclusion and Requested Actions\n\nUnder section 301(a) of the FD&C Act (21 U.S.C. § 331(a)), the introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated is a prohibited act.\n\nIn addition, compliance with the requirements of the FD&C Act under section 910(a)(2)(A)(i) of the FD&C Act (21 U.S.C. § 387j(a)(2)(A)(i)) includes payment of assessed user fees as set forth in section 919 of the FD&C Act. Accordingly, FDA is unable to issue an order finding a new tobacco product described in a pending or future substantial equivalence (SE) Report -- other than for products marketed between February 15, 2007 and March 22, 2011, and for which an SE report was submitted by March 22, 2011— to be substantially equivalent to the predicate tobacco product until a firm has paid its assessed fees in their entirety.\n\nPlease note that entering a repayment plan for assessed user fees does not render a product compliant with the requirements of the FD&C Act. A firm in arrears, even if on a repayment plan, “fails to pay a user fee assessed to such manufacturer or importer pursuant to section 919 by the date specified in section 919 or by the 30th day after final agency action on a resolution of any dispute as to the amount of such fee,” (section 902(4) of the FD&C Act) and thus its products are adulterated.\n\nIt is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions and your plan for maintaining compliance with the FD&C Act. Your response should include:\n\n1. Documentation showing that you have paid or have contacted OFM at userfees@fda.gov for information on how to pay your assessed user fees and set up a plan to pay those fees.\n\n2. Documentation to show the steps you have taken to prevent similar violations from occurring again in the future.\n\n3. If your firm’s planned corrections will occur over time, please include a timetable for implementation of those activities.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100098, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nor\n\nctpcompliance@fda.hhs.gov\n\nIf you have any questions about the content of this letter, please contact Kristina Peters, Office of Compliance and Enforcement, CTP, at (301) 796-4083 or kristina.peters@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc\n\nRhonda A. Anderson\n\n2655 LeJeune Road, Suite 540\n\nCoral Gables, FL 33134\n\nrandersonlaw@gmail.com","Jash International, Inc","jash-international-inc-613878-04062021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjash-international-inc-613878-04062021","2026-10-26T08:09:02.963419+00:00","2021-04-13","613878","Deepti Shah","2026-08-20T03:12:30.635+00:00",{"id":158,"raw":159,"subject":163,"body_html":164,"body_text":165,"firm_name":166,"letter_id":167,"created_at":168,"fei_number":19,"letter_url":169,"updated_at":170,"action_type":22,"case_status":23,"posted_date":171,"marcs_cms_no":172,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":173,"body_fetched_at":174,"delivery_method":175,"recipient_title":19,"reference_number":176,"action_taken_date":177,"medical_device_id":19,"response_letter_date":19},21923,[160,161,162,11,163,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-international-inc-733231-09292026\">Baxter International Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-132\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Andrew Hider\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Baxter International Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>One Baxter Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Deerfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 29, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-26-132\u003C\u002Fp>\u003Cp>To Andrew Hider:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Baxter Healthcare Corporation, FDA Establishment Identifier (FEI) 1416980, at 25212 W Illinois Route 120, Round Lake, from March 23 to April 2, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 23, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture various injectable drugs products including cephalosporins (a beta-lactam drug product) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products at your facility. You failed to ensure complete and comprehensive separation of cephalosporin and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products in this shared facility.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Complete and Comprehensive Separation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your facilities and controls were inadequate to prevent the conditions that would allow for cephalosporin contamination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs.\u003C\u002Fp>\u003Cp>Your building is divided into \u003Cstrong>(b)(4)\u003C\u002Fstrong> beta lactams, \u003Cstrong>(b)(4)\u003C\u002Fstrong> production. These building segments are separated by a physical wall that you consider to be fully sealed, along with dedicated HVAC units.\u003C\u002Fp>\u003Cp>However, since January 2025, your environmental monitoring (EM) program used to monitor containment of beta-lactam drug products has detected cephalosporin in several instances and in multiple areas of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> side of the building.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Cephalosporin Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>While your monitoring program detected recurring cross-contamination, it was inadequate to promptly detect loss of containment and cephalosporin contamination in your facility. For example:\u003C\u002Fp>\u003Cul>\u003Cli>EM sampling was insufficient in both number and location.\u003C\u002Fli>\u003Cli>Swab sampling qualification was inadequate to assure low-level recovery.\u003C\u002Fli>\u003Cli>Samples were evaluated beyond established solution stability time allowances.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These inadequacies create risk for underrepresentation of true contamination hazards throughout your facility, create potential for false negative results, and inhibit meaningful data collection upon which your quality unit (QU) can make sound risk-based decisions.\u003C\u002Fp>\u003Cp>A rigorous monitoring program is essential for facility qualification, early detection of contamination hazards, and timely corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>In addition, your testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products for potential contamination consisted of a single unit regardless of batch size. However, contamination is generally nonuniformly distributed. Results obtained from testing a small sample size are unlikely to detect contamination that may exist in a batch exposed to the contamination hazards identified at your firm. Consequently, substantial residual uncertainty remains regarding the actual variability of contamination that may exist in batches you produce.\u003C\u002Fp>\u003Cp>We also note that you mistakenly discarded multiple failing cephalosporin environmental samples before further analysis could be conducted.\u003C\u002Fp>\u003Cp>In your response, you commit to strengthen investigations into positive cephalosporin findings, create a tracking form to help prevent missed samples, and improve low-level recovery. Your response also indicates that significant uncertainty remains regarding the causes of the recurring findings of facility contamination. You indicate that personnel movement was a weakness in your containment strategy while adding that personnel movement is likely not the sole contributing factor.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to adequately address how you will ensure complete and comprehensive separation. You also failed to thoroughly reevaluate your original risk management decisions, including supportive risk assessments and associated risk controls, to ensure prevention of beta-lactam cross-contamination. Although your cephalosporin and \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas exist within the same external building structure that you claim is completely and comprehensively separated by a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, it is essential that your design completely precludes any potential for incidental air, personnel, materials, equipment, or other interaction that could be a vector of contamination. A rigorous quality risk management program should comprehensively assess the design and determine if it provides as much protection against cross-contamination as is achieved by manufacturing in a separate building.\u003C\u002Fp>\u003Cp>We note that data shared during our recall discussions revealed additional cephalosporin contamination events in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area, including as recently as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Contamination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with beta-lactam drugs presents a serious risk to patient safety, including potential life-threatening \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> responses can occur in susceptible patients exposed to \u003Cstrong>(b)(4)\u003C\u002Fstrong> beta-lactams. Therefore, no safe level of beta-lactam contamination has been determined to be a tolerable risk.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent evaluation of the sufficiency of facility modifications implemented in an attempt to achieve complete and comprehensive separation (e.g., physical wall, dedicated air handling) between cephalosporin and \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas.\u003C\u002Fli>\u003Cli>An updated comprehensive, independent risk assessment of all beta-lactam contamination hazards with respect to your procedures, equipment, and facilities, including but not limited to, the following:\u003Cbr>o Identification of all contamination hazards (e.g., personnel, material, air systems, infrastructure vulnerabilities).\u003Cbr>o Hazard identification using formal hazard identification tools.\u003Cbr>o Expanded risk-based EM including appropriate, scientifically justified, sampling methods, locations, and frequencies (e.g., inside production rooms, equipment surfaces, walls, contractor and operator garments, boots, shared forklifts trucks, shared lab cabinet, other potential cross-contamination locations), with consideration of all associated containment elements.\u003Cbr>o More responsive systems to vigilantly respond to any contamination, including enhanced trending systems.\u003Cbr>o Personnel flow and material flow (comprehensive mapping of all such potential interactions between all facilities that may introduce a potential hazard).\u003Cbr>o Scientifically justified sampling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug product batches.\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to design (e.g., facility changes) and explain how this CAPA plan will robustly remediate your deficiencies. Include a description of any residual risk that may remain following these remediations, and describe whether it enables risk acceptance. Also include a commitment to implement thorough change effectiveness activities and to revisit the risk assessment when necessary.\u003C\u002Fli>\u003Cli>A comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\u003C\u002Fli>\u003Cli>Full investigations and data pertaining to any failing cephalosporin samples that were discarded since August 2024, including but not limited to sampling location, date, recovery amount, and any extra testing that was to be performed.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)). Your firm also failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You operate \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing lines used to aseptically manufacture sterile injectable drug products for the U.S. market. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> were inadequately validated to ensure that they were capable of consistently \u003Cstrong>(b)(4)\u003C\u002Fstrong> interior surfaces of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines in preparation for aseptic production. In addition, your aseptic process simulations did not sufficiently represent worst-case conditions, and you lacked adequate sampling of your ISO 5 (Grade A) area.\u003C\u002Fp>\u003Cp>\u003Cem>Biological Indicator Recoveries and Inadequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Inadequacies in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process were demonstrated through a trend of routine recoveries of biological indicator (BI) growth at the completion of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle re-qualification (validation) runs since \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Notably, your acceptance criteria were inappropriate in that they allowed routine recovery of multiple BI survivors per re-qualification run. An adverse trend of numerous positive BIs were identified in multiple re-qualification cycles across multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines. For example, for line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, positive BIs occurred at numerous locations (\u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations) and the positive findings included multiple replicates per location (\u003Cstrong>(b)(4)\u003C\u002Fstrong> recoveries of \u003Cstrong>(b)(4)\u003C\u002Fstrong> replicates). In addition, other lines had similar substantial findings of positive BIs. However, you considered all re-qualification studies to be acceptable and did not further evaluate the excessive variability of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including the potential impact to product. These significant recurring BI failures indicate poor \u003Cstrong>(b)(4)\u003C\u002Fstrong> method efficacy and require further investigation.\u003C\u002Fp>\u003Cp>We also noted additional deficiencies in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> reliability. For example:\u003C\u002Fp>\u003Cul>\u003Cli>You lacked adequate scientific justification for BI locations.\u003C\u002Fli>\u003Cli>You allowed repetition of re-qualification cycles without proper investigation into observed BI growth.\u003C\u002Fli>\u003Cli>You did not align with technical references you cited in your procedures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We note that you recovered \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from an \u003Cstrong>(b)(4)\u003C\u002Fstrong> inside your \u003Cstrong>(b)(4)\u003C\u002Fstrong> during production.\u003C\u002Fp>\u003Cp>In your response, you commit to engaging a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help improve \u003Cstrong>(b)(4)\u003C\u002Fstrong>, revising acceptance criteria to align with industry standards, and initiating non-conformance reports to investigate the observed BI growth. You also commit to evaluating alternative \u003Cstrong>(b)(4)\u003C\u002Fstrong> technology.\u003C\u002Fp>\u003Cp>Your response is inadequate in that it does not provide sufficient detail or supporting documentation to describe how adequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> will be achieved during the interim period prior to completion of long-term remediation.\u003C\u002Fp>\u003Cp>Incomplete exposure of interior surfaces to \u003Cstrong>(b)(4)\u003C\u002Fstrong> compromises \u003Cstrong>(b)(4)\u003C\u002Fstrong> effectiveness and places your \u003Cstrong>(b)(4)\u003C\u002Fstrong> environment at risk. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Grade A) area is critical because sterile products are exposed during aseptic production and therefore vulnerable to contamination if operations are not well designed and diligently controlled. Aseptic processing operations should be designed and executed to minimize exposure of sterile articles to potential contamination hazards in the manufacturing operation. Flaws in the design or control of cleanrooms and aseptic processing operations can enable entry of contaminants into the critical \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing area and lead to product contamination.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Aseptic Process Simulation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The intervention of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was simulated approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> times during a media fill, but production records indicate a significantly higher occurrence of this intervention.\u003C\u002Fp>\u003Cp>In your response you commit to updating the minimum number of \u003Cstrong>(b)(4)\u003C\u002Fstrong> simulations to \u003Cstrong>(b)(4)\u003C\u002Fstrong> based on your 2026 retrospective review, which only covered approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response is inadequate as it does not ensure worst-case production activities and conditions are challenged across all \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug production, the state of process control and assurance of sterility cannot be accurately assessed.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing lines include critical operational steps conducted in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there was only a \u003Cstrong>(b)(4)\u003C\u002Fstrong> in one of these \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, surfaces were not monitored for microbiological contamination.\u003C\u002Fp>\u003Cp>Vigilant and responsive environmental monitoring programs provide meaningful information on the state of control of the aseptic processing operation and enable an early warning system that identifies emerging contamination hazards before sterility is compromised.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Airflow\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Although your \u003Cstrong>(b)(4)\u003C\u002Fstrong> configurations can vary (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> bag capacity, \u003Cstrong>(b)(4)\u003C\u002Fstrong> configuration), you lacked airflow visualization studies in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines. In addition, your airflow visualization studies were insufficient (e.g., worst-case \u003Cstrong>(b)(4)\u003C\u002Fstrong> conditions).\u003C\u002Fp>\u003Cp>We note that you have had a history of sporadic sterility test positives since 2013 (testing is routinely performed in a \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and persistent particulate contamination issues.\u003C\u002Fp>\u003Cp>Your airflow visualization studies also revealed substantial turbulence in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which critical process steps are performed. Your firm acknowledged turbulent non-unidirectional airflow within your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which houses processing equipment.\u003C\u002Fp>\u003Cp>Our overall findings indicate significant deficiencies in the design of your aseptic processing operation. Your current equipment, process, and airflow design pose excessive contamination risk.\u003C\u002Fp>\u003Cp>Turbulent airflow may be appropriate for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> that does not house aseptic processing equipment. In contrast, your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> that include processing line equipment.\u003C\u002Fp>\u003Cp>A strong quality system is essential to oversee design and construction of aseptic processing lines, cleanrooms, and supporting utilities, and to ensure ongoing proper operational control to safeguard against contamination hazards throughout the facility lifecycle.\u003C\u002Fp>\u003Cp>Well-designed aseptic processing \u003Cstrong>(b)(4)\u003C\u002Fstrong> represent a significant technological advance over traditional operational designs. Because all technologies have failure modes, it is essential to implement a robust design and control program that enables an ongoing state of control.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you commit to improving your EM program and performing airflow visualization studies on all of your lines. You also state that you will use data from these studies to identify locations for BIs and EM.\u003C\u002Fp>\u003Cp>Your response is inadequate as you lack a commitment to upgrade your manufacturing infrastructure, including equipment replacement, as part of your long-term remediation plan. In addition, the timeline for implementation of additional viable air monitoring in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is unclear.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> that includes vigilant monitoring to ensure an ongoing state of control.\u003C\u002Fli>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\u003Cbr>o All human interactions within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficiency of space for operations\u003Cbr>o Air quality in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area including, but not limited to, air unidirectionality\u003Cbr>o Facility layout\u003Cbr>o Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\u003Cbr>o \u003Cstrong>(b)(4)\u003C\u002Fstrong> practices and procedures (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> efficacy, appropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong> and configuration)\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will systematically remediate your deficient sterile manufacturing operations. Include detailed changes to the design of both your aseptic processing lines and cleanrooms. Your action plan should include both an interim plan as well as long-term steps to fully remediate your facility, equipment, and process design.\u003C\u002Fli>\u003Cli>An independent review, detailed report, CAPA, and timelines for remediation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> methods (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> parameters, optimized airflow, improved surface exposure). This comprehensive, independent analysis should incorporate any differences between the design and operation of each \u003Cstrong>(b)(4)\u003C\u002Fstrong> and its processing equipment (e.g., dimensions, orientation, \u003Cstrong>(b)(4)\u003C\u002Fstrong> design, air volume, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowls, bag capacity, etc.).\u003C\u002Fli>\u003Cli>An independent, comprehensive evaluation of airflow unidirectionality in your aseptic processing operations. Ensure smoke studies are conducted under dynamic conditions with thorough and complete assessments of aseptic processing line airflow unidirectionality, including the impact of aseptic interventions, worst-case \u003Cstrong>(b)(4)\u003C\u002Fstrong> pattern, and dynamic interactions with the surrounding cleanroom. Conduct these smoke studies after you remediate your aseptic operation and using proper practices (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> media) to appropriately visualize airflow.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your process simulation (e.g., media fill) program to ensure accurate simulations of commercial aseptic manufacturing operations, including, but not limited to, appropriate incorporation of worst-case conditions.\u003C\u002Fli>\u003Cli>A summary table of all EM (includes surfaces, air, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) results within your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines that revealed microbial growth since January 1, 2023. Include line sample location, date, colony forming unit (CFU) count, microorganism identification, and any associated investigations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your manual visual inspection program was inadequate to reliably detect defects and ensure your sterile injectable drug products were essentially free of visible particulates.\u003C\u002Fp>\u003Cp>For example, operators performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection were not properly qualified, as evidenced by the following:\u003C\u002Fp>\u003Cul>\u003Cli>Operators were not appropriately challenged to ensure they were capable of reliably detecting particulates within the lower end of the visible spectrum.\u003C\u002Fli>\u003Cli>Particulates in challenge kits were excessively large (e.g., greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong> microns), approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> times larger than what operators should be capable of reliably detecting.\u003C\u002Fli>\u003Cli>Operators’ rate of inspection was excessively fast (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> per unit) and did not align with the standards referenced in your procedures.\u003C\u002Fli>\u003Cli>Notably, you also demonstrated poor detection rates when you used significantly longer inspection times during Acceptable Quality Limit (AQL) sampling.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your approach to identifying product defects compromises reliable detection and the quality of data inputs to support batch release and CAPA decisions made by your quality unit.\u003C\u002Fp>\u003Cp>In addition, the significant particulate matter complaints received between 2023 to 2025 indicate an inadequate visual inspection program. For example, on May 9, 2025, after testing a returned cefazolin complainant sample you confirmed foreign particulate contamination was consistent with cardboard (approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> mm). Your investigation concluded that inadequacies of visual inspection were a contributing cause, but you did not implement sufficient CAPA to ensure remediation of your visual inspection program.\u003C\u002Fp>\u003Cp>Your investigation specifically cited potential for compromised product quality and potential patient safety risks, but stated that field action was not warranted. We acknowledge that on July 17, 2026, you agreed to voluntarily recall cefazolin, Lot LD175708, only after the Agency contacted you.\u003C\u002Fp>\u003Cp>In your response you commit to enhancing your visual inspection program including performing probability of detection (PoD) studies using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> per unit inspection duration.\u003C\u002Fp>\u003Cp>Your response is inadequate. You indicate that data from post-market complaint evaluations and retain sample reviews confirm that your controls remain effective. However, you have identified particulate matter in retain and complaint samples after product was released. In addition, your response does not adequately address the spike in particulate matter defects from 2024 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> defects) to 2025 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> defects). There remains a lack of assurance that your injectable drug products are essentially free from visible particulates while you work on long-term remediation.\u003C\u002Fp>\u003Cp>Visual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. At a minimum, personnel should reliably be capable of detecting particulates of \u003Cstrong>(b)(4)\u003C\u002Fstrong> microns or greater at a \u003Cstrong>(b)(4)\u003C\u002Fstrong>% probability of detection. It is important that any visible particulate contamination is appropriately evaluated and investigated. Particulates in injectable products should be avoided through appropriate preventive measures built into your design and production controls. When categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Extrinsic or foreign particulate contamination should occur very infrequently and trigger a thorough investigation and appropriate CAPA.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation, and the procedures governing them. Also include product-specific knowledge, process experience (e.g., thorough assessment of the spike of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate matter defects in 2025), deviation investigation analysis, and recall\u002Fcomplaint data. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness. Include a summary of the review and recommendations made by your independent consultant.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility that remains within expiry to meet the requirement of being essentially free of visible particles. This comprehensive review should include a review of all relevant in-process and finished product data obtained by your firm including all batch records.\u003C\u002Fli>\u003Cli>An interim plan for risk mitigation while you perform broader studies to improve your visual inspection program. Provide a detailed list of your risk mitigations (e.g., sampling plans and methods for your proposed destructive testing).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>There was a pattern of inadequate investigations into critical issues, including leaking drug products and sterility failures.\u003C\u002Fp>\u003Cp>\u003Cem>Leaking Units\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your investigations into the “systemic nature” of container-closure integrity failures lacked effective CAPA to address the significantly increased rate of leak defects in your injectable drug products. You did not implement sufficient CAPA to ensure remediation of your final inspection program. Further, since 2023, media fill units were found leaking during incubation and you have received numerous leak complaints for marketed products.\u003C\u002Fp>\u003Cp>All sterile drugs must be packaged using container-closure systems with robust protection that prevents the ingress of microorganisms. A product’s ability to maintain integrity throughout anticipated stresses and external factors during manufacture, storage, distribution, and consumer use is critical to ensure product quality and safety. Loss of container-closure integrity is a direct cause of non-sterility.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that strengthening your investigation system is warranted and you will evaluate whether \u003Cstrong>(b)(4)\u003C\u002Fstrong> container closure integrity testing (CCIT) could be an effective layered control. You also commit to a retrospective review of critical non-conformance reports (NCR) and laboratory investigations for the last year.\u003C\u002Fp>\u003Cp>Your response is inadequate. Limiting a retrospective review to \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacks adequate scientific justification as your leak trending data illustrated the leak rate has consistently increased annually from 2023 to 2026. You also do not sufficiently address how a lack of highly capable leak detection systems impacts already produced products, or sufficiently detail improvements to your CAPA system. In addition, data from your firm indicates that although leak rate has increased, the number of NCRs opened has decreased.\u003C\u002Fp>\u003Cp>\u003Cem>Sterility Failure\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your investigation into a 2025 sterility failure for cefazolin, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, assigned the root cause as a non-integral test container. Test records had been signed and dated indicating that container integrity was initially verified. However, after observing turbidity, you subsequently stated in your investigation that container integrity was not verified, classifying it as a “no-test.” Without conducting a Phase II investigation, you concluded there was no risk to the manufacturing process or finished product. You invalidated the sterility result without adequate scientific justification and released this lot in July 2025.\u003C\u002Fp>\u003Cp>Notably, the same container integrity problem had been observed in the sterility test of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you rejected.\u003C\u002Fp>\u003Cp>In addition, a “no-test” designation was used for an \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle requalification attempt that resulted in numerous positive BIs.\u003C\u002Fp>\u003Cp>In your response, you state your belief that the laboratory error of incubating non-integral sterility test containers was the definitive root cause. Your response is inadequate as it fails to address why your lab records described the test container as integral. It also fails to thoroughly address the lack of contemporaneous documentation of any subsequent deviation that could have theoretically occurred. You also commit to implementing a closed membrane sterility testing system in the future, but your proposal does not ensure timely remediation.\u003C\u002Fp>\u003Cp>Product contamination may go undetected for substantial periods if your firm employs unreliable sterility testing practices. It should also be noted that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and a prompt review of the qualification status of the aseptic process.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, \u003Cem>Q9(R1) Quality\u003C\u002Fem> \u003Cem>Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload, and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority, independence, and resources to effectively function. The assessment should also include, but not be limited to, the following:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for independent QU oversight throughout your CGMP operations to ensure satisfactory procedures and adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision, including all investigations\u003Cbr>o Oversight and approval of discharging of all QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also, describe how executive management supports robust quality assurance at your firm, including, but not limited to, timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\u003Cbr>o Staff competencies (including use of appropriate subject matter experts)\u003Cbr>o Written procedures\u003Cbr>o Scientific rigor and foundation\u003Cbr>o Scope determination\u003Cbr>o Root cause evaluations\u003Cbr>o CAPA effectiveness\u003Cbr>o Quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted\u003Cbr>o And, based on above, detailed systemic improvements to the investigation system\u003C\u002Fli>\u003Cli>An independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>Provide a comprehensive, independent process capability assessment of your aseptic processing lines, with special emphasis on the capability of critical operational steps, including but not limited to, all container-closure integrity failure modes, and any related CAPA to be initiated in response to the capability assessment.\u003C\u002Fli>\u003Cli>Perform a holistic assessment across your facilities for similar issues noted at this site and implement appropriate CAPA across your corporate network.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Observations at Multiple Sites\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous regulatory meeting held on January 15, 2025, FDA discussed similar CGMP violations at this facility. You proposed specific remediations for these violations in your response.\u003C\u002Fp>\u003Cp>FDA also cited similar CGMP violations at other facilities in your company’s network. These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>Your firm’s executive management remains responsible for fully resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On July 17, 2026, FDA held a teleconference with your firm and recommended that you voluntarily recall one lot of cefazolin and various \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs currently in distribution from the U.S. market, to which you agreed.\u003C\u002Fp>\u003Cp>The company announcement for the cardboard particulate recall was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbaxter-issues-voluntary-nationwide-recall-cefazolin-dextrose-injection-usp-2g-100ml-20mg-ml-single\u003C\u002Fp>\u003Cp>\u003Cstrong>Request for a Meeting with FDA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>After you submit your response to this warning letter, we recommend that you reach out to this office to arrange for a teleconference to discuss your corrective actions and preventive actions in detail. Direct your request to Kathryn Hall at CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Identify your written response with FEI 1416980 and ATTN: Compliance Officer Matthew Schnupp in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>Ivan Quadrio\u003Cbr>Site Director and Associate Vice President of Engineering\u003Cbr>Baxter Healthcare Corporation\u003Cbr>25212 W Il Route 120\u003Cbr>Round Lake, IL 60073\u003Cbr>Ivan_quadrio@baxter.com\u003C\u002Fp>\u003Cp>Scott Kaplan\u003Cbr>Head of Quality, Regulatory Affairs, and Patient Safety\u003Cbr>Baxter Healthcare Corporation\u003Cbr>1 Baxter Parkway\u003Cbr>Deerfield, IL 60015\u003Cbr>scott_kaplan@baxter.com\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n320-26-132\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Andrew Hider\n\nRecipient Title\n\nPresident and CEO\n\nBaxter International Inc.\n\nOne Baxter Parkway\n\nDeerfield, IL 60015\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 29, 2026\nWARNING LETTER\nReference number: 320-26-132\nTo Andrew Hider:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Baxter Healthcare Corporation, FDA Establishment Identifier (FEI) 1416980, at 25212 W Illinois Route 120, Round Lake, from March 23 to April 2, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 23, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)).\nYou manufacture various injectable drugs products including cephalosporins (a beta-lactam drug product) and (b)(4) drug products at your facility. You failed to ensure complete and comprehensive separation of cephalosporin and (b)(4) drug products in this shared facility.\nLack of Complete and Comprehensive Separation\nYour facilities and controls were inadequate to prevent the conditions that would allow for cephalosporin contamination of (b)(4) drugs.\nYour building is divided into (b)(4) beta lactams, (b)(4) production. These building segments are separated by a physical wall that you consider to be fully sealed, along with dedicated HVAC units.\nHowever, since January 2025, your environmental monitoring (EM) program used to monitor containment of beta-lactam drug products has detected cephalosporin in several instances and in multiple areas of the (b)(4) side of the building.\nInadequate Cephalosporin Monitoring\nWhile your monitoring program detected recurring cross-contamination, it was inadequate to promptly detect loss of containment and cephalosporin contamination in your facility. For example:\nEM sampling was insufficient in both number and location.\nSwab sampling qualification was inadequate to assure low-level recovery.\nSamples were evaluated beyond established solution stability time allowances.\nThese inadequacies create risk for underrepresentation of true contamination hazards throughout your facility, create potential for false negative results, and inhibit meaningful data collection upon which your quality unit (QU) can make sound risk-based decisions.\nA rigorous monitoring program is essential for facility qualification, early detection of contamination hazards, and timely corrective action and preventive action (CAPA).\nIn addition, your testing of (b)(4) drug products for potential contamination consisted of a single unit regardless of batch size. However, contamination is generally nonuniformly distributed. Results obtained from testing a small sample size are unlikely to detect contamination that may exist in a batch exposed to the contamination hazards identified at your firm. Consequently, substantial residual uncertainty remains regarding the actual variability of contamination that may exist in batches you produce.\nWe also note that you mistakenly discarded multiple failing cephalosporin environmental samples before further analysis could be conducted.\nIn your response, you commit to strengthen investigations into positive cephalosporin findings, create a tracking form to help prevent missed samples, and improve low-level recovery. Your response also indicates that significant uncertainty remains regarding the causes of the recurring findings of facility contamination. You indicate that personnel movement was a weakness in your containment strategy while adding that personnel movement is likely not the sole contributing factor.\nYour response is inadequate because it fails to adequately address how you will ensure complete and comprehensive separation. You also failed to thoroughly reevaluate your original risk management decisions, including supportive risk assessments and associated risk controls, to ensure prevention of beta-lactam cross-contamination. Although your cephalosporin and (b)(4) areas exist within the same external building structure that you claim is completely and comprehensively separated by a (b)(4), it is essential that your design completely precludes any potential for incidental air, personnel, materials, equipment, or other interaction that could be a vector of contamination. A rigorous quality risk management program should comprehensively assess the design and determine if it provides as much protection against cross-contamination as is achieved by manufacturing in a separate building.\nWe note that data shared during our recall discussions revealed additional cephalosporin contamination events in the (b)(4) area, including as recently as (b)(4).\nContamination of (b)(4) with beta-lactam drugs presents a serious risk to patient safety, including potential life-threatening (b)(4). (b)(4) responses can occur in susceptible patients exposed to (b)(4) beta-lactams. Therefore, no safe level of beta-lactam contamination has been determined to be a tolerable risk.\nIn response to this letter, provide:\nA comprehensive, independent evaluation of the sufficiency of facility modifications implemented in an attempt to achieve complete and comprehensive separation (e.g., physical wall, dedicated air handling) between cephalosporin and (b)(4) areas.\nAn updated comprehensive, independent risk assessment of all beta-lactam contamination hazards with respect to your procedures, equipment, and facilities, including but not limited to, the following:\no Identification of all contamination hazards (e.g., personnel, material, air systems, infrastructure vulnerabilities).\no Hazard identification using formal hazard identification tools.\no Expanded risk-based EM including appropriate, scientifically justified, sampling methods, locations, and frequencies (e.g., inside production rooms, equipment surfaces, walls, contractor and operator garments, boots, shared forklifts trucks, shared lab cabinet, other potential cross-contamination locations), with consideration of all associated containment elements.\no More responsive systems to vigilantly respond to any contamination, including enhanced trending systems.\no Personnel flow and material flow (comprehensive mapping of all such potential interactions between all facilities that may introduce a potential hazard).\no Scientifically justified sampling of (b)(4) finished drug product batches.\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to design (e.g., facility changes) and explain how this CAPA plan will robustly remediate your deficiencies. Include a description of any residual risk that may remain following these remediations, and describe whether it enables risk acceptance. Also include a commitment to implement thorough change effectiveness activities and to revisit the risk assessment when necessary.\nA comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\nFull investigations and data pertaining to any failing cephalosporin samples that were discarded since August 2024, including but not limited to sampling location, date, recovery amount, and any extra testing that was to be performed.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)). Your firm also failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\nYou operate (b)(4) processing lines used to aseptically manufacture sterile injectable drug products for the U.S. market. Your (b)(4) were inadequately validated to ensure that they were capable of consistently (b)(4) interior surfaces of your (b)(4) lines in preparation for aseptic production. In addition, your aseptic process simulations did not sufficiently represent worst-case conditions, and you lacked adequate sampling of your ISO 5 (Grade A) area.\nBiological Indicator Recoveries and Inadequate (b)(4) Validation\nInadequacies in your (b)(4) process were demonstrated through a trend of routine recoveries of biological indicator (BI) growth at the completion of (b)(4) cycle re-qualification (validation) runs since (b)(4).\nNotably, your acceptance criteria were inappropriate in that they allowed routine recovery of multiple BI survivors per re-qualification run. An adverse trend of numerous positive BIs were identified in multiple re-qualification cycles across multiple (b)(4) lines. For example, for line (b)(4), positive BIs occurred at numerous locations ((b)(4) of (b)(4) locations) and the positive findings included multiple replicates per location ((b)(4) recoveries of (b)(4) replicates). In addition, other lines had similar substantial findings of positive BIs. However, you considered all re-qualification studies to be acceptable and did not further evaluate the excessive variability of your (b)(4), including the potential impact to product. These significant recurring BI failures indicate poor (b)(4) method efficacy and require further investigation.\nWe also noted additional deficiencies in your (b)(4) reliability. For example:\nYou lacked adequate scientific justification for BI locations.\nYou allowed repetition of re-qualification cycles without proper investigation into observed BI growth.\nYou did not align with technical references you cited in your procedures.\nWe note that you recovered (b)(4), from an (b)(4) inside your (b)(4) during production.\nIn your response, you commit to engaging a (b)(4) to help improve (b)(4), revising acceptance criteria to align with industry standards, and initiating non-conformance reports to investigate the observed BI growth. You also commit to evaluating alternative (b)(4) technology.\nYour response is inadequate in that it does not provide sufficient detail or supporting documentation to describe how adequate (b)(4) will be achieved during the interim period prior to completion of long-term remediation.\nIncomplete exposure of interior surfaces to (b)(4) compromises (b)(4) effectiveness and places your (b)(4) environment at risk. The (b)(4) (Grade A) area is critical because sterile products are exposed during aseptic production and therefore vulnerable to contamination if operations are not well designed and diligently controlled. Aseptic processing operations should be designed and executed to minimize exposure of sterile articles to potential contamination hazards in the manufacturing operation. Flaws in the design or control of cleanrooms and aseptic processing operations can enable entry of contaminants into the critical (b)(4) processing area and lead to product contamination.\nInadequate Aseptic Process Simulation\nThe intervention of (b)(4) was simulated approximately (b)(4) times during a media fill, but production records indicate a significantly higher occurrence of this intervention.\nIn your response you commit to updating the minimum number of (b)(4) simulations to (b)(4) based on your 2026 retrospective review, which only covered approximately (b)(4). Your response is inadequate as it does not ensure worst-case production activities and conditions are challenged across all (b)(4) lines. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug production, the state of process control and assurance of sterility cannot be accurately assessed.\nInadequate Environmental Monitoring\nYour (b)(4) processing lines include critical operational steps conducted in (b)(4). However, there was only a (b)(4) in one of these (b)(4). In addition, surfaces were not monitored for microbiological contamination.\nVigilant and responsive environmental monitoring programs provide meaningful information on the state of control of the aseptic processing operation and enable an early warning system that identifies emerging contamination hazards before sterility is compromised.\nInadequate Airflow\nAlthough your (b)(4) configurations can vary (e.g., (b)(4) bag capacity, (b)(4) configuration), you lacked airflow visualization studies in (b)(4) of your (b)(4) lines. In addition, your airflow visualization studies were insufficient (e.g., worst-case (b)(4) conditions).\nWe note that you have had a history of sporadic sterility test positives since 2013 (testing is routinely performed in a (b)(4)) and persistent particulate contamination issues.\nYour airflow visualization studies also revealed substantial turbulence in your (b)(4), in which critical process steps are performed. Your firm acknowledged turbulent non-unidirectional airflow within your (b)(4), which houses processing equipment.\nOur overall findings indicate significant deficiencies in the design of your aseptic processing operation. Your current equipment, process, and airflow design pose excessive contamination risk.\nTurbulent airflow may be appropriate for a (b)(4) that does not house aseptic processing equipment. In contrast, your firm uses (b)(4) that include processing line equipment.\nA strong quality system is essential to oversee design and construction of aseptic processing lines, cleanrooms, and supporting utilities, and to ensure ongoing proper operational control to safeguard against contamination hazards throughout the facility lifecycle.\nWell-designed aseptic processing (b)(4) represent a significant technological advance over traditional operational designs. Because all technologies have failure modes, it is essential to implement a robust design and control program that enables an ongoing state of control.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn your response, you commit to improving your EM program and performing airflow visualization studies on all of your lines. You also state that you will use data from these studies to identify locations for BIs and EM.\nYour response is inadequate as you lack a commitment to upgrade your manufacturing infrastructure, including equipment replacement, as part of your long-term remediation plan. In addition, the timeline for implementation of additional viable air monitoring in the (b)(4) is unclear.\nIn response to this letter, provide:\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your (b)(4) that includes vigilant monitoring to ensure an ongoing state of control.\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\no All human interactions within the (b)(4) area (e.g., risk reduction or elimination of manual interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficiency of space for operations\no Air quality in the (b)(4) area including, but not limited to, air unidirectionality\no Facility layout\no Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\no (b)(4) practices and procedures (e.g., (b)(4) efficacy, appropriate (b)(4) and configuration)\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will systematically remediate your deficient sterile manufacturing operations. Include detailed changes to the design of both your aseptic processing lines and cleanrooms. Your action plan should include both an interim plan as well as long-term steps to fully remediate your facility, equipment, and process design.\nAn independent review, detailed report, CAPA, and timelines for remediation of your (b)(4) methods (e.g., (b)(4) parameters, optimized airflow, improved surface exposure). This comprehensive, independent analysis should incorporate any differences between the design and operation of each (b)(4) and its processing equipment (e.g., dimensions, orientation, (b)(4) design, air volume, (b)(4), (b)(4) bowls, bag capacity, etc.).\nAn independent, comprehensive evaluation of airflow unidirectionality in your aseptic processing operations. Ensure smoke studies are conducted under dynamic conditions with thorough and complete assessments of aseptic processing line airflow unidirectionality, including the impact of aseptic interventions, worst-case (b)(4) pattern, and dynamic interactions with the surrounding cleanroom. Conduct these smoke studies after you remediate your aseptic operation and using proper practices (e.g., (b)(4) media) to appropriately visualize airflow.\nA comprehensive, independent review of your process simulation (e.g., media fill) program to ensure accurate simulations of commercial aseptic manufacturing operations, including, but not limited to, appropriate incorporation of worst-case conditions.\nA summary table of all EM (includes surfaces, air, and (b)(4)) results within your (b)(4) lines that revealed microbial growth since January 1, 2023. Include line sample location, date, colony forming unit (CFU) count, microorganism identification, and any associated investigations.\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour manual visual inspection program was inadequate to reliably detect defects and ensure your sterile injectable drug products were essentially free of visible particulates.\nFor example, operators performing (b)(4) visual inspection were not properly qualified, as evidenced by the following:\nOperators were not appropriately challenged to ensure they were capable of reliably detecting particulates within the lower end of the visible spectrum.\nParticulates in challenge kits were excessively large (e.g., greater than (b)(4) microns), approximately (b)(4) times larger than what operators should be capable of reliably detecting.\nOperators’ rate of inspection was excessively fast (e.g., (b)(4) per unit) and did not align with the standards referenced in your procedures.\nNotably, you also demonstrated poor detection rates when you used significantly longer inspection times during Acceptable Quality Limit (AQL) sampling.\nYour approach to identifying product defects compromises reliable detection and the quality of data inputs to support batch release and CAPA decisions made by your quality unit.\nIn addition, the significant particulate matter complaints received between 2023 to 2025 indicate an inadequate visual inspection program. For example, on May 9, 2025, after testing a returned cefazolin complainant sample you confirmed foreign particulate contamination was consistent with cardboard (approximately (b)(4) mm). Your investigation concluded that inadequacies of visual inspection were a contributing cause, but you did not implement sufficient CAPA to ensure remediation of your visual inspection program.\nYour investigation specifically cited potential for compromised product quality and potential patient safety risks, but stated that field action was not warranted. We acknowledge that on July 17, 2026, you agreed to voluntarily recall cefazolin, Lot LD175708, only after the Agency contacted you.\nIn your response you commit to enhancing your visual inspection program including performing probability of detection (PoD) studies using the (b)(4) per unit inspection duration.\nYour response is inadequate. You indicate that data from post-market complaint evaluations and retain sample reviews confirm that your controls remain effective. However, you have identified particulate matter in retain and complaint samples after product was released. In addition, your response does not adequately address the spike in particulate matter defects from 2024 ((b)(4) defects) to 2025 ((b)(4) defects). There remains a lack of assurance that your injectable drug products are essentially free from visible particulates while you work on long-term remediation.\nVisual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. At a minimum, personnel should reliably be capable of detecting particulates of (b)(4) microns or greater at a (b)(4)% probability of detection. It is important that any visible particulate contamination is appropriately evaluated and investigated. Particulates in injectable products should be avoided through appropriate preventive measures built into your design and production controls. When categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Extrinsic or foreign particulate contamination should occur very infrequently and trigger a thorough investigation and appropriate CAPA.\nIn response to this letter, provide:\nA comprehensive, independent assessment and remediation plan of your systems for the visual inspection of sterile injectable drugs for defects, including the presence of particulate matter. The assessment should include acceptance and rejection criteria, personnel training, supervision, equipment and personnel qualification, equipment maintenance, and process validation, and the procedures governing them. Also include product-specific knowledge, process experience (e.g., thorough assessment of the spike of (b)(4) particulate matter defects in 2025), deviation investigation analysis, and recall\u002Fcomplaint data. Provide your detailed remediation action plan that includes dates by which each remediation activity will be completed and a periodic independent reassessment of the plan’s effectiveness. Include a summary of the review and recommendations made by your independent consultant.\nA comprehensive, independent assessment of each lot of sterile injectable drugs distributed from your facility that remains within expiry to meet the requirement of being essentially free of visible particles. This comprehensive review should include a review of all relevant in-process and finished product data obtained by your firm including all batch records.\nAn interim plan for risk mitigation while you perform broader studies to improve your visual inspection program. Provide a detailed list of your risk mitigations (e.g., sampling plans and methods for your proposed destructive testing).\n4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nThere was a pattern of inadequate investigations into critical issues, including leaking drug products and sterility failures.\nLeaking Units\nYour investigations into the “systemic nature” of container-closure integrity failures lacked effective CAPA to address the significantly increased rate of leak defects in your injectable drug products. You did not implement sufficient CAPA to ensure remediation of your final inspection program. Further, since 2023, media fill units were found leaking during incubation and you have received numerous leak complaints for marketed products.\nAll sterile drugs must be packaged using container-closure systems with robust protection that prevents the ingress of microorganisms. A product’s ability to maintain integrity throughout anticipated stresses and external factors during manufacture, storage, distribution, and consumer use is critical to ensure product quality and safety. Loss of container-closure integrity is a direct cause of non-sterility.\nIn your response, you acknowledge that strengthening your investigation system is warranted and you will evaluate whether (b)(4) container closure integrity testing (CCIT) could be an effective layered control. You also commit to a retrospective review of critical non-conformance reports (NCR) and laboratory investigations for the last year.\nYour response is inadequate. Limiting a retrospective review to (b)(4) lacks adequate scientific justification as your leak trending data illustrated the leak rate has consistently increased annually from 2023 to 2026. You also do not sufficiently address how a lack of highly capable leak detection systems impacts already produced products, or sufficiently detail improvements to your CAPA system. In addition, data from your firm indicates that although leak rate has increased, the number of NCRs opened has decreased.\nSterility Failure\nYour investigation into a 2025 sterility failure for cefazolin, lot (b)(4), assigned the root cause as a non-integral test container. Test records had been signed and dated indicating that container integrity was initially verified. However, after observing turbidity, you subsequently stated in your investigation that container integrity was not verified, classifying it as a “no-test.” Without conducting a Phase II investigation, you concluded there was no risk to the manufacturing process or finished product. You invalidated the sterility result without adequate scientific justification and released this lot in July 2025.\nNotably, the same container integrity problem had been observed in the sterility test of (b)(4), lot (b)(4), in (b)(4), which you rejected.\nIn addition, a “no-test” designation was used for an (b)(4) cycle requalification attempt that resulted in numerous positive BIs.\nIn your response, you state your belief that the laboratory error of incubating non-integral sterility test containers was the definitive root cause. Your response is inadequate as it fails to address why your lab records described the test container as integral. It also fails to thoroughly address the lack of contemporaneous documentation of any subsequent deviation that could have theoretically occurred. You also commit to implementing a closed membrane sterility testing system in the future, but your proposal does not ensure timely remediation.\nProduct contamination may go undetected for substantial periods if your firm employs unreliable sterility testing practices. It should also be noted that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and a prompt review of the qualification status of the aseptic process.\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9(R1) Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload, and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority, independence, and resources to effectively function. The assessment should also include, but not be limited to, the following:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for independent QU oversight throughout your CGMP operations to ensure satisfactory procedures and adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision, including all investigations\no Oversight and approval of discharging of all QU duties to ensure identity, strength, quality, and purity of all products\no Also, describe how executive management supports robust quality assurance at your firm, including, but not limited to, timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system, encompassing the following:\no Staff competencies (including use of appropriate subject matter experts)\no Written procedures\no Scientific rigor and foundation\no Scope determination\no Root cause evaluations\no CAPA effectiveness\no Quality unit lead functional roles, and oversight to ensure all phases of investigations are appropriately conducted\no And, based on above, detailed systemic improvements to the investigation system\nAn independent third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigation trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\nProvide a comprehensive, independent process capability assessment of your aseptic processing lines, with special emphasis on the capability of critical operational steps, including but not limited to, all container-closure integrity failure modes, and any related CAPA to be initiated in response to the capability assessment.\nPerform a holistic assessment across your facilities for similar issues noted at this site and implement appropriate CAPA across your corporate network.\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP.\nRepeat Observations at Multiple Sites\nIn a previous regulatory meeting held on January 15, 2025, FDA discussed similar CGMP violations at this facility. You proposed specific remediations for these violations in your response.\nFDA also cited similar CGMP violations at other facilities in your company’s network. These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\nYour firm’s executive management remains responsible for fully resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\nDrug Recall\nOn July 17, 2026, FDA held a teleconference with your firm and recommended that you voluntarily recall one lot of cefazolin and various (b)(4) drugs currently in distribution from the U.S. market, to which you agreed.\nThe company announcement for the cardboard particulate recall was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbaxter-issues-voluntary-nationwide-recall-cefazolin-dextrose-injection-usp-2g-100ml-20mg-ml-single\nRequest for a Meeting with FDA\nAfter you submit your response to this warning letter, we recommend that you reach out to this office to arrange for a teleconference to discuss your corrective actions and preventive actions in detail. Direct your request to Kathryn Hall at CDER-OC-OMQ-Communications@fda.hhs.gov.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter2. Identify your written response with FEI 1416980 and ATTN: Compliance Officer Matthew Schnupp in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc:\nIvan Quadrio\nSite Director and Associate Vice President of Engineering\nBaxter Healthcare Corporation\n25212 W Il Route 120\nRound Lake, IL 60073\nIvan_quadrio@baxter.com\nScott Kaplan\nHead of Quality, Regulatory Affairs, and Patient Safety\nBaxter Healthcare Corporation\n1 Baxter Parkway\nDeerfield, IL 60015\nscott_kaplan@baxter.com\n___________________________\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Baxter International Inc.","baxter-international-inc-733231-09292026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaxter-international-inc-733231-09292026","2026-11-17T01:02:03.701861+00:00","2026-10-20","733231","Mr. Andrew Hider","2026-10-27T01:19:00.064+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","320-26-132","2026-09-29",{"id":179,"raw":180,"subject":184,"body_html":185,"body_text":186,"firm_name":187,"letter_id":188,"created_at":189,"fei_number":19,"letter_url":190,"updated_at":191,"action_type":22,"case_status":23,"posted_date":192,"marcs_cms_no":193,"product_type":194,"closeout_date":19,"issuing_office":11,"recipient_name":195,"body_fetched_at":196,"delivery_method":76,"recipient_title":19,"reference_number":197,"action_taken_date":198,"medical_device_id":19,"response_letter_date":19},942,[181,182,183,11,184,13,13,13],"\u003Ctime datetime=\"2025-04-29T04:00:00Z\">04\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-14T04:00:00Z\">04\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosco-international-inc-701209-04142025\">Cosco International, Inc. \u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-65\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Peter M. Hoffman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cosco International, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1633 Sands Pl SE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marietta\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30067-8785\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-25-65\u003C\u002Fp>\u003Cp>April 14, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Hoffman:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosco International Inc, FEI 3000220439, at 1633 Sands Pl SE. Marietta, from October 15th to 25th 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, the drug products “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Additionally, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>We have not received a response from your firm stating the actions you are taking to address the deficiencies identified during the inspection and cited on our Form FDA 483.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Process Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You manufacture over-the-counter (OTC) drug products including topical drugs intended for wound treatment in children. You failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, your OTC drug products, Berberex Wound Gel, Asystem Pain Roll On, Forticept Antimicrobial Gel, and Forticept Antiseptic Ear Flush, were manufactured without adequate process qualification studies.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to perform appropriate cleaning validation studies for non-dedicated equipment used to manufacture your OTC drug products. For example, you manufacture products on shared equipment using active ingredients such as Menthol, Benzalkonium Chloride, Lidocaine, or Ketoconazole, in addition to cosmetic products. You failed to demonstrate that your cleaning procedures can prevent potential cross-contamination between the various drug and cosmetic products mixed and filled on the same shared equipment.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of the marketed drug products you produce.\u003C\u002Fli>\u003Cli>Process performance protocols and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>Timelines for completed PPQ for marketed drug products for which a state of control has not been adequately\u002Ffully established.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not have adequate stability data to demonstrate that the chemical and microbiological properties of your drug products met established specifications and remain acceptable throughout their labeled shelf-life. For example, you distributed drug products intended for wound treatment in children without conducting accelerated or long-term stability studies.\u003C\u002Fp>\u003Cp>Without appropriate stability studies, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked appropriate sampling and testing to ensure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water used as a component in your drug products is suitable for the intended use, including in drug products intended for wound treatment in children. Specifically, you did not perform adequate testing for bacteria, fungi, and objectionable microorganisms on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water (e.g., \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex (BCC), \u003Cem>Pseudomonas species\u003C\u002Fem>, etc.). In addition, neither of your test methods have been validated to demonstrate that they are equal to or superior to the compendial methodology. For example, you used \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> based microbiological test method, but you did not demonstrate that it was equivalent to or better than USP &lt;62&gt;. Your sampling plan was also not representative of daily use in manufacturing; it relied on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling point, despite your having \u003Cstrong>(b)(4)\u003C\u002Fstrong> points of use, vessels, and stages of treatment.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine and representative monitoring of microbial counts and identification of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\u003C\u002Fp>\u003Cp>Inadequate design, control, and\u002For maintenance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> water systems have led to contamination with BCC and other water-borne opportunistic pathogens. See FDA's guidance for industry, \u003Cem>Microbiological Quality Considerations in Non-Sterile Drug Manufacturing\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F152527\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of an adequate stability program (21 CFR 211.137).\u003C\u002Fli>\u003Cli>Establishment of adequate procedures for rejection or recertification of expired raw materials (21 CFR 211.87).\u003C\u002Fli>\u003Cli>Establishment of appropriate controls of computerized records and access permissions for authorized personnel (21 CFR 211.68(b)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\u003Cli>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Unapproved New Drug Violations and Misbranding Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>Carpe ANTIPERSPIRANT FOOT LOTION:\u003C\u002Fu>\u003Cbr>“Carpe . . . ANTIPERSPIRANT FOOT LOTION . . . CLINICALLY PROVEN TO REDUCE FOOT SWEAT . . . Directions . . . Wash and dry soles thoroughly before application . . . Apply a small, dime-sized amount of Carpe to soles . . . Rub Carpe into soles vigorously…” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>Carpe ANTIPERSPIRANT HAND LOTION:\u003C\u002Fu>\u003Cbr>“Carpe . . . ANTIPERSPIRANT HAND LOTION . . . CLINICALLY PROVEN TO REDUCE HAND SWEAT . . . Directions . . . Wash and dry hands thoroughly before application . . . Apply a small, pea-sized amount of Carpe to palms . . . Rub palms together vigorously…” [from the product label]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” is intended for use as a skin protectant drug product and “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” are intended for use as antiperspirant drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>\u003Cstrong>Skin Protectant Drug Product\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription skin protectant such as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” in order to be GRASE and not classified as new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, in this case, Over-the-Counter Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (hereafter referred to as “M016”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” does not conform to the conditions specified in M016 for the reasons described below.\u003C\u002Fp>\u003Cp>Specifically, the combination of active ingredients identified in the product label for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” does not conform to the conditions of use set forth in M016. For example, the product includes a combination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> as active ingredients in the same drug product. While each active ingredient is permitted by M016 individually at the listed concentration, the monograph does not permit this combination of active ingredients in a single drug product [see M016.20(a)].\u003C\u002Fp>\u003Cp>Thus, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” product does not comply with the applicable conditions specified in M016 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no application in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Antiperspirant Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>With respect to nonprescription antiperspirant drug products such as “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph Over-the-Counter Monograph M019: Antiperspirant Drug Products for Over-the-Counter Human Use (henceforth “M019”).1 However, “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” do not conform to the conditions specified in M019 for the reasons described below.\u003C\u002Fp>\u003Cp>As labeled, “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” have intended uses that are not permitted for antiperspirant drug products. For example, claims on these products for use as an antiperspirant on feet and hands, respectively, are not permitted by M019 or any other final administrative order in accordance with section 505G. M019 requires that the directions for use for antiperspirant products state “apply to underarms only” [see M019.50(d)].\u003C\u002Fp>\u003Cp>Thus, the “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” products do not comply with the applicable conditions specified in M019 and have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000220439 and ATTN: Zachary Bogorad.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M016 and M019 reflect the conditions set forth in the relevant final orders established and in effect under section 505G; see Order IDs OTC000005 and OTC000015, respectively, available at FDA’s website OTC Monographs @ FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-65\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Peter M. Hoffman\n\nRecipient Title\n\nChief Operating Officer\n\nCosco International, Inc.\n\n1633 Sands Pl SE\n\nMarietta, GA 30067-8785\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-65\nApril 14, 2025\nDear Mr. Hoffman:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosco International Inc, FEI 3000220439, at 1633 Sands Pl SE. Marietta, from October 15th to 25th 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, the drug products “(b)(4),” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Additionally, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nWe have not received a response from your firm stating the actions you are taking to address the deficiencies identified during the inspection and cited on our Form FDA 483.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nLack of Process Validation\nYou manufacture over-the-counter (OTC) drug products including topical drugs intended for wound treatment in children. You failed to adequately validate your manufacturing processes to demonstrate that your processes are reproducible and controlled to consistently yield drug products of uniform character and quality. For example, your OTC drug products, Berberex Wound Gel, Asystem Pain Roll On, Forticept Antimicrobial Gel, and Forticept Antiseptic Ear Flush, were manufactured without adequate process qualification studies.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nLack of Cleaning Validation\nYou failed to perform appropriate cleaning validation studies for non-dedicated equipment used to manufacture your OTC drug products. For example, you manufacture products on shared equipment using active ingredients such as Menthol, Benzalkonium Chloride, Lidocaine, or Ketoconazole, in addition to cosmetic products. You failed to demonstrate that your cleaning procedures can prevent potential cross-contamination between the various drug and cosmetic products mixed and filled on the same shared equipment.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of the marketed drug products you produce.\nProcess performance protocols and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nTimelines for completed PPQ for marketed drug products for which a state of control has not been adequately\u002Ffully established.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (211.166(a)).\nYour firm did not have adequate stability data to demonstrate that the chemical and microbiological properties of your drug products met established specifications and remain acceptable throughout their labeled shelf-life. For example, you distributed drug products intended for wound treatment in children without conducting accelerated or long-term stability studies.\nWithout appropriate stability studies, you lack adequate scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\nIn your response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability.\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (211.160(b)).\nYou lacked appropriate sampling and testing to ensure the (b)(4) water used as a component in your drug products is suitable for the intended use, including in drug products intended for wound treatment in children. Specifically, you did not perform adequate testing for bacteria, fungi, and objectionable microorganisms on your (b)(4) water (e.g., Burkholderia cepacia complex (BCC), Pseudomonas species, etc.). In addition, neither of your test methods have been validated to demonstrate that they are equal to or superior to the compendial methodology. For example, you used (b)(4), a (b)(4) based microbiological test method, but you did not demonstrate that it was equivalent to or better than USP \u003C62>. Your sampling plan was also not representative of daily use in manufacturing; it relied on a (b)(4) sampling point, despite your having (b)(4) points of use, vessels, and stages of treatment.\n(b)(4) water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine and representative monitoring of microbial counts and identification of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\nInadequate design, control, and\u002For maintenance of (b)(4) water systems have led to contamination with BCC and other water-borne opportunistic pathogens. See FDA's guidance for industry, Microbiological Quality Considerations in Non-Sterile Drug Manufacturing https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F152527\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces water that meets (b)(4) Water, (b)(4) monograph specifications and appropriate microbial limits.\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA comprehensive, independent assessment of your water system design, control, and maintenance.\nA (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\nEstablishment of an adequate stability program (21 CFR 211.137).\nEstablishment of adequate procedures for rejection or recertification of expired raw materials (21 CFR 211.87).\nEstablishment of appropriate controls of computerized records and access permissions for authorized personnel (21 CFR 211.68(b)).\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nIn your response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nUnapproved New Drug Violations and Misbranding Drug Violations\n“(b)(4),” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “(b)(4),” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n(b)(4):\n“(b)(4)” [from the product label]\nCarpe ANTIPERSPIRANT FOOT LOTION:\n“Carpe . . . ANTIPERSPIRANT FOOT LOTION . . . CLINICALLY PROVEN TO REDUCE FOOT SWEAT . . . Directions . . . Wash and dry soles thoroughly before application . . . Apply a small, dime-sized amount of Carpe to soles . . . Rub Carpe into soles vigorously…” [from the product label]\nCarpe ANTIPERSPIRANT HAND LOTION:\n“Carpe . . . ANTIPERSPIRANT HAND LOTION . . . CLINICALLY PROVEN TO REDUCE HAND SWEAT . . . Directions . . . Wash and dry hands thoroughly before application . . . Apply a small, pea-sized amount of Carpe to palms . . . Rub palms together vigorously…” [from the product label]\nBased on the above labeling evidence, “(b)(4)” is intended for use as a skin protectant drug product and “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” are intended for use as antiperspirant drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nSkin Protectant Drug Product\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription skin protectant such as “(b)(4),” in order to be GRASE and not classified as new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, in this case, Over-the-Counter Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (hereafter referred to as “M016”).1 However, “(b)(4)” does not conform to the conditions specified in M016 for the reasons described below.\nSpecifically, the combination of active ingredients identified in the product label for “(b)(4)” does not conform to the conditions of use set forth in M016. For example, the product includes a combination of (b)(4) and (b)(4) as active ingredients in the same drug product. While each active ingredient is permitted by M016 individually at the listed concentration, the monograph does not permit this combination of active ingredients in a single drug product [see M016.20(a)].\nThus, the “(b)(4)” product does not comply with the applicable conditions specified in M016 and has not otherwise been found GRASE.2 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no application in effect for this product, this product is an unapproved new drug.\nThe introduction or delivery for introduction of this unapproved new drug product into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nAntiperspirant Drug Products\nWith respect to nonprescription antiperspirant drug products such as “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph Over-the-Counter Monograph M019: Antiperspirant Drug Products for Over-the-Counter Human Use (henceforth “M019”).1 However, “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” do not conform to the conditions specified in M019 for the reasons described below.\nAs labeled, “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” have intended uses that are not permitted for antiperspirant drug products. For example, claims on these products for use as an antiperspirant on feet and hands, respectively, are not permitted by M019 or any other final administrative order in accordance with section 505G. M019 requires that the directions for use for antiperspirant products state “apply to underarms only” [see M019.50(d)].\nThus, the “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” products do not comply with the applicable conditions specified in M019 and have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, “(b)(4),” “Carpe ANTIPERSPIRANT FOOT LOTION,” and “Carpe ANTIPERSPIRANT HAND LOTION” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000220439 and ATTN: Zachary Bogorad.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 M016 and M019 reflect the conditions set forth in the relevant final orders established and in effect under section 505G; see Order IDs OTC000005 and OTC000015, respectively, available at FDA’s website OTC Monographs @ FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the “(b)(4)” product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the “Carpe ANTIPERSPIRANT FOOT LOTION” and “Carpe ANTIPERSPIRANT HAND LOTION” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Cosco International, Inc.","cosco-international-inc-701209-04142025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosco-international-inc-701209-04142025","2026-10-26T08:08:18.298654+00:00","2025-04-29","701209","Drugs Over-the-Counter Drugs","Mr. Peter M. Hoffman","2026-08-19T16:49:56.231+00:00","320-25-65","2025-04-14",{"id":200,"raw":201,"subject":163,"body_html":205,"body_text":206,"firm_name":207,"letter_id":208,"created_at":132,"fei_number":19,"letter_url":209,"updated_at":210,"action_type":22,"case_status":23,"posted_date":211,"marcs_cms_no":212,"product_type":26,"closeout_date":19,"issuing_office":63,"recipient_name":213,"body_fetched_at":214,"delivery_method":76,"recipient_title":19,"reference_number":19,"action_taken_date":215,"medical_device_id":19,"response_letter_date":19},1413,[202,203,204,63,163,13,13,13],"\u003Ctime datetime=\"2024-06-18T13:20:00Z\">06\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-12T04:00:00Z\">06\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flandy-international-679066-06122024\">Landy International\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Yong (Roger) Ding\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Landy International\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 192-196 Tianfeng Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jimei Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Xiamen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fujian Sheng\u003C\u002Fspan>, \u003Cspan>361021\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-43\u003C\u002Fp>\n\n\u003Cp>June 12, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Ding:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Landy International, FEI 3005698871, at No. 192-196, Tianfeng Road, Jimei District, Xiamen, from December 11 to 14, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 29, 2023 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During the inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) hand sanitizers drug products.1 Your firm failed to adequately test batches of your hand sanitizer drug products for the identity and strength of your active ingredient, ethanol, before release and distribution. This is a repeat observation from the previous January 2017 FDA inspection.\u003C\u002Fp>\n\n\u003Cp>In your response, you state “21CFR211.110 was not fully understood” by your employees and that you will conduct training on 21 CFR part 211. You also state you will perform testing on samples of finished batches that remained in your warehouse. Your response is inadequate. You failed to provide sufficient details of your corrective actions, cited the incorrect regulatory requirement, and did not commit to performing a risk assessment of products released without appropriate assay testing.\u003C\u002Fp>\n\n\u003Cp>Because you lacked adequate testing of each batch of your drug product, you do not know whether they conform to all appropriate finished product specifications and are suitable for release and distribution.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>\n&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all&nbsp;appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Ethanol\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You also failed to adequately test your incoming ethanol, used as an active pharmaceutical ingredient, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In your response, you state “21CFR211.84 was not fully understood” by your employees, that you will conduct training, and that you will perform identity or impurities testing on the lots of components that remain in your warehouse. Your response is inadequate. You did not discuss how you will verify the reliability of your suppliers’ COA, nor how you will perform qualification of your suppliers. Further, you did not consider retrospective identity testing of reserve samples, or assessment by other methods, of the components used in your OTC drug products that were manufactured, distributed, and remain within expiry.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003Cbr>\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003Cbr>\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003Cbr>\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003Cbr>\n• A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003Cbr>\n• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003Cbr>\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately design, monitor, and maintain your water system to ensure it was suitable for use in the manufacture of your drug products. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system was not continuously circulated, and the pipes were not under pressure. Stagnant water and lack of water pressure enable bacteria to cling to walls and form biofilms. Notably, biofilm was observed in your water storage tanks. Nevertheless, your firm used water from the storage tank observed with biofilm to manufacture drug products that were later released. When asked about the biofilm during the inspection, you stated that microbial growth was inevitable in the water storage tanks and your firm could not control it. Moreover, numerous leaks and pooling water were observed at various points in your water system. Leaks and pooling water can allow filth and microorganisms to grow and spread throughout the manufacturing areas.\u003C\u002Fp>\n\n\u003Cp>You also failed to provide justification for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and monitoring schedules, and your water system cleaning logs did not include appropriate details such as cleaning solutions and contact time.\u003C\u002Fp>\n\n\u003Cp>In your response, you state FDA regulations “were not fully understood” and that you would conduct training. You also state you will conduct an overhaul of your water system, including revalidating the system and revisions to your written procedures. You will also conduct microbiological testing on reserve samples for products distributed to the U.S. market and failing batches will be recalled and destroyed. Your response is inadequate. You did not adequately describe details of your overhaul and revisions to your procedures to ensure your water system will consistently produce water that is appropriate for its intended use.\u003C\u002Fp>\n\n\u003Cp>Water is a major ingredient in many of your drug products, which include aqueous-based dosage forms. It is essential that you employ a water system that is robustly designed, and that you effectively control, maintain, and monitor the system to ensure it consistently produces water suitable for pharmaceutical use. (See also 21 CFR 211.113(a) and 211.160(b)).\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003Cbr>\n• A comprehensive, independent assessment of your water system design, control, and maintenance.\u003Cbr>\n• A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits.\u003Cbr>\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003Cbr>\n• A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your stand-alone gas chromatogram (GC) computer system lacked appropriate controls, such as an audit trail and individual log-in access to prevent the deletion of data. For example, investigators found numerous analysis reports, test methods, raw data calibration, and system directories in the GC computer’s recycling bin. Additionally, your laboratory personnel used a shared password, located in an unsecured drawer, to access the GC software.\u003C\u002Fp>\n\n\u003Cp>In your response, you state “21 CFR 211.68 was not fully understood,” that you will conduct training, and conduct a retrospective review of deleted files and records. You will also contact the supplier of the software to upgrade, as needed, to ensure audit trail functionality, in addition to validating the software. Your response is inadequate because it did not provide sufficient details describing how you will fully secure your GC software and associated stand-alone computer. You did not discuss user access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\u003C\u002Fp>\n\n\u003Cp>Your response also did not describe how you will ensure the integrity of the data generated by your computerized systems in the interim, prior to the full implementation of your corrections.\u003C\u002Fp>\n\n\u003Cp>It is essential that your firm keep track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FData-Integrity-and-Compliance-With-Current-Good-Manufacturing-Practice-Guidance-for-Industry.pdf.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain an independent third-party qualified consultant to assist in your remediation.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>\n&nbsp; &nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; &nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; &nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003Cbr>\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\n• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003Cbr>\n&nbsp; &nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; &nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; &nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; &nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; &nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; &nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; &nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&amp;C Act (21 U.S.C. 361(c)) if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetic you manufacture to be adulterated. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)) it is a prohibited act to introduce, or deliver for introduction into interstate commerce, a cosmetic that is adulterated.\u003C\u002Fp>\n\n\u003Cp>Further, your facility may be subject to requirements under the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection, dated January 9 to 13, 2017, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on May 24, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Landy International, FEI 3005698871, at No. 192-196, Tianfeng Road, Jimei District Xiamen, Fujian, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005698871 and ATTN: Daniel W. Brisker.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered US Agent:\u003Cbr>\nApax International, Inc\u003Cbr>\n6775 Verde Ridge Rd\u003Cbr>\nRancho Palos Verdes, California\u003Cbr>\n90275-4648\u003Cbr>\njames@sino2us.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Landy International’s hand sanitizer products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Yong (Roger) Ding\n\nRecipient Title\n\nPresident\n\nLandy International\n\nNo. 192-196 Tianfeng Road\n\nJimei Qu\n\nXiamen Shi\n\nFujian Sheng, 361021\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-43\n\nJune 12, 2024\n\nDear Mr. Ding:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Landy International, FEI 3005698871, at No. 192-196, Tianfeng Road, Jimei District, Xiamen, from December 11 to 14, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 29, 2023 response to our Form FDA 483 in detail.\n\nDuring the inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm manufactures over-the-counter (OTC) hand sanitizers drug products.1 Your firm failed to adequately test batches of your hand sanitizer drug products for the identity and strength of your active ingredient, ethanol, before release and distribution. This is a repeat observation from the previous January 2017 FDA inspection.\n\nIn your response, you state “21CFR211.110 was not fully understood” by your employees and that you will conduct training on 21 CFR part 211. You also state you will perform testing on samples of finished batches that remained in your warehouse. Your response is inadequate. You failed to provide sufficient details of your corrective actions, cited the incorrect regulatory requirement, and did not commit to performing a risk assessment of products released without appropriate assay testing.\n\nBecause you lacked adequate testing of each batch of your drug product, you do not know whether they conform to all appropriate finished product specifications and are suitable for release and distribution.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2).\n\nYou failed to perform adequate identity testing of each component lot used in the manufacture of your OTC drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nEthanol\n\nYou also failed to adequately test your incoming ethanol, used as an active pharmaceutical ingredient, for methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nGlycerin\n\nYou failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components2 includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn your response, you state “21CFR211.84 was not fully understood” by your employees, that you will conduct training, and that you will perform identity or impurities testing on the lots of components that remain in your warehouse. Your response is inadequate. You did not discuss how you will verify the reliability of your suppliers’ COA, nor how you will perform qualification of your suppliers. Further, you did not consider retrospective identity testing of reserve samples, or assessment by other methods, of the components used in your OTC drug products that were manufactured, distributed, and remain within expiry.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\n\nIn your response, provide:\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n• A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n\n• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to adequately design, monitor, and maintain your water system to ensure it was suitable for use in the manufacture of your drug products. Your (b)(4) water system was not continuously circulated, and the pipes were not under pressure. Stagnant water and lack of water pressure enable bacteria to cling to walls and form biofilms. Notably, biofilm was observed in your water storage tanks. Nevertheless, your firm used water from the storage tank observed with biofilm to manufacture drug products that were later released. When asked about the biofilm during the inspection, you stated that microbial growth was inevitable in the water storage tanks and your firm could not control it. Moreover, numerous leaks and pooling water were observed at various points in your water system. Leaks and pooling water can allow filth and microorganisms to grow and spread throughout the manufacturing areas.\n\nYou also failed to provide justification for your (b)(4) and (b)(4) cleaning and monitoring schedules, and your water system cleaning logs did not include appropriate details such as cleaning solutions and contact time.\n\nIn your response, you state FDA regulations “were not fully understood” and that you would conduct training. You also state you will conduct an overhaul of your water system, including revalidating the system and revisions to your written procedures. You will also conduct microbiological testing on reserve samples for products distributed to the U.S. market and failing batches will be recalled and destroyed. Your response is inadequate. You did not adequately describe details of your overhaul and revisions to your procedures to ensure your water system will consistently produce water that is appropriate for its intended use.\n\nWater is a major ingredient in many of your drug products, which include aqueous-based dosage forms. It is essential that you employ a water system that is robustly designed, and that you effectively control, maintain, and monitor the system to ensure it consistently produces water suitable for pharmaceutical use. (See also 21 CFR 211.113(a) and 211.160(b)).\n\nIn response to this letter, provide:\n\n• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\n• A comprehensive, independent assessment of your water system design, control, and maintenance.\n\n• A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits.\n\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\n• A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\n4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour stand-alone gas chromatogram (GC) computer system lacked appropriate controls, such as an audit trail and individual log-in access to prevent the deletion of data. For example, investigators found numerous analysis reports, test methods, raw data calibration, and system directories in the GC computer’s recycling bin. Additionally, your laboratory personnel used a shared password, located in an unsecured drawer, to access the GC software.\n\nIn your response, you state “21 CFR 211.68 was not fully understood,” that you will conduct training, and conduct a retrospective review of deleted files and records. You will also contact the supplier of the software to upgrade, as needed, to ensure audit trail functionality, in addition to validating the software. Your response is inadequate because it did not provide sufficient details describing how you will fully secure your GC software and associated stand-alone computer. You did not discuss user access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\n\nYour response also did not describe how you will ensure the integrity of the data generated by your computerized systems in the interim, prior to the full implementation of your corrections.\n\nIt is essential that your firm keep track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002Fdrugs\u002Fpublished\u002FData-Integrity-and-Compliance-With-Current-Good-Manufacturing-Practice-Guidance-for-Industry.pdf.\n\nWe strongly recommend that you retain an independent third-party qualified consultant to assist in your remediation.\n\nIn response to this letter, provide:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\nCosmetics Manufactured for Distribution in the United States\n\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&C Act (21 U.S.C. 361(c)) if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetic you manufacture to be adulterated. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)) it is a prohibited act to introduce, or deliver for introduction into interstate commerce, a cosmetic that is adulterated.\n\nFurther, your facility may be subject to requirements under the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nRepeat Observations at Facility\n\nIn a previous inspection, dated January 9 to 13, 2017, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on May 24, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Landy International, FEI 3005698871, at No. 192-196, Tianfeng Road, Jimei District Xiamen, Fujian, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005698871 and ATTN: Daniel W. Brisker.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered US Agent:\n\nApax International, Inc\n\n6775 Verde Ridge Rd\n\nRancho Palos Verdes, California\n\n90275-4648\n\njames@sino2us.com\n\n______________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Landy International’s hand sanitizer products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 Components with higher risk of DEG or EG contamination compared to other drug components.","Landy International","landy-international-679066-06122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flandy-international-679066-06122024","2026-10-26T08:09:12.342542+00:00","2024-06-18","679066","Mr. Yong (Roger) Ding","2026-08-20T00:01:43.729+00:00","2024-06-12",{"id":217,"raw":218,"subject":222,"body_html":223,"body_text":224,"firm_name":225,"letter_id":226,"created_at":90,"fei_number":19,"letter_url":227,"updated_at":228,"action_type":22,"case_status":23,"posted_date":229,"marcs_cms_no":230,"product_type":26,"closeout_date":19,"issuing_office":63,"recipient_name":231,"body_fetched_at":232,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":233,"medical_device_id":19,"response_letter_date":19},2805,[219,220,221,63,222,13,13,13],"\u003Ctime datetime=\"2022-03-17T14:00:00Z\">03\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-15T04:00:00Z\">03\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiotech-international-llc-617715-03152022\">Iotech International, LLC\u003C\u002Fa>","Unapproved New Drug and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Herb Moskowitz, DDS\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Iotech International, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6560 E. Rogers Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boca Raton\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33487\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:herbmoskowitz@iotechinternational.com\"> herbmoskowitz@iotechinternational.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: March 15, 2022\u003C\u002Fp>\n\n\u003Cp>Unapproved New Drug and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address www.iotechinternational.com on July 30 and September 9, 2021; and March 9, 2022, respectively. We have also reviewed your Facebook and Instagram social media website at the Internet addresses, https:\u002F\u002Fwww.facebook.com\u002Fiotechintl\u002F and https:\u002F\u002Fwww.instagram.com\u002Fiotech.international\u002F, respectively, where you direct consumers to your website, www.iotechinternational.com, to purchase your products.\u003C\u002Fp>\n\n\u003Cp>The FDA has observed that your website offers “ioRinse” (also referred to as “ioRinse™ RTU”) and “ioCleanse Molecular iodine Hand Cleanser” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502(ee) of the FD&amp;C Act, 21 U.S.C. § 352 (ee). The introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331 (a) and (d). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19 that subsequently has been extended.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on the “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your products, and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include but may not be limited to, the following:\u003Cbr>\n• “A New Super Class of Anti-microbials that kill #coronavirus . . . @iotech.international developed novel Anti-microbials that kill #coronavirus and surpass Chlorihexidine Gluconate in Efficacy. Safe . . . Highly engineered products created by a dentist and chemists. Order today: @iotech.international” [from a March 10, 2020 post on your Instagram webpage, https:\u002F\u002Fwww.instagram.com\u002Fiotech.international\u002F]\u003Cbr>\n• “The aim of the present study was to evaluate and compare the efficacy and cytotoxicity of four different mouthwashes containing 1.5% hydrogen peroxide, 0.2% povidone, 0.12% chlorhexidine and 100 ppm molecular iodine for the ability to inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . . . \u003Cstrong>Conclusion:\u003C\u002Fstrong> The spread of infection through aerosol and splatter has long been considered one of the main concerns in the dental community. A preprocedural rinse with 100 ppm molecular iodine will play a vital role in combating COVID-19 pandemic by preventing the spread of infection.” [from an article entitled “Comparative Analysis of Antiviral Efficacy of Four Different Mouthwashes against Severe Acute Respiratory Syndrome Coronavirus 2: An In Vitro Study” that you provide a link to on your website and that accompanies your products]\u003Cbr>\n• “Iotech International’s formula 100-S [containing molecular iodine] displayed the greatest antiviral activity of all the tested rinses, completely inactivating SARS-COV-2 within 30 seconds.” [from an article entitled “Comparative Analysis of Antiviral Efficacy of Four Different Mouthwashes against Severe Acute Respiratory Syndrome Coronavirus 2: An In Vitro Study” that you provide a link to on your website and that accompanies your products]\u003Cbr>\n• “Introducing ioCleanse . . . Non-Staining IoCleanse Hand Cleanser contains the most powerful form of iodine, Molecular Iodine . . . Successfully tested to destroy normal Coronavirus (strain #229E) within seconds. . . . Clinically Proven: Iodine is more effective as an ANTIVIRAL AGENT than Alcohol Sanitizers” [from an April 18, 2020 post on your Facebook webpage, https:\u002F\u002Fwww.facebook.com\u002Fiotechintl\u002F]\u003C\u002Fp>\n\n\u003Cp>Based on the above claims, “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” are intended for use as an oral antiseptic rinse and as a consumer topical antiseptic, respectively.\u003C\u002Fp>\n\n\u003Cp>This oral antiseptic rinse and topical antiseptic are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for these products, as further described below) or under other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products, like \"ioCleanse Molecular iodine Hand Cleanser,” had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Oral antiseptics like “ioRinse” were addressed in a TFM entitled “Oral Health Care Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Oral Antiseptic Drug Products”; Proposed Rule, 59 FR 6084 (February 9, 1994) (Oral Antiseptics Proposed Rule). The Oral Antiseptics Proposed Rule classified a number of active ingredients, including iodine, as Category III for use by consumers in antiseptic-containing drug products applied topically to the oral cavity to help prevent infection in minor cuts, scrapes or oral irritation caused by dental procedures, dentures, orthodontic appliances, or accidental injury, because additional effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as an OTC oral antiseptic (59 FR 6084 at 6121-6122).\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they meet the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, your “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” products do not conform to the 1994 TFM, the Oral Antiseptics Proposed Rule, or any other TFM, proposed rule, or final rule and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>Specifically, your labeling claims\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> suggesting that your oral antiseptic rinse and topical antiseptic products are effective in inactivating and thus preventing infection or disease from the novel coronavirus that causes COVID-19 go beyond merely describing the general intended uses of an antiseptic as set forth in the Oral Antiseptic Proposed Rule and the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, respectively.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition, your “ioCleanse Molecular iodine Hand Cleanser” product contains an active ingredient, molecular iodine, which was not one of the three active ingredients classified as Category III in the 1994 TFM. Although molecular iodine is not explicitly identified as an active ingredient on the label of your “ioCleanse Molecular iodine Hand Cleanser” products, your label and labeling clearly represent molecular iodine as an active ingredient, which is defined as a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body (see 21 CFR 201.66(b)(2)). Your labeling includes statements such as, “ioTECH International is the leading molecular iodine research and manufacturing company dispensing a patented, breakthrough germicidal product line branded as ioRinse and ioCleanse.”\u003C\u002Fp>\n\n\u003Cp>In addition, “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by FDA, the published list will be updated to indicate that your firm has taken such corrective actions. We note however, removal from the published list should not be interpreted to mean that you have properly addressed all other violations for your products and that you are free to proceed with their continued marketing.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley&nbsp;\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\njgolden@goldendentalsolutions.com\u003Cbr>\nCurt Lawler, Goldendent LLC\u003Cbr>\n27115 Gratiot Ave. Ste B\u003Cbr>\nRoseville, MI 48066\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> We note that “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” also do not conform to any temporary policy FDA has implemented during the public health emergency. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 public health emergency (PHE). Because your non-alcohol-based consumer antiseptic products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act. Additionally, on December 31, 2021 these guidances were withdrawn, and firms must cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> The FD&amp;C Act defines labeling in broad terms, such that labeling means all labels and “other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article (see section 201(m) of the FD&amp;C Act (21 U.S.C. 321(m)). This definition does not require labeling to be physically attached to a drug product.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nHerb Moskowitz, DDS\n\nIotech International, LLC\n\n6560 E. Rogers Circle\n\nBoca Raton, FL 33487\n\nUnited States\n\nherbmoskowitz@iotechinternational.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nDATE: March 15, 2022\n\nUnapproved New Drug and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address www.iotechinternational.com on July 30 and September 9, 2021; and March 9, 2022, respectively. We have also reviewed your Facebook and Instagram social media website at the Internet addresses, https:\u002F\u002Fwww.facebook.com\u002Fiotechintl\u002F and https:\u002F\u002Fwww.instagram.com\u002Fiotech.international\u002F, respectively, where you direct consumers to your website, www.iotechinternational.com, to purchase your products.\n\nThe FDA has observed that your website offers “ioRinse” (also referred to as “ioRinse™ RTU”) and “ioCleanse Molecular iodine Hand Cleanser” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502(ee) of the FD&C Act, 21 U.S.C. § 352 (ee). The introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331 (a) and (d). These violations are described in more detail below.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19 that subsequently has been extended.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nExamples of the claims observed on the “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” product labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your products, and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include but may not be limited to, the following:\n\n• “A New Super Class of Anti-microbials that kill #coronavirus . . . @iotech.international developed novel Anti-microbials that kill #coronavirus and surpass Chlorihexidine Gluconate in Efficacy. Safe . . . Highly engineered products created by a dentist and chemists. Order today: @iotech.international” [from a March 10, 2020 post on your Instagram webpage, https:\u002F\u002Fwww.instagram.com\u002Fiotech.international\u002F]\n\n• “The aim of the present study was to evaluate and compare the efficacy and cytotoxicity of four different mouthwashes containing 1.5% hydrogen peroxide, 0.2% povidone, 0.12% chlorhexidine and 100 ppm molecular iodine for the ability to inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . . . Conclusion: The spread of infection through aerosol and splatter has long been considered one of the main concerns in the dental community. A preprocedural rinse with 100 ppm molecular iodine will play a vital role in combating COVID-19 pandemic by preventing the spread of infection.” [from an article entitled “Comparative Analysis of Antiviral Efficacy of Four Different Mouthwashes against Severe Acute Respiratory Syndrome Coronavirus 2: An In Vitro Study” that you provide a link to on your website and that accompanies your products]\n\n• “Iotech International’s formula 100-S [containing molecular iodine] displayed the greatest antiviral activity of all the tested rinses, completely inactivating SARS-COV-2 within 30 seconds.” [from an article entitled “Comparative Analysis of Antiviral Efficacy of Four Different Mouthwashes against Severe Acute Respiratory Syndrome Coronavirus 2: An In Vitro Study” that you provide a link to on your website and that accompanies your products]\n\n• “Introducing ioCleanse . . . Non-Staining IoCleanse Hand Cleanser contains the most powerful form of iodine, Molecular Iodine . . . Successfully tested to destroy normal Coronavirus (strain #229E) within seconds. . . . Clinically Proven: Iodine is more effective as an ANTIVIRAL AGENT than Alcohol Sanitizers” [from an April 18, 2020 post on your Facebook webpage, https:\u002F\u002Fwww.facebook.com\u002Fiotechintl\u002F]\n\nBased on the above claims, “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. § 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” are intended for use as an oral antiseptic rinse and as a consumer topical antiseptic, respectively.\n\nThis oral antiseptic rinse and topical antiseptic are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for these products, as further described below) or under other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).4\n\nWe note that over-the-counter (OTC) topical antiseptic products, like \"ioCleanse Molecular iodine Hand Cleanser,” had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nOral antiseptics like “ioRinse” were addressed in a TFM entitled “Oral Health Care Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Oral Antiseptic Drug Products”; Proposed Rule, 59 FR 6084 (February 9, 1994) (Oral Antiseptics Proposed Rule). The Oral Antiseptics Proposed Rule classified a number of active ingredients, including iodine, as Category III for use by consumers in antiseptic-containing drug products applied topically to the oral cavity to help prevent infection in minor cuts, scrapes or oral irritation caused by dental procedures, dentures, orthodontic appliances, or accidental injury, because additional effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as an OTC oral antiseptic (59 FR 6084 at 6121-6122).\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they meet the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements.\n\nHowever, your “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” products do not conform to the 1994 TFM, the Oral Antiseptics Proposed Rule, or any other TFM, proposed rule, or final rule and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nSpecifically, your labeling claims5 suggesting that your oral antiseptic rinse and topical antiseptic products are effective in inactivating and thus preventing infection or disease from the novel coronavirus that causes COVID-19 go beyond merely describing the general intended uses of an antiseptic as set forth in the Oral Antiseptic Proposed Rule and the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, respectively.6\n\nIn addition, your “ioCleanse Molecular iodine Hand Cleanser” product contains an active ingredient, molecular iodine, which was not one of the three active ingredients classified as Category III in the 1994 TFM. Although molecular iodine is not explicitly identified as an active ingredient on the label of your “ioCleanse Molecular iodine Hand Cleanser” products, your label and labeling clearly represent molecular iodine as an active ingredient, which is defined as a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body (see 21 CFR 201.66(b)(2)). Your labeling includes statements such as, “ioTECH International is the leading molecular iodine research and manufacturing company dispensing a patented, breakthrough germicidal product line branded as ioRinse and ioCleanse.”\n\nIn addition, “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by FDA, the published list will be updated to indicate that your firm has taken such corrective actions. We note however, removal from the published list should not be interpreted to mean that you have properly addressed all other violations for your products and that you are free to proceed with their continued marketing.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\ncc:\n\njgolden@goldendentalsolutions.com\n\nCurt Lawler, Goldendent LLC\n\n27115 Gratiot Ave. Ste B\n\nRoseville, MI 48066\n\n_________________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 We note that “ioRinse” and “ioCleanse Molecular iodine Hand Cleanser” also do not conform to any temporary policy FDA has implemented during the public health emergency. In March 2020, the Agency published three guidance documents to provide regulatory flexibility to certain firms to help meet the demand for alcohol-based hand sanitizer during the COVID-19 public health emergency (PHE). Because your non-alcohol-based consumer antiseptic products are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act. Additionally, on December 31, 2021 these guidances were withdrawn, and firms must cease distribution, by March 31, 2022, of any remaining hand sanitizer products that were prepared under the temporary policies before or on December 31, 2021. See, 86 FR 56960, October 13, 2021.\n\n5 The FD&C Act defines labeling in broad terms, such that labeling means all labels and “other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article (see section 201(m) of the FD&C Act (21 U.S.C. 321(m)). This definition does not require labeling to be physically attached to a drug product.\n\n6 The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.","Iotech International, LLC","iotech-international-llc-617715-03152022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiotech-international-llc-617715-03152022","2026-10-26T08:09:00.79313+00:00","2022-03-17","617715","Herb Moskowitz, DDS","2026-08-20T02:05:39.552+00:00","2022-03-15",{"id":235,"raw":236,"subject":107,"body_html":240,"body_text":241,"firm_name":242,"letter_id":243,"created_at":45,"fei_number":19,"letter_url":244,"updated_at":245,"action_type":22,"case_status":23,"posted_date":246,"marcs_cms_no":247,"product_type":116,"closeout_date":19,"issuing_office":127,"recipient_name":248,"body_fetched_at":249,"delivery_method":98,"recipient_title":19,"reference_number":19,"action_taken_date":250,"medical_device_id":19,"response_letter_date":19},3261,[237,238,239,127,107,13,13,13],"\u003Ctime datetime=\"2021-07-13T13:20:00Z\">07\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-29T04:00:00Z\">06\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkuiyi-international-inc-614706-06292021\">Kuiyi International Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kui Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Kuiyi International Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2311 E Locust Ct\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ontario\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91761-7614\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 29, 2021\u003Cbr>\n\u003Cbr>\nRe: CMS 614706\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kui Zhang:\u003C\u002Fp>\n\n\u003Cp>From February 11 to March 5, 2021, the Food and Drug Administration (FDA) initated an inspection in person and conducted the remainder of the Foreign Supplier Verification Program (FSVP) inspection remotely for Kuiyi International Inc. located at 2311 E Locust Ct Ontario, CA 91761. We also conducted an inspection on April 24, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffoodsafety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-foodhumans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During our most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for food products that you import, including your Baked Rice Chips imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Unif Kumquat Green Tea and Unif Sneaking Around Tea imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Potato Chips imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not have FSVPs for these or any of the products you import. Because of these significant violations, you are not in compliance with Section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>This inspection was initiated as a follow up to a consumer complaint that resulted in injury due to anaphylactic reaction to undeclared milk allergens in one of these products. Import records and distribution records for the most recent shipment confirmed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> Potato Chips is supplied by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and was imported by your firm Kuiyi International Inc. Undeclared allergens are a serious adverse health consequences or death to humans or animals (SAHCODHA) hazard.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the initial FSVP inspection on April 24, 2019 and the follow-up inspection on March 5, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. As of the date of this letter, we have not received your response to either Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a)1. Specifically, you did not develop, maintain, and follow an FSVP for any of the products you import, including each of the following food products:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Baked Rice Chips imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Unif Kumquat Green Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Unif Sneaking Around Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Potato Chips,\u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should repond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, you noted that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you chose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 and 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, 1 World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #614706 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Kui Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nKuiyi International Inc.\n\n2311 E Locust Ct\n\nOntario, CA 91761-7614\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nJune 29, 2021\n\nRe: CMS 614706\n\nDear Mr. Kui Zhang:\n\nFrom February 11 to March 5, 2021, the Food and Drug Administration (FDA) initated an inspection in person and conducted the remainder of the Foreign Supplier Verification Program (FSVP) inspection remotely for Kuiyi International Inc. located at 2311 E Locust Ct Ontario, CA 91761. We also conducted an inspection on April 24, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffoodsafety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-foodhumans-and-animals.\n\nDuring our most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for food products that you import, including your Baked Rice Chips imported from (b)(4), located in (b)(4); Unif Kumquat Green Tea and Unif Sneaking Around Tea imported from (b)(4), located in (b)(4); and (b)(4) Potato Chips imported from (b)(4), located in (b)(4). You did not have FSVPs for these or any of the products you import. Because of these significant violations, you are not in compliance with Section 805 of the FD&C Act.\n\nThis inspection was initiated as a follow up to a consumer complaint that resulted in injury due to anaphylactic reaction to undeclared milk allergens in one of these products. Import records and distribution records for the most recent shipment confirmed that (b)(4) Potato Chips is supplied by (b)(4), located in (b)(4) and was imported by your firm Kuiyi International Inc. Undeclared allergens are a serious adverse health consequences or death to humans or animals (SAHCODHA) hazard.\n\nAt the conclusion of the initial FSVP inspection on April 24, 2019 and the follow-up inspection on March 5, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. As of the date of this letter, we have not received your response to either Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a)1. Specifically, you did not develop, maintain, and follow an FSVP for any of the products you import, including each of the following food products:\n\nBaked Rice Chips imported from (b)(4), located in (b)(4)\n\nUnif Kumquat Green Tea imported from (b)(4), located in (b)(4)\n\nUnif Sneaking Around Tea imported from (b)(4), located in (b)(4)\n\n(b)(4) Potato Chips,(b)(4) imported from (b)(4), located in (b)(4)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should repond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nAdditionally, we offer the following comment:\n\nDuring the most recent inspection, you noted that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you chose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 and 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (21 CFR 1.512(b)(3)(i)).\n\nPlease send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, 1 World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #614706 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","Kuiyi International Inc.","kuiyi-international-inc-614706-06292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkuiyi-international-inc-614706-06292021","2026-10-26T08:09:10.648181+00:00","2021-07-13","614706","Mr. Kui Zhang","2026-08-20T02:58:44.447+00:00","2021-06-29",{"id":252,"raw":253,"subject":163,"body_html":258,"body_text":259,"firm_name":260,"letter_id":261,"created_at":262,"fei_number":19,"letter_url":263,"updated_at":264,"action_type":22,"case_status":23,"posted_date":265,"marcs_cms_no":266,"product_type":26,"closeout_date":19,"issuing_office":257,"recipient_name":267,"body_fetched_at":268,"delivery_method":269,"recipient_title":19,"reference_number":19,"action_taken_date":270,"medical_device_id":19,"response_letter_date":19},6168,[254,255,256,257,163,13,13,13],"\u003Ctime datetime=\"2022-07-26T13:20:00Z\">07\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-30T04:00:00Z\">06\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbi-coastal-pharma-international-628196-06302022\">Bi-Coastal Pharma International\u003C\u002Fa>","Office of Pharmaceutical Quality Operations Division I","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ralph Massa, Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bi-Coastal Pharma International\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1161 Broad St Ste 216\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shrewsbury\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07702-4362\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 628196\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 30, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Massa:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Bi-Coastal Pharma International, FEI 3013263547, located at 1161 Broad St Ste 216, Shrewsbury, New Jersey, from December 15, 2021, to January 14, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 2, 2022, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192. (21 CFR 211.198(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately investigate a complaint. On June 2, 2020, FDA notified your firm of a complaint that reported an adverse reaction after taking Chlordiazepoxide Hydrochloride (HCl) and Clidinium Bromide (Br), 5 mg\u002F2.5 mg, distributed by your firm. This notification also included the complainant’s contact information. During this inspection we observed there was no investigation initiated to evaluate the manufacturing and packaging of Chlordiazepoxide HCl and Clidinium Br in accordance with your established procedure. On July 6, 2020, you responded to FDA you reviewed “all” certificates of analysis provided by your contract manufacturing organization (CMO) and concluded results were consistent with all previously released batches. This drug product was manufactured by your CMO \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA issued a Warning Letter\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which specifically noted a violation related to potential for mix-ups of various drug products including Chlordiazepoxide HCl and Clidinium Br. However, at the time of receiving the complaint, you did not attempt to obtain samples of the drug or additional information from the complainant.\u003C\u002Fp>\n\n\u003Cp>You stated during the inspection that your CMO was no longer in business, and you were unable to share the complaint with the CMO for further investigation. However, as the product owner, you are ultimately responsible for ensuring adequate control over outsourced activities, including quality oversight of the drug products you distribute.\u003C\u002Fp>\n\n\u003Cp>In your response, you explained you will revise your process for handling complaints. Your response is inadequate. You failed to provide evidence of your investigation into the product quality impact of this complaint, including the two batches of Chlordiazepoxide HCl and Clidinium Br, 5 mg\u002F2.5 mg manufactured since 2018. In addition, your response lacks systemic evaluation of complaint investigations to ensure adequate and sustainable corrections and corrective actions are implemented in a timely manner.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out of specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>\n• A retrospective review of all records that may constitute a complaint for U.S. products and provide a report summarizing the findings of this review including any actions that your firm may take based on the review.\u003Cbr>\n• An evaluation of your existing processes and procedures that define, establish, and document quality and manufacturing related controls to ensure CGMP responsibilities will be carried out if a CMO is no longer in business. Provide a summary of this evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to establish adequate written responsibilities and procedures for reviewing manufacturing operations performed by your CMOs. You also failed to follow your established procedures, and review each batch produced for you to determine appropriate disposition. For example:\u003C\u002Fp>\n\n\u003Cp>A. Lack of Quality Unit (QU) oversight over CMO\u003C\u002Fp>\n\n\u003Cp>• You use a CMO, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture Hydroquinone USP 4% Skin Bleaching Cream. Your CMO released batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> to you on November 16, 2020. You distributed this batch to numerous customers. During the inspection you were unable to provide adequate stability data for your batch and formulation.\u003C\u002Fp>\n\n\u003Cp>• You use a CMO, \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture the following products:\u003Cbr>\n&nbsp; o Hydroquinone USP 4% Skin Bleaching Cream\u003Cbr>\n&nbsp; o Sodium Sulfacetamide 10% &amp; Sulfur 5% Cleanser\u003Cbr>\n&nbsp; o Sodium Sulfacetamide 10% and Sulfur 2% Cleanser\u003Cbr>\n&nbsp; o Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser\u003Cbr>\n&nbsp; o Selenium Sulfide 2.25% Shampoo\u003C\u002Fp>\n\n\u003Cp>Your manufacturing and supply agreement requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure products manufactured on your behalf will not be in violation of FDA regulations. However, this document lacks specificity in defining responsibilities for documenting and performing various oversight activities related to reviewing OOS results, deviations, complaints, and change controls.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. We acknowledge receipt of your CMO’s annual review for Hydroquinone 4% Cream. However, the review does not provide stability characteristics representative of this batch over its shelf life. In addition, you state you will establish written responsibilities for managing your CMOs. However, you have not provided details of your interim controls or an evaluation of the adequacy of your existing agreements with each of your CMOs.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A retrospective evaluation of all drug product batches currently in distribution to ensure regulatory responsibilities are adequately delineated between your firm and your CMO to ensure compliance. Provide a summary of this evaluation.\u003Cbr>\n• A summary of your program for qualifying and overseeing CMOs that perform CGMP activities on your behalf. This summary should document the roles and responsibilities of each packager, labeler, distributor, contract manufacturer, contract testing laboratory, or other organization performing activities related to your drug product. Include names, addresses, FDA registration information, and a description of services provided.\u003C\u002Fp>\n\n\u003Cp>B. Failure to follow procedures and lack of written responsibilities\u003C\u002Fp>\n\n\u003Cp>• You failed to follow your established procedure for batch record review and release. During the inspection, you stated you do not receive or verify executed batch records unless requested by FDA during inspections. This is despite a requirement in your procedure that states you will review and verify executed batch records for completeness prior to drug product release. Numerous batches of various drug products have been distributed since December 2019 without your firm receiving or verifying executed batch records.\u003C\u002Fp>\n\n\u003Cp>In addition, after verification of the executed batch record, your procedure requires signatures for the “Reviewed by” space and the “Reviewed and Released by” space in your Certificate of Release. However, our inspection found that Hydroquinone Gel 4% bulk lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong> was released for distribution though the “Reviewed by” space was not signed.\u003Cbr>\n\u003Cbr>\n• Your training procedure states a QU representative will counter sign and date employee training forms, confirming that the employee is appropriately trained on the procedures. However, QU representative signatures were missing on 2020 and 2021 employee training records for various individuals, including QU staff who continued to perform quality duties.\u003C\u002Fp>\n\n\u003Cp>Establishing and following adequate written procedures is essential for the proper functioning of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You failed to provide an investigation into the impact of inadequate batch review and release practices on batches that have been released and remain on the market within their expiry period.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>• A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n• A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to ensure that each person responsible for supervising the manufacture, processing, packing, or holding of a drug product has the education, training or experience, or any combination thereof, to perform assigned functions in such a manner as to provide assurance that the drug product has the safety, identity, strength, quality, and purity that it purports or is represented to possess (21 CFR 211.25(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure personnel with oversight of quality related functions have the appropriate combination of training, education, and experience to perform the job adequately. For example, your QA manager:\u003C\u002Fp>\n\n\u003Cp>• Does not have previous experience or educational training in quality assurance, the pharmaceutical industry, or the sciences. Nonetheless, he is responsible for overseeing CMOs, certificates of analysis, and batch release; and\u003Cbr>\n• Was unaware of CGMP stability testing and process validation requirements for drug products manufactured by CMOs on your behalf.\u003C\u002Fp>\n\n\u003Cp>Adequate training and personnel qualifications are essential to ensure proper performance of job functions by your employees, including those responsible for oversight and management of the quality system.\u003C\u002Fp>\n\n\u003Cp>In your response you stated your firm’s “Vice President &amp; General Manager” will help ensure proper adherence to procedures while you seek to hire a new quality assurance manager. This response is inadequate. You failed to provide evidence showing this individual is qualified to provide oversight of CGMP activities. In addition, you have not provided details as to how you will ensure the new quality assurance manager will have the appropriate combination of training, education, and experience to perform the job adequately.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and CAPA for your training program, including practices, records, staff competencies, and effectiveness throughout your operations. Specific gaps should be identified for remediation after assessing the capability of your program to ensure:\u003Cbr>\n&nbsp; o Qualified individuals perform training\u003Cbr>\n&nbsp; o Provisions are implemented for evaluating staff comprehension, training effectiveness, and ensuring appropriate modifications where needed\u003Cbr>\n• A summary of your current training program.\u003Cbr>\n• Your plan to improve oversight of your training program.\u003Cbr>\n• An assessment of the impact of the lack of appropriate training on marketed drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at h\u003Ca>ttps:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that the FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #628196 and include FEI number 3013263547.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and “cc” Compliance Officers, CAPT Liatte Closs (Liatte.Closs@fda.hhs.gov) and Nancy Scheraga (Nancy.Scheraga@fda.hhs.gov).\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision I\u002FNew Jersey District\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fandapharm-llc-566492-02282019\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nElectronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ralph Massa, Jr.\n\nRecipient Title\n\nPresident and CEO\n\nBi-Coastal Pharma International\n\n1161 Broad St Ste 216\n\nShrewsbury, NJ 07702-4362\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations Division I\n\nUnited States\n\nWarning Letter 628196\n\nJune 30, 2022\n\nDear Mr. Massa:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Bi-Coastal Pharma International, FEI 3013263547, located at 1161 Broad St Ste 216, Shrewsbury, New Jersey, from December 15, 2021, to January 14, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 2, 2022, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192. (21 CFR 211.198(a)).\n\nYou failed to adequately investigate a complaint. On June 2, 2020, FDA notified your firm of a complaint that reported an adverse reaction after taking Chlordiazepoxide Hydrochloride (HCl) and Clidinium Bromide (Br), 5 mg\u002F2.5 mg, distributed by your firm. This notification also included the complainant’s contact information. During this inspection we observed there was no investigation initiated to evaluate the manufacturing and packaging of Chlordiazepoxide HCl and Clidinium Br in accordance with your established procedure. On July 6, 2020, you responded to FDA you reviewed “all” certificates of analysis provided by your contract manufacturing organization (CMO) and concluded results were consistent with all previously released batches. This drug product was manufactured by your CMO (b)(4), located in (b)(4). FDA issued a Warning Letter1 to (b)(4), on (b)(4), which specifically noted a violation related to potential for mix-ups of various drug products including Chlordiazepoxide HCl and Clidinium Br. However, at the time of receiving the complaint, you did not attempt to obtain samples of the drug or additional information from the complainant.\n\nYou stated during the inspection that your CMO was no longer in business, and you were unable to share the complaint with the CMO for further investigation. However, as the product owner, you are ultimately responsible for ensuring adequate control over outsourced activities, including quality oversight of the drug products you distribute.\n\nIn your response, you explained you will revise your process for handling complaints. Your response is inadequate. You failed to provide evidence of your investigation into the product quality impact of this complaint, including the two batches of Chlordiazepoxide HCl and Clidinium Br, 5 mg\u002F2.5 mg manufactured since 2018. In addition, your response lacks systemic evaluation of complaint investigations to ensure adequate and sustainable corrections and corrective actions are implemented in a timely manner.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out of specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A retrospective review of all records that may constitute a complaint for U.S. products and provide a report summarizing the findings of this review including any actions that your firm may take based on the review.\n\n• An evaluation of your existing processes and procedures that define, establish, and document quality and manufacturing related controls to ensure CGMP responsibilities will be carried out if a CMO is no longer in business. Provide a summary of this evaluation.\n\n2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\n\nYou failed to establish adequate written responsibilities and procedures for reviewing manufacturing operations performed by your CMOs. You also failed to follow your established procedures, and review each batch produced for you to determine appropriate disposition. For example:\n\nA. Lack of Quality Unit (QU) oversight over CMO\n\n• You use a CMO, (b)(4), to manufacture Hydroquinone USP 4% Skin Bleaching Cream. Your CMO released batch (b)(4) to you on November 16, 2020. You distributed this batch to numerous customers. During the inspection you were unable to provide adequate stability data for your batch and formulation.\n\n• You use a CMO, (b)(4) to manufacture the following products:\n\no Hydroquinone USP 4% Skin Bleaching Cream\n\no Sodium Sulfacetamide 10% & Sulfur 5% Cleanser\n\no Sodium Sulfacetamide 10% and Sulfur 2% Cleanser\n\no Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser\n\no Selenium Sulfide 2.25% Shampoo\n\nYour manufacturing and supply agreement requires (b)(4) to ensure products manufactured on your behalf will not be in violation of FDA regulations. However, this document lacks specificity in defining responsibilities for documenting and performing various oversight activities related to reviewing OOS results, deviations, complaints, and change controls.\n\nYour response is inadequate. We acknowledge receipt of your CMO’s annual review for Hydroquinone 4% Cream. However, the review does not provide stability characteristics representative of this batch over its shelf life. In addition, you state you will establish written responsibilities for managing your CMOs. However, you have not provided details of your interim controls or an evaluation of the adequacy of your existing agreements with each of your CMOs.\n\nIn response to this letter, provide:\n\n• A retrospective evaluation of all drug product batches currently in distribution to ensure regulatory responsibilities are adequately delineated between your firm and your CMO to ensure compliance. Provide a summary of this evaluation.\n\n• A summary of your program for qualifying and overseeing CMOs that perform CGMP activities on your behalf. This summary should document the roles and responsibilities of each packager, labeler, distributor, contract manufacturer, contract testing laboratory, or other organization performing activities related to your drug product. Include names, addresses, FDA registration information, and a description of services provided.\n\nB. Failure to follow procedures and lack of written responsibilities\n\n• You failed to follow your established procedure for batch record review and release. During the inspection, you stated you do not receive or verify executed batch records unless requested by FDA during inspections. This is despite a requirement in your procedure that states you will review and verify executed batch records for completeness prior to drug product release. Numerous batches of various drug products have been distributed since December 2019 without your firm receiving or verifying executed batch records.\n\nIn addition, after verification of the executed batch record, your procedure requires signatures for the “Reviewed by” space and the “Reviewed and Released by” space in your Certificate of Release. However, our inspection found that Hydroquinone Gel 4% bulk lot number (b)(4) was released for distribution though the “Reviewed by” space was not signed.\n\n• Your training procedure states a QU representative will counter sign and date employee training forms, confirming that the employee is appropriately trained on the procedures. However, QU representative signatures were missing on 2020 and 2021 employee training records for various individuals, including QU staff who continued to perform quality duties.\n\nEstablishing and following adequate written procedures is essential for the proper functioning of your manufacturing operations.\n\nYour response is inadequate. You failed to provide an investigation into the impact of inadequate batch review and release practices on batches that have been released and remain on the market within their expiry period.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\n• A determination of whether procedures used by your firm are robust and appropriate\n\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\n• A complete and final review of each batch and its related information before the QU disposition decision\n\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n3. Your firm failed to ensure that each person responsible for supervising the manufacture, processing, packing, or holding of a drug product has the education, training or experience, or any combination thereof, to perform assigned functions in such a manner as to provide assurance that the drug product has the safety, identity, strength, quality, and purity that it purports or is represented to possess (21 CFR 211.25(b)).\n\nYou failed to ensure personnel with oversight of quality related functions have the appropriate combination of training, education, and experience to perform the job adequately. For example, your QA manager:\n\n• Does not have previous experience or educational training in quality assurance, the pharmaceutical industry, or the sciences. Nonetheless, he is responsible for overseeing CMOs, certificates of analysis, and batch release; and\n\n• Was unaware of CGMP stability testing and process validation requirements for drug products manufactured by CMOs on your behalf.\n\nAdequate training and personnel qualifications are essential to ensure proper performance of job functions by your employees, including those responsible for oversight and management of the quality system.\n\nIn your response you stated your firm’s “Vice President & General Manager” will help ensure proper adherence to procedures while you seek to hire a new quality assurance manager. This response is inadequate. You failed to provide evidence showing this individual is qualified to provide oversight of CGMP activities. In addition, you have not provided details as to how you will ensure the new quality assurance manager will have the appropriate combination of training, education, and experience to perform the job adequately.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and CAPA for your training program, including practices, records, staff competencies, and effectiveness throughout your operations. Specific gaps should be identified for remediation after assessing the capability of your program to ensure:\n\no Qualified individuals perform training\n\no Provisions are implemented for evaluating staff comprehension, training effectiveness, and ensuring appropriate modifications where needed\n\n• A summary of your current training program.\n\n• Your plan to improve oversight of your training program.\n\n• An assessment of the impact of the lack of appropriate training on marketed drug products.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that the FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #628196 and include FEI number 3013263547.\n\nIf you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and “cc” Compliance Officers, CAPT Liatte Closs (Liatte.Closs@fda.hhs.gov) and Nancy Scheraga (Nancy.Scheraga@fda.hhs.gov).\n\nSincerely,\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations\n\nDivision I\u002FNew Jersey District\n\n______________________\n\n1 https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fandapharm-llc-566492-02282019","Bi-Coastal Pharma International","bi-coastal-pharma-international-628196-06302022","2026-08-19T04:06:54.551565+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbi-coastal-pharma-international-628196-06302022","2026-10-26T08:08:04.263092+00:00","2022-07-26","628196","Mr. Ralph Massa, Jr.","2026-08-20T01:43:38.828+00:00","Electronic Mail","2022-06-30",{"id":272,"raw":273,"subject":39,"body_html":277,"body_text":278,"firm_name":279,"letter_id":280,"created_at":69,"fei_number":19,"letter_url":281,"updated_at":282,"action_type":22,"case_status":23,"posted_date":283,"marcs_cms_no":284,"product_type":51,"closeout_date":19,"issuing_office":38,"recipient_name":285,"body_fetched_at":286,"delivery_method":287,"recipient_title":19,"reference_number":288,"action_taken_date":289,"medical_device_id":19,"response_letter_date":19},1533,[274,275,276,38,39,13,13,13],"\u003Ctime datetime=\"2024-04-04T12:45:00Z\">04\u002F04\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-03T04:00:00Z\">04\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fepd-international-sro-680790-04032024\">EPD International S.R.O.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402131\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dino Ismet Sinanovic\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>EPD International S.R.O.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Czechia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 3, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dino Ismet Sinanovic:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fsnussie.com and determined that the nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order: ZYN Cucumber Lime Slim Normal and ZYN Espressino Mini Dry Normal.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402131, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nEle Ibarra-Pratt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>EPD International, S.R.O.\u003Cbr>\ninfo@europouches.com\u003C\u002Fp>\n\n\u003Cp>Ascio Technologies, Inc. Danmark - Filial af Ascio Technologies, Inc.\u003Cbr>\nabuse@ascio.com\u003C\u002Fp>\n\n\u003Cp>Cloudflare, Inc.\u003Cbr>\nabuse@cloudflare.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\nRW2402131\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDino Ismet Sinanovic\n\nEPD International S.R.O.\n\nCzechia\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nApril 3, 2024\n\nWARNING LETTER\n\nDear Dino Ismet Sinanovic:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fsnussie.com and determined that the nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order: ZYN Cucumber Lime Slim Normal and ZYN Espressino Mini Dry Normal.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402131, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nEle Ibarra-Pratt\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nEPD International, S.R.O.\n\ninfo@europouches.com\n\nAscio Technologies, Inc. Danmark - Filial af Ascio Technologies, Inc.\n\nabuse@ascio.com\n\nCloudflare, Inc.\n\nabuse@cloudflare.com","EPD International S.R.O.","epd-international-sro-680790-04032024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fepd-international-sro-680790-04032024","2026-10-26T08:08:35.841341+00:00","2024-04-04","680790","Dino Ismet Sinanovic","2026-08-20T00:11:48.265+00:00","VIA Electronic Mail","RW2402131","2024-04-03",{"id":291,"raw":292,"subject":39,"body_html":295,"body_text":296,"firm_name":279,"letter_id":297,"created_at":69,"fei_number":19,"letter_url":298,"updated_at":299,"action_type":22,"case_status":23,"posted_date":300,"marcs_cms_no":19,"product_type":51,"closeout_date":19,"issuing_office":38,"recipient_name":285,"body_fetched_at":301,"delivery_method":287,"recipient_title":19,"reference_number":19,"action_taken_date":289,"medical_device_id":19,"response_letter_date":19},1514,[293,275,294,38,39,13,13,13],"\u003Ctime datetime=\"2024-04-16T13:20:00Z\">04\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fepd-international-sro-680790-04032024-0\">EPD International S.R.O.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dino Ismet Sinanovic\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>EPD International S.R.O.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Czechia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@snussie.com\"> info@snussie.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:order@snussie.com\"> order@snussie.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:parcel@snussie.com\"> parcel@snussie.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 3, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dino Ismet Sinanovic:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fsnussie.com and determined that the nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order: ZYN Cucumber Lime Slim Normal and ZYN Espressino Mini Dry Normal.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders# PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402131, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003Cbr>\n\u003Cbr>\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ele Ibarra-Pratt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>EPD International, S.R.O.\u003Cbr>\ninfo@europouches.com\u003C\u002Fp>\n\n\u003Cp>Ascio Technologies, Inc. Danmark - Filial af Ascio Technologies, Inc.\u003Cbr>\nabuse@ascio.com\u003C\u002Fp>\n\n\u003Cp>Cloudflare, Inc.\u003Cbr>\nabuse@cloudflare.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDino Ismet Sinanovic\n\nEPD International S.R.O.\n\nCzechia\n\ninfo@snussie.com\n\norder@snussie.com\n\nparcel@snussie.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nApril 3, 2024\n\nWARNING LETTER\n\nDear Dino Ismet Sinanovic:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fsnussie.com and determined that the nicotine pouch products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobaccoproducts\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States nicotine pouch products that lack a marketing authorization order: ZYN Cucumber Lime Slim Normal and ZYN Espressino Mini Dry Normal.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketingorders# PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and promptly take any necessary actions to bring the tobacco products you offer for sale or distribution in the United States into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402131, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nEle Ibarra-Pratt\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA Electronic Mail\n\ncc:\n\nEPD International, S.R.O.\n\ninfo@europouches.com\n\nAscio Technologies, Inc. Danmark - Filial af Ascio Technologies, Inc.\n\nabuse@ascio.com\n\nCloudflare, Inc.\n\nabuse@cloudflare.com","epd-international-sro-680790-04032024-0","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fepd-international-sro-680790-04032024-0","2026-10-26T08:08:35.877701+00:00","2024-04-16","2026-08-20T00:10:29.601+00:00",{"id":303,"raw":304,"subject":163,"body_html":308,"body_text":309,"firm_name":310,"letter_id":311,"created_at":69,"fei_number":19,"letter_url":312,"updated_at":313,"action_type":22,"case_status":23,"posted_date":314,"marcs_cms_no":315,"product_type":26,"closeout_date":19,"issuing_office":63,"recipient_name":316,"body_fetched_at":317,"delivery_method":76,"recipient_title":19,"reference_number":19,"action_taken_date":318,"medical_device_id":19,"response_letter_date":19},1647,[305,306,307,63,163,13,13,13],"\u003Ctime datetime=\"2024-01-30T14:20:00Z\">01\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-26T05:00:00Z\">01\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fs-j-international-enterprises-public-company-limited-668482-01262024\">S &amp; J International Enterprises Public Company Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Praj Srichandra\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Factory Division Manager, Board Member of Saha Group\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>S &amp; J International Enterprises Public Company Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>600\u002F4 Moo.11 Sukaphiban 8 Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nongkharm\u003C\u002Fspan>, \u003Cspan>Si Racha\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chon Buri\u003C\u002Fspan> \u003Cspan>20230\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thailand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-17\u003C\u002Fp>\n\n\u003Cp>January 26, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Srichandra:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, S &amp; J International Enterprises Public Company Limited, FEI 3005979923, at 600\u002F4 Moo.11 Sukaphiban 8 Road, Nongkharm, Si Racha, from July 17 to July 21, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Furthermore, during the inspection you delayed or limited access to or copying of records requested. Due to your delay and limiting access to or copying of records during the inspection, the drug products you manufacture are also deemed adulterated within the meaning of section 501(j) of the FD&amp;C Act, 21 U.S.C. 351(j).\u003C\u002Fp>\n\n\u003Cp>We reviewed your response\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight and control over your drug manufacturing operations. Specifically, your QU did not implement adequate controls to prevent the alteration of production records, to ensure the complete documentation of laboratory preparation, and to ensure the review of raw analytical data. For example, production staff are able to alter master batch records, including modifying batch formulations and other parameters or formulations before printing. Laboratory sample preparation is not documented, and weight print-outs are not retained. Lastly, your QU only reviews analytical results entered into your enterprise system and does not review raw analytical data before releasing quarantined materials or finished drug products.\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\n\t\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\n\t\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fli>\n\t\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You recorded production data on laminated sheets using erasable markers that could be easily altered or lost. These logs were used to record \u003Cstrong>(b)(4)\u003C\u002Fstrong> weight verification checks for balances and scales, room cleaning checklists, employee health and hygiene checks, operator shoe cleaning, pest control checks, facility and equipment checks, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature and humidity monitoring in manufacturing areas. You stated that these temporary records are scanned and retained. However, you could not provide the permanent version of these records and stated that only production staff and production supervisors, and not the QU, have access to the scanned sheets and logs. Without adequate and complete batch records, you cannot assure the uniformity of your drug products from batch to batch and may impact your ability to adequately investigate any product deviations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Delaying, Denying, Limiting, or Refusing a Drug Inspection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You delayed and limited access to or copying of records requested during the inspection. During the inspection, our investigator provided a list of requested documents and made numerous repeat requests during the inspection for these documents. Yet, your firm only provided or allowed access to a limited number of documents.\u003C\u002Fp>\n\n\u003Cp>For example, upon request for the current labeling for your United States (U.S.) drug product, you provided a single photograph of the primary and secondary drug product packaging on the last day of the inspection, which was of poor quality and not legible.\u003C\u002Fp>\n\n\u003Cp>Additionally, upon request for a list of all laboratory non-conformances and investigations during the inspection, your staff initially stated that there were no out-of-trend, out-of-specification (OOS), incidents, non-conformances, or investigations, and provided blank logs for years 2021-2023. However, later during the inspection, our investigator observed logs for these years on an electronic drive that contained non-conformance report numbers, dates, descriptions, and close-out dates, and appeared to include a raw material OOS entry for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the active ingredient in your U.S. drug product. Only after discovery by our investigator were these logs provided to our investigator.\u003C\u002Fp>\n\n\u003Cp>When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&amp;C Act. See FDA’s guidance document \u003Cem>Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on January 23, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at S &amp; J International Enterprises Public Company Limited, 600\u002F4 Moo.11 Sukaphiban 8 Road, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005979923 and ATTN: Christina Capacci-Daniel.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Response provided by email on December 19, 2023 following the July 17 to July 21, 2023 inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Praj Srichandra\n\nRecipient Title\n\nFactory Division Manager, Board Member of Saha Group\n\nS & J International Enterprises Public Company Limited\n\n600\u002F4 Moo.11 Sukaphiban 8 Road\n\nNongkharm, Si Racha\n\nChon Buri 20230\n\nThailand\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWarning Letter 320-24-17\n\nJanuary 26, 2024\n\nDear Mr. Srichandra:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, S & J International Enterprises Public Company Limited, FEI 3005979923, at 600\u002F4 Moo.11 Sukaphiban 8 Road, Nongkharm, Si Racha, from July 17 to July 21, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nFurthermore, during the inspection you delayed or limited access to or copying of records requested. Due to your delay and limiting access to or copying of records during the inspection, the drug products you manufacture are also deemed adulterated within the meaning of section 501(j) of the FD&C Act, 21 U.S.C. 351(j).\n\nWe reviewed your response1 to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight and control over your drug manufacturing operations. Specifically, your QU did not implement adequate controls to prevent the alteration of production records, to ensure the complete documentation of laboratory preparation, and to ensure the review of raw analytical data. For example, production staff are able to alter master batch records, including modifying batch formulations and other parameters or formulations before printing. Laboratory sample preparation is not documented, and weight print-outs are not retained. Lastly, your QU only reviews analytical results entered into your enterprise system and does not review raw analytical data before releasing quarantined materials or finished drug products.\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\nA determination of whether procedures used by your firm are robust and appropriate.\n\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\nA complete and final review of each batch and its related information before the QU disposition decision.\n\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products. Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n2. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\n\nYou recorded production data on laminated sheets using erasable markers that could be easily altered or lost. These logs were used to record (b)(4) weight verification checks for balances and scales, room cleaning checklists, employee health and hygiene checks, operator shoe cleaning, pest control checks, facility and equipment checks, and (b)(4) temperature and humidity monitoring in manufacturing areas. You stated that these temporary records are scanned and retained. However, you could not provide the permanent version of these records and stated that only production staff and production supervisors, and not the QU, have access to the scanned sheets and logs. Without adequate and complete batch records, you cannot assure the uniformity of your drug products from batch to batch and may impact your ability to adequately investigate any product deviations.\n\nIn response to this letter, provide a complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nDelaying, Denying, Limiting, or Refusing a Drug Inspection\n\nYou delayed and limited access to or copying of records requested during the inspection. During the inspection, our investigator provided a list of requested documents and made numerous repeat requests during the inspection for these documents. Yet, your firm only provided or allowed access to a limited number of documents.\n\nFor example, upon request for the current labeling for your United States (U.S.) drug product, you provided a single photograph of the primary and secondary drug product packaging on the last day of the inspection, which was of poor quality and not legible.\n\nAdditionally, upon request for a list of all laboratory non-conformances and investigations during the inspection, your staff initially stated that there were no out-of-trend, out-of-specification (OOS), incidents, non-conformances, or investigations, and provided blank logs for years 2021-2023. However, later during the inspection, our investigator observed logs for these years on an electronic drive that contained non-conformance report numbers, dates, descriptions, and close-out dates, and appeared to include a raw material OOS entry for (b)(4), the active ingredient in your U.S. drug product. Only after discovery by our investigator were these logs provided to our investigator.\n\nWhen an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act. See FDA’s guidance document Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on January 23, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at S & J International Enterprises Public Company Limited, 600\u002F4 Moo.11 Sukaphiban 8 Road, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005979923 and ATTN: Christina Capacci-Daniel.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n_________________\n\n1 Response provided by email on December 19, 2023 following the July 17 to July 21, 2023 inspection.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","S & J International Enterprises Public Company Limited","s-j-international-enterprises-public-company-limited-668482-01262024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fs-j-international-enterprises-public-company-limited-668482-01262024","2026-10-26T08:09:52.159638+00:00","2024-01-30","668482","Mr. Praj Srichandra","2026-08-20T00:21:40.309+00:00","2024-01-26",{"id":320,"raw":321,"subject":326,"body_html":327,"body_text":328,"firm_name":329,"letter_id":330,"created_at":132,"fei_number":19,"letter_url":331,"updated_at":332,"action_type":22,"case_status":23,"posted_date":333,"marcs_cms_no":334,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":335,"body_fetched_at":336,"delivery_method":337,"recipient_title":19,"reference_number":338,"action_taken_date":339,"medical_device_id":19,"response_letter_date":19},1117,[322,323,324,11,325,13,13,13],"\u003Ctime datetime=\"2024-12-24T14:20:00Z\">12\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-17T05:00:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrands-international-corporation-689983-12172024\">Brands International Corporation\u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAdulterated\u002FRefusal to Allow Inspection\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceutical\u002FAdulterated\u002FRefusal to Allow Inspection","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-25\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. David Kahan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Partner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Brands International Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>101 Chase Avenue Suite 204\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lakewood\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-25\u003C\u002Fp>\u003Cp>December 17, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Kahan:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brands International Corporation, FEI 3007389902, at 594 Newpark Blvd, Newmarket, Ontario L3X 2S2, Canada, from June 17 to 21, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Our investigators documented your firm limited and\u002For delayed an FDA inspection. Under section 501(j) of the FD&amp;C Act, 21 U.S.C. 351(j), your drugs are adulterated in that they have been manufactured, processed, packed, or held in an establishment where the owner or operator has limited inspection and\u002For delayed inspection.\u003C\u002Fp>\u003Cp>Additionally, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your July 15, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During the inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Delaying, Denying, and Limiting the Inspection\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm limited and delayed the FDA inspection as follows:\u003C\u002Fp>\u003Cp>• At the start of the second day of the inspection, June 18, 2024, investigators were admitted into the building and left in a conference room. Investigators went to your laboratory to continue discussions with your Quality Control (QC) Supervisor from the day before. Later, your Quality Manager entered the laboratory and exhibited hostility by shoving and shouting at our investigators for conducting the inspection without their presence. Additionally, laboratory staff refused to open a drug stability chamber based on his hostile behavior. Your management staff’s behavior impeded our investigators during the inspection.\u003C\u002Fp>\u003Cp>• While attempting to ask questions to additional quality staff, our investigators were intercepted multiple times by your Quality Manager. For example, investigators requested drug product testing specifications from your QC Supervisor. However, your Quality Manager interrupted and stated that only he can explain and answer the requests. He also interfered when the investigators asked your supervisor questions about temperature monitoring and would not allow investigators to fully review temperature records used to support drug retention samples.\u003C\u002Fp>\u003Cp>• Investigators requested complaint records on June 17, 2024. You then provided a list of complaints on June 18, 2024. FDA later found positive mold samples for Kissable Oatmeal Daily Moisturizing Body Lotion batches in the QC laboratory office linked to a customer complaint. This complaint, and its associated investigations, were not disclosed in the list of complaints provided to FDA.\u003C\u002Fp>\u003Cp>• While interviewing an employee regarding the undisclosed positive mold results for your Kissable Oatmeal Daily Moisturizing Body Lotion, your Quality Manager entered the room and began berating the employee, who then left the room, impeding FDA’s review of your contamination investigation required under CGMP.\u003C\u002Fp>\u003Cp>• Investigators requested a list of batches distributed to the U.S. market multiple times during the inspection. Your Quality Assurance Supervisor initially claimed that you had no system to track batches of drugs shipped to the United States. This was later refuted by another employee and eventually you provided the requested list after a significant delay.\u003C\u002Fp>\u003Cp>\u003Cstrong>Delaying, Denying, Limiting, or Refusing a Drug Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&amp;C Act. See FDA’s guidance document:\u003Cbr>\u003Cem>Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection (June 2024)\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately investigate customer complaints. For example, your customer reported mold contamination in a batch of Kissable Oatmeal Daily Moisturizing Body Lotion. You determined the root cause was related to the container closure delivery system, specifically the pumps, used in the packaging of this product. However, your investigation did not clearly identify the scope of the contamination, and you failed to extend your investigation to other products packaged with the same pumps. Though you recalled two batches of Kissable Oatmeal Daily Moisturizing Body Lotion due to mold contamination, you lacked adequate evidence to support the contamination was limited to only two batches of finished product. You later committed to expanding the recall to other products packaged with these pumps.\u003C\u002Fp>\u003Cp>In your response, you state a procedure for investigations and root cause analysis will be developed. Furthermore, you explain there is no need for further investigation of the mold contamination issue because manufacturing and sales of this product have stopped.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack evidence that you have properly evaluated the root cause and scope of the mold contamination. You also fail to provide a comprehensive assessment of your complaint handling system to ensure all complaints have been adequately investigated.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\u003Cp>• Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including customer notifications and recalls.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test drug products you manufactured, including the identity and strength of each active ingredient prior to release and distribution into the U.S. market. For example, your QU released multiple batches of drug products without performing active ingredient assay. Additionally, we noted your test methods are not validated.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release.\u003C\u002Fp>\u003Cp>In your response, you state you will implement a procedure for finished product testing, and a protocol for validating your analytical procedures.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient evidence that distributed drug products conform to all appropriate finished product specifications. You also fail to address the product quality impact and risk of releasing drug products based on test results from analytical methods that have not been validated.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>&nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>&nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately test incoming components, including active pharmaceutical ingredients (APIs), for identity before using them in the manufacture of your drug products. Additionally, your firm released APIs for use based on your supplier’s certificates of analysis (COAs) without establishing the reliability of your suppliers’ test analyses at appropriate intervals. Furthermore, you did not demonstrate that you adequately performed identity testing on incoming glycerin, which is at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination.\u003C\u002Fp>\u003Cp>In your response, you state a procedure will be developed to ensure incoming active ingredients will be tested by an external or internal laboratory. You also commit to developing a plan to test glycerin for DEG and EG content.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack evidence that your current raw material inventory conforms with identity requirements and all other appropriate specifications. You also lack sufficient detail describing how you will qualify your suppliers and validate their COAs. Furthermore, you did not provide a retroactive risk assessment of distributed products containing components at high-risk for DEG or EG contamination.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fp>\u003Cp>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fp>\u003Cp>• The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fp>\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fp>\u003Cp>• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fp>\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\u003Cp>• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fp>\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products with adequate space for the orderly placement of equipment and materials to prevent mixups and contamination (21 CFR 211.42(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your drug manufacturing facility lacked adequate controls. For example:\u003C\u002Fp>\u003Cp>\u003Cem>A. Material storage\u003C\u002Fem>\u003Cbr>Investigators observed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> truck trailers on your property used for the storage of components, finished products, and other items. These trailers were not climate controlled, and you were unable to accurately describe the contents of the trailers due to your inadequate inventory management system. Furthermore, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an API in your drug products, was stored outdoors and exposed to the elements.\u003C\u002Fp>\u003Cp>\u003Cem>B. Pest control\u003C\u002Fem>\u003Cbr>Pest traps inside your raw material storage area were covered with filth and insects, and reports from your pest control service provider showed an ongoing pest issue.\u003C\u002Fp>\u003Cp>In your response, you state a procedure will be developed for managing inventories, including the dispositioning of nonconforming material in your warehouse and shipping trucks. You also state your pest control procedure will be improved and followed effectively.\u003C\u002Fp>\u003Cp>Your response is inadequate. You fail to demonstrate adequate controls over your inventory, including materials stored in trailers outside your facility. You also fail to comprehensively evaluate the scope and product quality risk of your pest control issue.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\u003Cp>• Your plans to provide sufficient space for the orderly storage of materials and adequate protection from environmental elements.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked a QU with appropriate oversight for the manufacture of your drug products. For example, we observed the following deficiencies:\u003C\u002Fp>\u003Cp>A. You failed to establish and implement adequate procedures to validate your processes and qualify the equipment used to manufacture your drug products. (21 CFR 211.100(a))\u003C\u002Fp>\u003Cp>B. You failed to perform cleaning validation studies for non-dedicated equipment used to manufacture your drug products (21 CFR 211.67(b)).\u003C\u002Fp>\u003Cp>C. You failed to establish and maintain an ongoing testing program to support the labeled expiry on your distributed drug products. Therefore, there is no assurance your drug products will remain acceptable throughout their labeled expiry period (21 CFR 211.137).\u003C\u002Fp>\u003Cp>In your response, you state you will update procedures to clarify responsibilities and authorities of the QU and other departments. You also state you will develop, improve, and implement process and cleaning validation procedures. Furthermore, you state you will develop a stability testing program.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a comprehensive review of your QU’s authority and ability to carry out its responsibility to ensure compliance with CGMP. You also lack sufficient details of your plans to fully execute process and cleaning validation studies. Furthermore, you do not provide results of reserve sample testing or any additional scientific evidence to support your expiration dates.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fp>\u003Cp>• A timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fp>\u003Cp>• A risk assessment for the distributed drug product(s) produced without performing any process validation studies.\u003C\u002Fp>\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>&nbsp; o Drugs with higher toxicities\u003Cbr>&nbsp; o Drugs with higher drug potencies\u003Cbr>&nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>&nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>&nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>&nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\u003Cp>• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>&nbsp; o Stability indicating methods.\u003Cbr>&nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>&nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>&nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\u003Cp>• All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 10, 2024, you initiated a voluntary recall of Kissable Oatmeal Daily Moisturizing Body Lotion due to the presence of mold contamination. The company announcement was posted to the FDA website: \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm#tabNav_advancedSearch.\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm#tabNav_advancedSearch.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>On November 13, 2024, you initiated a voluntary recall of additional products due to CGMP violations and potential mold contamination. However, as of the date of this letter, you have not answered our requests for additional information regarding the expanded recall.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We also note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&amp;C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded. Further, your facility may be subject to requirements of the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\">https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 28, 2024.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Brands International Corporation, located at 594 Newpark Blvd, Newmarket, Ontario L3X 2S2, Canada, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007389902 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>cc:\u003Cbr>David Price\u003Cbr>Chief Revenue Officer\u003Cbr>594 Newpark Blvd.\u003Cbr>Newmarket, ON L3X 2S2\u003Cbr>Canada\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-25\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. David Kahan\n\nRecipient Title\n\nManaging Partner\n\nBrands International Corporation\n\n101 Chase Avenue Suite 204\n\nLakewood, NJ 08701\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-25\nDecember 17, 2024\nDear Mr. Kahan:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brands International Corporation, FEI 3007389902, at 594 Newpark Blvd, Newmarket, Ontario L3X 2S2, Canada, from June 17 to 21, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nOur investigators documented your firm limited and\u002For delayed an FDA inspection. Under section 501(j) of the FD&C Act, 21 U.S.C. 351(j), your drugs are adulterated in that they have been manufactured, processed, packed, or held in an establishment where the owner or operator has limited inspection and\u002For delayed inspection.\nAdditionally, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your July 15, 2024 response to our Form FDA 483 in detail.\nDuring the inspection, our investigators observed specific violations including, but not limited to, the following.\nDelaying, Denying, and Limiting the Inspection\nYour firm limited and delayed the FDA inspection as follows:\n• At the start of the second day of the inspection, June 18, 2024, investigators were admitted into the building and left in a conference room. Investigators went to your laboratory to continue discussions with your Quality Control (QC) Supervisor from the day before. Later, your Quality Manager entered the laboratory and exhibited hostility by shoving and shouting at our investigators for conducting the inspection without their presence. Additionally, laboratory staff refused to open a drug stability chamber based on his hostile behavior. Your management staff’s behavior impeded our investigators during the inspection.\n• While attempting to ask questions to additional quality staff, our investigators were intercepted multiple times by your Quality Manager. For example, investigators requested drug product testing specifications from your QC Supervisor. However, your Quality Manager interrupted and stated that only he can explain and answer the requests. He also interfered when the investigators asked your supervisor questions about temperature monitoring and would not allow investigators to fully review temperature records used to support drug retention samples.\n• Investigators requested complaint records on June 17, 2024. You then provided a list of complaints on June 18, 2024. FDA later found positive mold samples for Kissable Oatmeal Daily Moisturizing Body Lotion batches in the QC laboratory office linked to a customer complaint. This complaint, and its associated investigations, were not disclosed in the list of complaints provided to FDA.\n• While interviewing an employee regarding the undisclosed positive mold results for your Kissable Oatmeal Daily Moisturizing Body Lotion, your Quality Manager entered the room and began berating the employee, who then left the room, impeding FDA’s review of your contamination investigation required under CGMP.\n• Investigators requested a list of batches distributed to the U.S. market multiple times during the inspection. Your Quality Assurance Supervisor initially claimed that you had no system to track batches of drugs shipped to the United States. This was later refuted by another employee and eventually you provided the requested list after a significant delay.\nDelaying, Denying, Limiting, or Refusing a Drug Inspection\nWhen an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act. See FDA’s guidance document:\nCircumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection (June 2024) at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86328\u002Fdownload.\nCGMP Violations\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou failed to adequately investigate customer complaints. For example, your customer reported mold contamination in a batch of Kissable Oatmeal Daily Moisturizing Body Lotion. You determined the root cause was related to the container closure delivery system, specifically the pumps, used in the packaging of this product. However, your investigation did not clearly identify the scope of the contamination, and you failed to extend your investigation to other products packaged with the same pumps. Though you recalled two batches of Kissable Oatmeal Daily Moisturizing Body Lotion due to mold contamination, you lacked adequate evidence to support the contamination was limited to only two batches of finished product. You later committed to expanding the recall to other products packaged with these pumps.\nIn your response, you state a procedure for investigations and root cause analysis will be developed. Furthermore, you explain there is no need for further investigation of the mold contamination issue because manufacturing and sales of this product have stopped.\nYour response is inadequate. You lack evidence that you have properly evaluated the root cause and scope of the mold contamination. You also fail to provide a comprehensive assessment of your complaint handling system to ensure all complaints have been adequately investigated.\nIn response to this letter, provide:\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n• Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including customer notifications and recalls.\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYou failed to adequately test drug products you manufactured, including the identity and strength of each active ingredient prior to release and distribution into the U.S. market. For example, your QU released multiple batches of drug products without performing active ingredient assay. Additionally, we noted your test methods are not validated.\nWithout adequate testing, you do not have scientific evidence that your drug product batches conform to appropriate specifications prior to release.\nIn your response, you state you will implement a procedure for finished product testing, and a protocol for validating your analytical procedures.\nYour response is inadequate. You do not provide sufficient evidence that distributed drug products conform to all appropriate finished product specifications. You also fail to address the product quality impact and risk of releasing drug products based on test results from analytical methods that have not been validated.\nIn response to this letter, provide:\n• A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm failed to adequately test incoming components, including active pharmaceutical ingredients (APIs), for identity before using them in the manufacture of your drug products. Additionally, your firm released APIs for use based on your supplier’s certificates of analysis (COAs) without establishing the reliability of your suppliers’ test analyses at appropriate intervals. Furthermore, you did not demonstrate that you adequately performed identity testing on incoming glycerin, which is at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination.\nIn your response, you state a procedure will be developed to ensure incoming active ingredients will be tested by an external or internal laboratory. You also commit to developing a plan to test glycerin for DEG and EG content.\nYour response is inadequate. You lack evidence that your current raw material inventory conforms with identity requirements and all other appropriate specifications. You also lack sufficient detail describing how you will qualify your suppliers and validate their COAs. Furthermore, you did not provide a retroactive risk assessment of distributed products containing components at high-risk for DEG or EG contamination.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn response to this letter, provide:\n• A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\n• The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n4. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products with adequate space for the orderly placement of equipment and materials to prevent mixups and contamination (21 CFR 211.42(b)).\nYour drug manufacturing facility lacked adequate controls. For example:\nA. Material storage\nInvestigators observed approximately (b)(4) truck trailers on your property used for the storage of components, finished products, and other items. These trailers were not climate controlled, and you were unable to accurately describe the contents of the trailers due to your inadequate inventory management system. Furthermore, (b)(4), an API in your drug products, was stored outdoors and exposed to the elements.\nB. Pest control\nPest traps inside your raw material storage area were covered with filth and insects, and reports from your pest control service provider showed an ongoing pest issue.\nIn your response, you state a procedure will be developed for managing inventories, including the dispositioning of nonconforming material in your warehouse and shipping trucks. You also state your pest control procedure will be improved and followed effectively.\nYour response is inadequate. You fail to demonstrate adequate controls over your inventory, including materials stored in trailers outside your facility. You also fail to comprehensively evaluate the scope and product quality risk of your pest control issue.\nIn response to this letter, provide:\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n• Your plans to provide sufficient space for the orderly storage of materials and adequate protection from environmental elements.\n5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYou lacked a QU with appropriate oversight for the manufacture of your drug products. For example, we observed the following deficiencies:\nA. You failed to establish and implement adequate procedures to validate your processes and qualify the equipment used to manufacture your drug products. (21 CFR 211.100(a))\nB. You failed to perform cleaning validation studies for non-dedicated equipment used to manufacture your drug products (21 CFR 211.67(b)).\nC. You failed to establish and maintain an ongoing testing program to support the labeled expiry on your distributed drug products. Therefore, there is no assurance your drug products will remain acceptable throughout their labeled expiry period (21 CFR 211.137).\nIn your response, you state you will update procedures to clarify responsibilities and authorities of the QU and other departments. You also state you will develop, improve, and implement process and cleaning validation procedures. Furthermore, you state you will develop a stability testing program.\nYour response is inadequate. You do not provide a comprehensive review of your QU’s authority and ability to carry out its responsibility to ensure compliance with CGMP. You also lack sufficient details of your plans to fully execute process and cleaning validation studies. Furthermore, you do not provide results of reserve sample testing or any additional scientific evidence to support your expiration dates.\nIn response to this letter, provide:\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n• A timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\n• A risk assessment for the distributed drug product(s) produced without performing any process validation studies.\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\n• A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n• All procedures that describe these and other elements of your remediated stability program.\nQuality Unit Authority\nSignificant findings in this letter indicate that your QU is not able to fully exercise its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nDrug Recall\nOn June 10, 2024, you initiated a voluntary recall of Kissable Oatmeal Daily Moisturizing Body Lotion due to the presence of mold contamination. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm#tabNav_advancedSearch.\nOn November 13, 2024, you initiated a voluntary recall of additional products due to CGMP violations and potential mold contamination. However, as of the date of this letter, you have not answered our requests for additional information regarding the expanded recall.\nCosmetics Manufactured for Distribution in the United States\nWe also note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded. Further, your facility may be subject to requirements of the Modernization of Cosmetic Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 28, 2024.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Brands International Corporation, located at 594 Newpark Blvd, Newmarket, Ontario L3X 2S2, Canada, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007389902 and ATTN: Matthew Jensen.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\ncc:\nDavid Price\nChief Revenue Officer\n594 Newpark Blvd.\nNewmarket, ON L3X 2S2\nCanada\n_______________________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Brands International Corporation","brands-international-corporation-689983-12172024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrands-international-corporation-689983-12172024","2026-10-26T08:08:08.546712+00:00","2024-12-24","689983","Mr. David Kahan","2026-08-19T17:06:35.49+00:00","Via Email","320-25-25","2024-12-17",{"id":341,"raw":342,"subject":346,"body_html":347,"body_text":348,"firm_name":349,"letter_id":350,"created_at":132,"fei_number":19,"letter_url":351,"updated_at":352,"action_type":22,"case_status":23,"posted_date":353,"marcs_cms_no":354,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":355,"body_fetched_at":356,"delivery_method":337,"recipient_title":19,"reference_number":19,"action_taken_date":357,"medical_device_id":19,"response_letter_date":19},1295,[343,344,345,11,346,13,13,13],"\u003Ctime datetime=\"2024-08-27T13:20:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-20T04:00:00Z\">08\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanumed-international-llc-674310-08202024\">AnuMed International, LLC\u003C\u002Fa>","Finished Pharmaceutical\u002FUnapproved New Drug\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Julie R. Alcantar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AnuMed International, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3908 E Broadway Rd, Suite 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85040-2995\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:julie@anumed-intl.com\"> julie@anumed-intl.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 20, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 674310\u003C\u002Fp>\n\n\u003Cp>Dear Julie Alcantar:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, AnuMed International, LLC, FEI 3010164449, at 3908 E Broadway Rd, Suite 110, Phoenix, Arizona from November 1 to 7, 2023.\u003C\u002Fp>\n\n\u003Cp>FDA also reviewed your website at the Internet address https:\u002F\u002Fwww.anumed-intl.com\u002F in February and April 2024 and has observed that your website offers “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products for sale in the United States. As described below, your above-mentioned products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>In addition, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B). We reviewed your November 28, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your product labeling obtained during FDA’s inspection and on your website, your “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your product labeling and website https:\u002F\u002Fwww.anumed-intl.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Semaglutide Homeopathic Formula\u003C\u002Fu>\u003Cbr>\nOn the product label:\u003Cbr>\n• “CRAVINGS\u003Cbr>\nAPPETITE\u003Cbr>\nWEIGHT LOSS”\u003C\u002Fp>\n\n\u003Cp>• “INDICATIONS:\u003Cbr>\nIt may help to temporarily reduce minor hunger pangs and control appetite to support weight loss efforts.”\u003C\u002Fp>\n\n\u003Cp>• “DIRECTIONS: . . . For maximum effectiveness repeat 2 to 3 times per day until desired weight or craving control is achieved. Continue as needed if cravings arise and to help avoid weight regain.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Magnesium 50 mg Body Cream\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Highly Effective for Leg Cramps, Muscle Soreness, Nighttime Leg Discomfort, Inflammation Relief”\u003Cbr>\n• “Magnesium is important for many processes in the body. It helps regulate muscle and nerve function, blood sugar levels, blood pressure, making protein, bone and DNA. Studies have shown that deficiency of Magnesium results in cramping and several muscular pain.”\u003Cbr>\n• “Magnesium Chloride helps with the normal functioning of cells, nerves, bones, and the heart.”\u003Cbr>\n• “Niacin (vitamin B3) helps support the cardiovascular system and the heart. It contributes to healthy metabolic function, supports the pancreas, and works to support brain &amp; nerve function.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ 25mg Per Pump PROGESTERONE CREAM and AnuMed™ 75mg Per Pump PROGESTERONE CREAM\u003C\u002Fu>\u003Cbr>\nOn the product label:\u003Cbr>\n• “75 mg Per Pump PROGESTERONE CREAM . . . Hormones \u002F Mood \u002F Sleep . . . Use 1 pump a day 1 to 3 minutes before a meal, or as recommended by your practitioner.”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>5 Benefits of Natural Progesterone Cream with ISO99:\u003C\u002Fstrong> . . . Relieves Menopause Symptoms . . . promote bone density . . . Boosts Fertility . . . preventing miscarriage. . . . Treats Fibroid Tumors . . . Helps Endometriosis . . . Balance Hormones and Relieve PMS Symptoms . . . Relieves Inflammation”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP and AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>Natural Bio-Identical BIO-EST 2.5mg\u003C\u002Fstrong> may help with menopause symptoms. . . . \u003Cstrong>BENEFITS\u003C\u002Fstrong> . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\u003Cbr>\n• “\u003Cstrong>Natural Bio-Identical Bio-EST 5mg\u003C\u002Fstrong> may help with menopause symptoms. . . . \u003Cstrong>BENEFITS\u003C\u002Fstrong> . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ 2.5 All Natural ESTRIOL CREAM and AnuMed™ 5.0 All Natural ESTRIOL CREAM\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>Natural Bioidentical Estriol Cream 2.5 with Hyaluronic Acid\u003C\u002Fstrong> . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\u003Cbr>\n• “\u003Cstrong>Natural Bioidentical Estriol Cream 5.0 with Hyaluronic Acid\u003C\u002Fstrong> . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ Bio-Identical DHEA 20 CREAM and AnuMed™ Bio-Identical DHEA 50 CREAM\u003C\u002Fu>\u003Cbr>\nFrom your storefront on Amazon’s webpage https:\u002F\u002Fwww.amazon.com\u002FANUMED-Bioidentical-Dehydroepiandrosterone-Hyaluronic-Essential\u002Fdp\u002FB0BNHH4R8Q?th=1\u003Cbr>\n• “ANUMED – All Natural Bioidentical DHEA 20mg Cream . . . for Hormone Balance, Mood, Immune System . . . Natural Balancing of Hormone Levels, Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>All Natural Bioidentical DHEA 50mg Cream (Dehydroepiandrosterone) + Hyaluronic Acid . . . Hormone Balance, Mood, Energy, Immune System\u003C\u002Fstrong> . . . Natural Balancing of Hormone Levels. Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>50,000 IU Vitamin D3+K2 CREAM\u003C\u002Fu>\u003Cbr>\nOn the product label:\u003Cbr>\n• “With Hyaluronic Acid . . . May Increase Calcium Absorption . . . PSORIASIS &amp; ECZEMA RELIEF . . . May help relieve skin flares caused by Psoriasis &amp; Eczema. . . . Vitamin D is necessary for strong bones and teeth. . . . May Help muscle function &amp; support immune system. . . . May help heal wounds faster such as fading bruising.”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Vitamin D3 50,000 IU cream is our most potent vitamin-based solution created with the intent of replenishing the lowest vitamin deficiencies and relieving the symptoms of various conditions such as psoriasis and eczema in a minimal time frame. It can help with boosting immune system.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support\u003C\u002Fu>\u003Cbr>\n• In the name of the product – “Parasite Cleanser”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “A proprietary blend of herbals along with zinc to help fight and eliminate parasites in the body”\u003Cbr>\n• “Wormwood kills adult parasites and especially pinworms.”\u003Cbr>\n• “Black Walnut which has anti-fungal and antibacterial properties and can kill intestinal parasites like roundworm and tapeworm. It helps to clean out any toxins and dangerous pathogens.”\u003Cbr>\n• “Clove Bud kills the parasite eggs that may be lingering in the intestinal tract along with worms . . . Thus, helps relieve indigestion and constipation problems. . . . These compounds provide potent antiseptic and anti-inflammatory benefits.”\u003Cbr>\n• “Fennel is helpful in reducing diarrhea if it is caused by bacterial infection because some components of the essential oil in fennel such as anetol and cineole have disinfectant and antibacterial properties.” • “Ginger is known as an anti-parasitic. Researchers show that it can inhibit a variety of worms and parasites..”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Vitamin C Booster - 2000mg\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Best protection support from cold, flu [influenza], virus [viral infection]”\u003Cbr>\n• “Zinc may help with wound healting [sic]”\u003Cbr>\n• “L-Lysine . . . Also, may help people with the herpes simplex virus (HSV) [viral infection] and diabetes.”\u003Cbr>\n• “Ultimate Defense from cold, Flu [influenza], Virus [viral infection], allergy”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Immune Booster 90 Capsules\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Has Zinc for which . . . may help combat colds, upper respiratory infections and viruses [viral infection]. . . . This product not only boosts immune system to help make body strong in order to combat most viruses [viral infection] and infections”\u003Cbr>\nVegan Vitamin D3 K2 60ct Capsules\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Research studies have indicated that K2 intake can decrease bone loss among those with Osteoporosis.”\u003Cbr>\n• “Vitamin D deficiencies have been linked by researchers to . . . sleeping disorders.”\u003Cbr>\n• “Research has indicated that vitamin D, while in combination with other bodily properties, plays a pivotal role in fortifying the antibacterial potency of the essential immune cells.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Heart Disease: Research has found that B-12 in combination with B-6 and folic acid may help regulate and decrease the levels of homocysteine in the blood system, which are known to increase the chances of cardiovascular disease.”\u003Cbr>\n• “Dementia and Cognitive Abilities: . . . Research has indicated an association between low levels of B-12 and cognitive decline. As a result, the B-12 . . . solution may help support and replace the lack of the nutrient while improving cognitive function.”\u003Cbr>\n• “When the body has a deficiency of the vitamin, harmful bacteria begins to grow. A consistent intake of B-12 has demonstrated that it can help remove bad bacteria . . . and potentially prevent gastrointestinal disorders.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>2oz Vitamin C Booster Drops\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Has been recommended to try and help ease cold and flu [influenza] symptoms.”\u003Cbr>\n• “Be prepared for fighting illness and germs.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>2oz Anumed Zinc Drops\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Ultimate Defense from Cold, Flu [influenza], Virus [viral infection], Allergy”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Turmeric Curcumin Drops 775mg with Black Pepper Extract\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Curcumin and other chemicals in turmeric might decrease swelling (inflammation). Because of this, turmeric might be beneficial for treating conditions that involve inflammation. Has been known to help with the reduction of inflammation, pain”\u003Cbr>\n\u003Cbr>\nYour “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” and “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because the product labels and\u002For websites include statements that misleadingly suggest that the drug products are approved or endorsed by FDA in some way. For example, the website for Magnesium 50 mg Body Cream includes the image of a blue circle with the claim, “FDA * APPROVED * FACILITY.” Further, the product labels and\u002For websites for the other seven before-listed products include statements that these products are made or manufactured in an “FDA inspected and Certified Facility,” a “Certified FDA registered facility,” and\u002For a “FDA registered facility.” FDA’s regulations provide that “[r]egistration of an establishment or listing of a drug does not denote approval of the establishment, the drug, or other drugs of the establishment, nor does it mean that a product may be legally marketed” (21 CFR 207.77(a)). However, the general public is not likely to be familiar with the details of FDA’s regulations. The above assertions misleadingly suggest that the above-mentioned drug products are approved or endorsed by FDA in some way. Your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” products are not the subjects of an FDA-approved application. Therefore, these products are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because their labeling is false or misleading. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Additionally, a drug is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act, 21 U.S.C. 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” and “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your before-noted products fail to bear adequate directions for their intended uses and, therefore, are misbranded under section 502(f)(1) of the Act, 21 U.S.C. 352(f)(1). The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing, including specific identity testing as appropriate, for each shipment of each lot of components, such as glycerin and ethyl alcohol (ethanol; alcohol), used in the manufacture of your drug products. During the inspection, you indicated that you were not aware testing was required and that you rely upon your supplier’s certificate of analysis (COA) for acceptance of incoming materials.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Alcohol (Ethanol)\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Identity testing for pharmaceutical alcohol (ethanol and isopropyl alcohol) includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Identity testing for glycerin and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you are reviewing options for identity testing of raw materials. Your response is inadequate because you did not provide sufficient detail or evidence of corrective actions (e.g., assessing retain samples).\u003C\u002Fp>\n\n\u003Cp>Without appropriate testing of components, you cannot ensure the quality and safety of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003Cbr>\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003Cbr>\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003Cbr>\n• A commitment to provide test results for components used in the manufacture of your drug products, no later than 30 calendar days from the date of this letter, including testing retains for all lots of drug components at high-risk for DEG and EG contamination, and pharmaceutical alcohol for methanol contamination. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG, EG, and methanol.\u003C\u002Fp>\n\n\u003Cp>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG, EG, or methanol contamination (including, but not limited to, glycerin and ethyl alcohol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG, EG, or methanol including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Process Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate your processes used to manufacture your drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that your process validation procedure will be reviewed and personnel trained. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Water System\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm uses water as a component to manufacture your drug products. You failed to adequately qualify your purified water system. You also failed to show that your water system is adequately monitored to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that your quality unit will begin conducting regular inspections to ensure the water system is adequate. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\u003C\u002Fp>\n\n\u003Cp>Purified water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you manufacture drug products (including hormones) and non-pharmaceutical products (e.g., cosmetics) using shared equipment (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and filling lines). In your response, you state that your cleaning validation procedure will be reviewed and revised to include the necessary cleaning validation studies. Adequate cleaning procedures are required as chemical and microbial residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003Cbr>\n• A timeline for performing PPQ for each of your marketed drug products.\u003Cbr>\n• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003Cbr>\n• A comprehensive, independent assessment of your water system design, control, and maintenance.\u003Cbr>\n• A thorough remediation plan to assure you operate a suitable water system, including any redesign. Include a robust ongoing control, maintenance, and monitoring program to ensure the system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\u003Cbr>\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003Cbr>\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o Maximum hold times before cleaning\u003Cbr>\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003Cbr>\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate your non-compendial microbial methods used to test drug products and assure the methods were equivalent to or better than USP methods. For example, you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> to analyze total count and yeast and mold in finished product. Additionally, you failed to follow the instructions for use and the investigator observed the use of expired \u003Cstrong>(b)(4)\u003C\u002Fstrong> test materials for finished product testing.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicate that you ceased use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-compendial tests. Your response is inadequate as you did not provide sufficient detail or evidence of corrective actions, including validation or verification of appropriate microbial methods for drug product testing by your contract laboratory or your internal laboratory, and to demonstrate that the methods used are equivalent to or better than USP methods. You also did not commit to conducting retrospective review of products tested using your non-compendial, non-validated tests.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision. Include specifications for drug products within expiration that are already distributed within the United States and specifications for future drug products.\u003Cbr>\n&nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003Cbr>\n• Chemical and microbial test method verification or validation reports and supporting data for internal and contracted testing of your components and drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003Cbr>\n• An adequate system for retention of production, control, or distribution records associated for all batches of drug product (21 CFR 211.180(a)).\u003Cbr>\n• Batch production and control records include documentation of the accomplishment of each significant step in the manufacture and processing for each batch of drug product (21 CFR 211.188(b)).\u003Cbr>\n• Performance of periodic (i.e., at least annually) product reviews (21 CFR 211.180(e)).\u003Cbr>\n• Adequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. The QU must be accountable for implementing all the controls and reviewing the results of manufacture to ensure that product quality standards have been met. In smaller firms, it is recommended that another qualified individual, not involved in the production operation, conduct an additional, periodic review of QU activities. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection ending December 13, 2017, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Your AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM, “AnuMed™ Bio-Identical DHEA 20 CREAM” and “AnuMed™ Bio-Identical DHEA 50 CREAM” drugs are hormone containing products that are deemed to be new drugs under a final determination issued under 21 CFR part 330, as published in the Federal Register on September 9, 1993 (see 58 FR 47610). There, the Agency has determined that any OTC drug product other than hydrocortisone that is labeled, represented, or promoted as a topically applied hormone-containing product for drug use are not generally recognized as safe and effective under section 201(p)(1) of the FD&amp;C Act and that all such products are deemed to be new drugs and require an approved new drug application under section 505 of the FD&amp;C Act to be lawfully marketed. 21 CFR 310.530.\u003C\u002Fp>\n\n\u003Cp>Furthermore, as an OTC combination psoriasis\u002Fskin protectant drug products, your “50,000 IU Vitamin D3+K2 CREAM” must conform to the conditions of use set forth in the Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use (henceforth “M032”), encompassed under the final administrative order OTC000021 and the Over-the-Counter Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”) encompassed under the final administrative order OTC000005. However, your “50,000 IU Vitamin D3+K2 CREAM” does not conform to conditions specified in either M032 or M016 because its labeling has intended uses such as, “PSORIASIS &amp; ECZEMA RELIEF” and “help heal wounds” that go beyond the general intended uses described in M032 and M016. Neither final order allows for such a combination of a psoriasis and a skin protectant. There is no basis under the FD&amp;C Act under which these products would be legally marketed without an approved application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “Semaglutide Homeopathic Formula” labeling describes the products as being “homeopathic.”\u003C\u002Fp>\n\n\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product includes semaglutide, which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJulie R. Alcantar\n\nRecipient Title\n\nOwner\n\nAnuMed International, LLC\n\n3908 E Broadway Rd, Suite 110\n\nPhoenix, AZ 85040-2995\n\nUnited States\n\njulie@anumed-intl.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nAugust 20, 2024\n\nRE: 674310\n\nDear Julie Alcantar:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, AnuMed International, LLC, FEI 3010164449, at 3908 E Broadway Rd, Suite 110, Phoenix, Arizona from November 1 to 7, 2023.\n\nFDA also reviewed your website at the Internet address https:\u002F\u002Fwww.anumed-intl.com\u002F in February and April 2024 and has observed that your website offers “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products for sale in the United States. As described below, your above-mentioned products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nIn addition, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B). We reviewed your November 28, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nUnapproved New Drugs\n\nBased on a review of your product labeling obtained during FDA’s inspection and on your website, your “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your product labeling and website https:\u002F\u002Fwww.anumed-intl.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nSemaglutide Homeopathic Formula\n\nOn the product label:\n\n• “CRAVINGS\n\nAPPETITE\n\nWEIGHT LOSS”\n\n• “INDICATIONS:\n\nIt may help to temporarily reduce minor hunger pangs and control appetite to support weight loss efforts.”\n\n• “DIRECTIONS: . . . For maximum effectiveness repeat 2 to 3 times per day until desired weight or craving control is achieved. Continue as needed if cravings arise and to help avoid weight regain.”\n\nMagnesium 50 mg Body Cream\n\nOn the product webpage:\n\n• “Highly Effective for Leg Cramps, Muscle Soreness, Nighttime Leg Discomfort, Inflammation Relief”\n\n• “Magnesium is important for many processes in the body. It helps regulate muscle and nerve function, blood sugar levels, blood pressure, making protein, bone and DNA. Studies have shown that deficiency of Magnesium results in cramping and several muscular pain.”\n\n• “Magnesium Chloride helps with the normal functioning of cells, nerves, bones, and the heart.”\n\n• “Niacin (vitamin B3) helps support the cardiovascular system and the heart. It contributes to healthy metabolic function, supports the pancreas, and works to support brain & nerve function.”\n\nAnuMed™ 25mg Per Pump PROGESTERONE CREAM and AnuMed™ 75mg Per Pump PROGESTERONE CREAM\n\nOn the product label:\n\n• “75 mg Per Pump PROGESTERONE CREAM . . . Hormones \u002F Mood \u002F Sleep . . . Use 1 pump a day 1 to 3 minutes before a meal, or as recommended by your practitioner.”\n\nOn the product webpage:\n\n• “5 Benefits of Natural Progesterone Cream with ISO99: . . . Relieves Menopause Symptoms . . . promote bone density . . . Boosts Fertility . . . preventing miscarriage. . . . Treats Fibroid Tumors . . . Helps Endometriosis . . . Balance Hormones and Relieve PMS Symptoms . . . Relieves Inflammation”\n\nAnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP and AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump\n\nOn the product webpage:\n\n• “Natural Bio-Identical BIO-EST 2.5mg may help with menopause symptoms. . . . BENEFITS . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\n\n• “Natural Bio-Identical Bio-EST 5mg may help with menopause symptoms. . . . BENEFITS . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\n\nAnuMed™ 2.5 All Natural ESTRIOL CREAM and AnuMed™ 5.0 All Natural ESTRIOL CREAM\n\nOn the product webpage:\n\n• “Natural Bioidentical Estriol Cream 2.5 with Hyaluronic Acid . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\n\n• “Natural Bioidentical Estriol Cream 5.0 with Hyaluronic Acid . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\n\nAnuMed™ Bio-Identical DHEA 20 CREAM and AnuMed™ Bio-Identical DHEA 50 CREAM\n\nFrom your storefront on Amazon’s webpage https:\u002F\u002Fwww.amazon.com\u002FANUMED-Bioidentical-Dehydroepiandrosterone-Hyaluronic-Essential\u002Fdp\u002FB0BNHH4R8Q?th=1\n\n• “ANUMED – All Natural Bioidentical DHEA 20mg Cream . . . for Hormone Balance, Mood, Immune System . . . Natural Balancing of Hormone Levels, Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\n\nOn the product webpage:\n\n• “All Natural Bioidentical DHEA 50mg Cream (Dehydroepiandrosterone) + Hyaluronic Acid . . . Hormone Balance, Mood, Energy, Immune System . . . Natural Balancing of Hormone Levels. Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\n\n50,000 IU Vitamin D3+K2 CREAM\n\nOn the product label:\n\n• “With Hyaluronic Acid . . . May Increase Calcium Absorption . . . PSORIASIS & ECZEMA RELIEF . . . May help relieve skin flares caused by Psoriasis & Eczema. . . . Vitamin D is necessary for strong bones and teeth. . . . May Help muscle function & support immune system. . . . May help heal wounds faster such as fading bruising.”\n\nOn the product webpage:\n\n• “Vitamin D3 50,000 IU cream is our most potent vitamin-based solution created with the intent of replenishing the lowest vitamin deficiencies and relieving the symptoms of various conditions such as psoriasis and eczema in a minimal time frame. It can help with boosting immune system.”\n\nTravel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support\n\n• In the name of the product – “Parasite Cleanser”\n\nOn the product webpage:\n\n• “A proprietary blend of herbals along with zinc to help fight and eliminate parasites in the body”\n\n• “Wormwood kills adult parasites and especially pinworms.”\n\n• “Black Walnut which has anti-fungal and antibacterial properties and can kill intestinal parasites like roundworm and tapeworm. It helps to clean out any toxins and dangerous pathogens.”\n\n• “Clove Bud kills the parasite eggs that may be lingering in the intestinal tract along with worms . . . Thus, helps relieve indigestion and constipation problems. . . . These compounds provide potent antiseptic and anti-inflammatory benefits.”\n\n• “Fennel is helpful in reducing diarrhea if it is caused by bacterial infection because some components of the essential oil in fennel such as anetol and cineole have disinfectant and antibacterial properties.” • “Ginger is known as an anti-parasitic. Researchers show that it can inhibit a variety of worms and parasites..”\n\nVitamin C Booster - 2000mg\n\nOn the product webpage:\n\n• “Best protection support from cold, flu [influenza], virus [viral infection]”\n\n• “Zinc may help with wound healting [sic]”\n\n• “L-Lysine . . . Also, may help people with the herpes simplex virus (HSV) [viral infection] and diabetes.”\n\n• “Ultimate Defense from cold, Flu [influenza], Virus [viral infection], allergy”\n\nImmune Booster 90 Capsules\n\nOn the product webpage:\n\n• “Has Zinc for which . . . may help combat colds, upper respiratory infections and viruses [viral infection]. . . . This product not only boosts immune system to help make body strong in order to combat most viruses [viral infection] and infections”\n\nVegan Vitamin D3 K2 60ct Capsules\n\nOn the product webpage:\n\n• “Research studies have indicated that K2 intake can decrease bone loss among those with Osteoporosis.”\n\n• “Vitamin D deficiencies have been linked by researchers to . . . sleeping disorders.”\n\n• “Research has indicated that vitamin D, while in combination with other bodily properties, plays a pivotal role in fortifying the antibacterial potency of the essential immune cells.”\n\nB-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)\n\nOn the product webpage:\n\n• “Heart Disease: Research has found that B-12 in combination with B-6 and folic acid may help regulate and decrease the levels of homocysteine in the blood system, which are known to increase the chances of cardiovascular disease.”\n\n• “Dementia and Cognitive Abilities: . . . Research has indicated an association between low levels of B-12 and cognitive decline. As a result, the B-12 . . . solution may help support and replace the lack of the nutrient while improving cognitive function.”\n\n• “When the body has a deficiency of the vitamin, harmful bacteria begins to grow. A consistent intake of B-12 has demonstrated that it can help remove bad bacteria . . . and potentially prevent gastrointestinal disorders.”\n\n2oz Vitamin C Booster Drops\n\nOn the product webpage:\n\n• “Has been recommended to try and help ease cold and flu [influenza] symptoms.”\n\n• “Be prepared for fighting illness and germs.”\n\n2oz Anumed Zinc Drops\n\nOn the product webpage:\n\n• “Ultimate Defense from Cold, Flu [influenza], Virus [viral infection], Allergy”\n\nTurmeric Curcumin Drops 775mg with Black Pepper Extract\n\nOn the product webpage:\n\n• “Curcumin and other chemicals in turmeric might decrease swelling (inflammation). Because of this, turmeric might be beneficial for treating conditions that involve inflammation. Has been known to help with the reduction of inflammation, pain”\n\nYour “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” and “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here1, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.2 Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nMisbranded Drugs\n\n“Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because the product labels and\u002For websites include statements that misleadingly suggest that the drug products are approved or endorsed by FDA in some way. For example, the website for Magnesium 50 mg Body Cream includes the image of a blue circle with the claim, “FDA * APPROVED * FACILITY.” Further, the product labels and\u002For websites for the other seven before-listed products include statements that these products are made or manufactured in an “FDA inspected and Certified Facility,” a “Certified FDA registered facility,” and\u002For a “FDA registered facility.” FDA’s regulations provide that “[r]egistration of an establishment or listing of a drug does not denote approval of the establishment, the drug, or other drugs of the establishment, nor does it mean that a product may be legally marketed” (21 CFR 207.77(a)). However, the general public is not likely to be familiar with the details of FDA’s regulations. The above assertions misleadingly suggest that the above-mentioned drug products are approved or endorsed by FDA in some way. Your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” products are not the subjects of an FDA-approved application. Therefore, these products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because their labeling is false or misleading. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAdditionally, a drug is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act, 21 U.S.C. 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” and “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your before-noted products fail to bear adequate directions for their intended uses and, therefore, are misbranded under section 502(f)(1) of the Act, 21 U.S.C. 352(f)(1). The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Violations\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou failed to perform adequate identity testing, including specific identity testing as appropriate, for each shipment of each lot of components, such as glycerin and ethyl alcohol (ethanol; alcohol), used in the manufacture of your drug products. During the inspection, you indicated that you were not aware testing was required and that you rely upon your supplier’s certificate of analysis (COA) for acceptance of incoming materials.\n\nAlcohol (Ethanol)\n\nIdentity testing for pharmaceutical alcohol (ethanol and isopropyl alcohol) includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nGlycerin\n\nIdentity testing for glycerin and certain other high-risk drug components3 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn your response, you state that you are reviewing options for identity testing of raw materials. Your response is inadequate because you did not provide sufficient detail or evidence of corrective actions (e.g., assessing retain samples).\n\nWithout appropriate testing of components, you cannot ensure the quality and safety of your drug products.\n\nIn response to this letter, provide:\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• A commitment to provide test results for components used in the manufacture of your drug products, no later than 30 calendar days from the date of this letter, including testing retains for all lots of drug components at high-risk for DEG and EG contamination, and pharmaceutical alcohol for methanol contamination. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG, EG, and methanol.\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG, EG, or methanol contamination (including, but not limited to, glycerin and ethyl alcohol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG, EG, or methanol including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nLack of Process Validation\n\nYou failed to adequately validate your processes used to manufacture your drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\n\nIn your response, you state that your process validation procedure will be reviewed and personnel trained. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nInadequate Water System\n\nYour firm uses water as a component to manufacture your drug products. You failed to adequately qualify your purified water system. You also failed to show that your water system is adequately monitored to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\n\nIn your response, you state that your quality unit will begin conducting regular inspections to ensure the water system is adequate. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\n\nPurified water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nFurthermore, you manufacture drug products (including hormones) and non-pharmaceutical products (e.g., cosmetics) using shared equipment (e.g., (b)(4) tanks, (b)(4), and filling lines). In your response, you state that your cleaning validation procedure will be reviewed and revised to include the necessary cleaning validation studies. Adequate cleaning procedures are required as chemical and microbial residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\n\nIn response to this letter, provide:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing PPQ for each of your marketed drug products.\n\n• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\n• A comprehensive, independent assessment of your water system design, control, and maintenance.\n\n• A thorough remediation plan to assure you operate a suitable water system, including any redesign. Include a robust ongoing control, maintenance, and monitoring program to ensure the system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\n\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYou failed to validate your non-compendial microbial methods used to test drug products and assure the methods were equivalent to or better than USP methods. For example, you use (b)(4) to analyze total count and yeast and mold in finished product. Additionally, you failed to follow the instructions for use and the investigator observed the use of expired (b)(4) test materials for finished product testing.\n\nIn your response, you indicate that you ceased use of the (b)(4) non-compendial tests. Your response is inadequate as you did not provide sufficient detail or evidence of corrective actions, including validation or verification of appropriate microbial methods for drug product testing by your contract laboratory or your internal laboratory, and to demonstrate that the methods used are equivalent to or better than USP methods. You also did not commit to conducting retrospective review of products tested using your non-compendial, non-validated tests.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision. Include specifications for drug products within expiration that are already distributed within the United States and specifications for future drug products.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n• Chemical and microbial test method verification or validation reports and supporting data for internal and contracted testing of your components and drug products.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• An adequate system for retention of production, control, or distribution records associated for all batches of drug product (21 CFR 211.180(a)).\n\n• Batch production and control records include documentation of the accomplishment of each significant step in the manufacture and processing for each batch of drug product (21 CFR 211.188(b)).\n\n• Performance of periodic (i.e., at least annually) product reviews (21 CFR 211.180(e)).\n\n• Adequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. The QU must be accountable for implementing all the controls and reviewing the results of manufacture to ensure that product quality standards have been met. In smaller firms, it is recommended that another qualified individual, not involved in the production operation, conduct an additional, periodic review of QU activities. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nRepeat Observations at Facility\n\nIn a previous inspection ending December 13, 2017, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________\n\n1 Your AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM, “AnuMed™ Bio-Identical DHEA 20 CREAM” and “AnuMed™ Bio-Identical DHEA 50 CREAM” drugs are hormone containing products that are deemed to be new drugs under a final determination issued under 21 CFR part 330, as published in the Federal Register on September 9, 1993 (see 58 FR 47610). There, the Agency has determined that any OTC drug product other than hydrocortisone that is labeled, represented, or promoted as a topically applied hormone-containing product for drug use are not generally recognized as safe and effective under section 201(p)(1) of the FD&C Act and that all such products are deemed to be new drugs and require an approved new drug application under section 505 of the FD&C Act to be lawfully marketed. 21 CFR 310.530.\n\nFurthermore, as an OTC combination psoriasis\u002Fskin protectant drug products, your “50,000 IU Vitamin D3+K2 CREAM” must conform to the conditions of use set forth in the Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use (henceforth “M032”), encompassed under the final administrative order OTC000021 and the Over-the-Counter Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”) encompassed under the final administrative order OTC000005. However, your “50,000 IU Vitamin D3+K2 CREAM” does not conform to conditions specified in either M032 or M016 because its labeling has intended uses such as, “PSORIASIS & ECZEMA RELIEF” and “help heal wounds” that go beyond the general intended uses described in M032 and M016. Neither final order allows for such a combination of a psoriasis and a skin protectant. There is no basis under the FD&C Act under which these products would be legally marketed without an approved application.\n\n2 We recognize that the “Semaglutide Homeopathic Formula” labeling describes the products as being “homeopathic.”\n\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product includes semaglutide, which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\n\n3 Components with higher risk of DEG or EG contamination compared to other drug components.","AnuMed International, LLC","anumed-international-llc-674310-08202024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanumed-international-llc-674310-08202024","2026-10-26T08:07:56.270514+00:00","2024-08-27","674310","Julie R. Alcantar","2026-08-19T23:51:57.526+00:00","2024-08-20",{"id":359,"raw":360,"subject":39,"body_html":364,"body_text":365,"firm_name":366,"letter_id":367,"created_at":368,"fei_number":19,"letter_url":369,"updated_at":370,"action_type":22,"case_status":23,"posted_date":371,"marcs_cms_no":372,"product_type":51,"closeout_date":19,"issuing_office":38,"recipient_name":373,"body_fetched_at":374,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":375,"medical_device_id":19,"response_letter_date":19},2055,[361,362,363,38,39,13,13,13],"\u003Ctime datetime=\"2023-06-13T13:20:00Z\">06\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-25T04:00:00Z\">05\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fu-mart-international-inc-659734-05252023\">U Mart International, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mingzhe Pang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>U Mart International, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4 Brighton Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Allston\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02135\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:we.care@umartgo.com\"> we.care@umartgo.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:umartinternational@gmail.com\"> umartinternational@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 25, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mingzhe Pang:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.umartgo.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your RELX Classic Replacement Pod – Dark Sparkle (Cola) ENDS product is misbranded under section 903(a)(7)(B) of the FD&amp;C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tobacco Product Sold to an Individual Under the Age of 21 are Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA’s investigation of the website https:\u002F\u002Fwww.umartgo.com revealed that you sold an ENDS product to an individual under the age of 21.1 Specifically, during our investigation of https:\u002F\u002Fwww.umartgo.com, a person younger than 21 years of age purchased RELX Classic Replacement Pod – Dark Sparkle (Cola) ENDS product from your website. No retailer may sell tobacco products to a person younger than 21 years of age under section 906(d)(5) of the FD&amp;C Act (21 U.S.C. § 387f(d)(5)). Under section 903(a)(7)(B) of the FD&amp;C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed in violation of section 906(d)(5) of the FD&amp;C Act (21 U.S.C. § 387f(d)(5)). Because this tobacco product is sold or distributed to persons younger than 21 years of age in violation of section 906(d)(5) of the FD&amp;C Act (21 U.S.C. § 387f(d)(5)), this product is misbranded under section 903(a)(7)(B) of the FD&amp;C Act (21 U.S.C. § 387c(a)(7)(B)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please be aware that the FD&amp;C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007. See Section 910(a) of the FD&amp;C Act. Retailers should discuss with their suppliers the current marketing status of any particular tobacco product’s application or any product’s marketing authorization.\u003C\u002Fp>\n\n\u003Cp>The violation discussed in this letter does not necessarily constitute an exhaustive list. You should address any violation that is referenced above, as well as violations that are the same as or similar to the one stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301920, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>U Mart International Inc\u003Cbr>\nAttn: Mingzhe Pang and Jin Gao\u003Cbr>\n75 Braintree St Apt 215\u003Cbr>\nAllston, Massachusetts 02134-1858\u003C\u002Fp>\n\n\u003Cp>Name.com, Inc.\u003Cbr>\nabuse@name.com\u003C\u002Fp>\n\n\u003Cp>Fastly, Inc.\u003Cbr>\nabuse@fastly.com\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Effective December 20, 2019, an amendment to the FD&amp;C Act raises the minimum age of sale of tobacco products to age 21. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Fnewly-signed-legislation-raises-federal-minimum-age-sale-tobacco-products-21.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMingzhe Pang\n\nU Mart International, Inc.\n\n4 Brighton Ave\n\nAllston, MA 02135\n\nUnited States\n\nwe.care@umartgo.com\n\numartinternational@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 25, 2023\n\nWARNING LETTER\n\nDear Mingzhe Pang:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.umartgo.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS are required to be in compliance with the requirements in the FD&C Act.\n\nFDA has determined that your RELX Classic Replacement Pod – Dark Sparkle (Cola) ENDS product is misbranded under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age.\n\nTobacco Product Sold to an Individual Under the Age of 21 are Misbranded\n\nFDA’s investigation of the website https:\u002F\u002Fwww.umartgo.com revealed that you sold an ENDS product to an individual under the age of 21.1 Specifically, during our investigation of https:\u002F\u002Fwww.umartgo.com, a person younger than 21 years of age purchased RELX Classic Replacement Pod – Dark Sparkle (Cola) ENDS product from your website. No retailer may sell tobacco products to a person younger than 21 years of age under section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)). Under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed in violation of section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)). Because this tobacco product is sold or distributed to persons younger than 21 years of age in violation of section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)), this product is misbranded under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)).\n\nConclusion and Requested Actions\n\nIt is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease be aware that the FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007. See Section 910(a) of the FD&C Act. Retailers should discuss with their suppliers the current marketing status of any particular tobacco product’s application or any product’s marketing authorization.\n\nThe violation discussed in this letter does not necessarily constitute an exhaustive list. You should address any violation that is referenced above, as well as violations that are the same as or similar to the one stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301920, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nU Mart International Inc\n\nAttn: Mingzhe Pang and Jin Gao\n\n75 Braintree St Apt 215\n\nAllston, Massachusetts 02134-1858\n\nName.com, Inc.\n\nabuse@name.com\n\nFastly, Inc.\n\nabuse@fastly.com\n\n___________________________\n\n1 Effective December 20, 2019, an amendment to the FD&C Act raises the minimum age of sale of tobacco products to age 21. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Fnewly-signed-legislation-raises-federal-minimum-age-sale-tobacco-products-21.","U Mart International, Inc.","u-mart-international-inc-659734-05252023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fu-mart-international-inc-659734-05252023","2026-10-26T08:10:16.646849+00:00","2023-06-13","659734","Mingzhe Pang","2026-08-20T01:03:26.387+00:00","2023-05-25",{"id":377,"raw":378,"subject":85,"body_html":385,"body_text":386,"firm_name":387,"letter_id":388,"created_at":45,"fei_number":19,"letter_url":389,"updated_at":390,"action_type":22,"case_status":48,"posted_date":391,"marcs_cms_no":392,"product_type":95,"closeout_date":393,"issuing_office":382,"recipient_name":394,"body_fetched_at":395,"delivery_method":76,"recipient_title":19,"reference_number":19,"action_taken_date":396,"medical_device_id":19,"response_letter_date":19},3065,[379,380,381,382,383,13,384,13],"\u003Ctime datetime=\"2021-10-26T13:20:00Z\">10\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-13T04:00:00Z\">10\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forgana-international-corp-613018-10132021\">Organa International Corp.\u003C\u002Fa>","Office of Human and Animal Food Operations Division West 4","Unapproved New Drugs\u002FMisbranded ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forgana-international-corp-613018-09302024\">\u003Ctime datetime=\"2024-10-04T04:00:00Z\">10\u002F04\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Larry Mills\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Organa International Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>533 N 1650 W\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Springville\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84663\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations Division West 4\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 13, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ref: CMS Case #613018\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mills:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.organa.net and your social media website at www.facebook.com\u002Forganainternational in June 2021. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at the Internet address www.organa.net in June 2021 and has determined that you take orders there for your products Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Relieve Progesterone Cream, and Silver Gel. We have also reviewed your social media website, www.facebook.com\u002Forganainternational, which directs consumers to your webpage at www.organa.net to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)] in that they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Copper product page\u003C\u002Fstrong>\u003Cbr>\n• “Anemia…A copper deficiency can lead to anemia…”\u003Cbr>\n• “Heart Problems…Low intakes of copper may be associated with increased LDL ‘bad’ cholesterol and decreased HDL ‘good’ cholesterol. This may account for low copper levels being a potential contributing factor in heart and circulatory problems, which may lead to full blown heart disease.”\u003Cbr>\n• “Infections: A lack of copper in the diet may lower the body’s immune system. Normal intakes may help to reduce the risk of infection.”\u003Cbr>\n• “Osteoporosis: …[A] mild deficiency of copper may trigger, then worsen, osteoporotic lesions in bones. Boosting…intakes may help reduce the risk of osteoporosis.”\u003Cbr>\n• “Wound and Burn Treatment: …Colloidal copper promotes healing of skin burns and cuts. . .. [C]opper applied directly to the wound promotes faster healing and skin regeneration.”\u003Cbr>\n• “According to researchers…free radicals can offer a “pathway for cancer…and a variety of diseases.” Antioxidants, like those found in Colloidal copper, eliminate free radicals from the body.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Rhodium product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “May be effective in treating HIV and cancer.”\u003Cbr>\n• “Early research has shown that rhodium has a positive effect on tumors in mice… Later research has determined that mismatched DNA is associated with carcinogenesis. Studies have shown that rhodium will bind with mismatched DNA and inhibit the damage associated with these cells.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Ruthenium product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Reported to neutralize cancer cells.”\u003Cbr>\n• “Antibacterial…Studies have shown that ruthenium particles have antibacterial properties. Studies have shown that ruthenium is more effective against Gram positive and Gram negative pathogenic bacteria.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Zinc product\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Essential in wound healing.”\u003Cbr>\n• “Zinc: . . .. Essential in wound healing.”\u003Cbr>\n• “…Zinc deficiency may be contributing to the development or progression of chronic eye diseases, such as macular degeneration . . ..”\u003Cbr>\n• “[T]here is a growing body of evidence that indicates that poor zinc intake is related to…cataract formation; and optic neuritis, the inflammation of the optic nerve.”\u003Cbr>\n• “Many patients who get frequent colds and sore throats have shown a marked decrease in these outbreaks with zinc supplementation.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Uplift product page\u003C\u002Fstrong>\u003Cbr>\n• Product label:\u003Cbr>\n&nbsp; o “Uplift is a product designed to target illness. Specific colloidal minerals are added to Organa Mineral Drink to … fight viruses and bacteria.”\u003Cbr>\n&nbsp; o “Silver [an ingredient in Uplift]: A natural antibiotic\u003Cbr>\n&nbsp; o “Zinc [an ingredient in Uplift]: Reduces the duration of colds and illnesses”\u003Cbr>\n&nbsp; o “Gold [an ingredient in Uplift]: Has anti-inflammatory properties”\u003Cbr>\n&nbsp; o “Essential Oil Blend [an ingredient in Uplift]: Antibacterial and antiviral properties…”\u003Cbr>\n• “Uplift is a product which targets the health and wellness of the body as well as the ability to fight off colds and viruses…”\u003Cbr>\n• “A special blend of pure essential oils is added [to Uplift]. These oils together all have anti-bacterial, anti-parasitic, anti-septic...properties.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Immune Boost product page\u003C\u002Fstrong>\u003Cbr>\n• Product label:\u003Cbr>\n&nbsp; o “Reduces Allergy Symptoms”\u003Cbr>\n• “… a tool to prevent illnesses from occurring.”\u003Cbr>\n• “sigA antibodies help by trapping bacteria before they cause harm.”\u003Cbr>\n• “When taken consistently, many have reported improvement in chronic allergy conditions, autoimmune problems...”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Essiac Tea product page\u003C\u002Fstrong>\u003Cbr>\n• Both the website and the images of your product label bear the following claims about ingredients in Essiac Tea:\u003Cbr>\n&nbsp; o “Burdock…May help reduce inflammation.”\u003Cbr>\n&nbsp; o “Slippery Elm…Soothes gastrointestinal … inflammation.”\u003Cbr>\n&nbsp; o “Turkish Rhubarb…May help reduce inflammation...”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Organa.net Gold product page\u003C\u002Fstrong>\u003Cbr>\n• “Anti-inflammatory properties: Research shows that colloidal gold can ease the swelling associated with inflammatory conditions like arthritis, bursitis, rheumatism, and tendinitis.”\u003Cbr>\n• “[G]old…may help individuals who are suffering from imbalanced emotional or mental states like anxiety, depression...”\u003Cbr>\n• “Neurological Improvements: Using colloidal gold may help improve neurological diseases in some patients, according to the Meridian Institute’s Health and Rejuvenation Research Center. The Institute followed the case of a woman with essential tremor, a neurological disorder, who found that her symptoms subsided when she took colloidal gold and came back when she stopped taking it.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Indium product page\u003C\u002Fstrong>\u003Cbr>\n• “Indium manages the vital functions that are performed by the adrenals, pituitary gland and hypothalamus. These regulate many complex functions of the body, including…perception of pain…inflammations…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Iron product page\u003C\u002Fstrong>\u003Cbr>\n• “Iron is an important component of hemoglobin, the substance in red blood cells . . .. A lack of red blood cells leads to anemia.”\u003Cbr>\n• “[I]ron is directly related to brain health and its functions. Proper flow of blood in the brain can … help to create new neural pathways to prevent cognitive disorders like dementia and Alzheimer’s disease . . ..”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Magnesium product page\u003C\u002Fstrong>\u003Cbr>\n• “[L]ack of magnesium…can result in serious deficiencies which cause illness and make you prone to infection and virus.”\u003Cbr>\n• “Blood Sugar: Magnesium allows your body to regulate blood sugar properly. Diabetes can occur when your body does not properly regulate the amount of sugar in your body.”\u003Cbr>\n• “Headaches: Magnesium has a surprisingly significant effect on migraines and headaches by helping to stop them from happening in the first place.”\u003Cbr>\n• “Depression”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Manganese product page\u003C\u002Fstrong>\u003Cbr>\n• “Although research has yet to consistently prove that manganese can prevent osteoporosis, it is believed to be one of the contributing factors that slow down the progress of that debilitating disease.”\u003Cbr>\n• “Manganese has been seen to alleviate anxiety…depression….”\u003Cbr>\n• Inflammation and Sprains: Manganese is a widely known remedy for sprains as well as inflammation as it helps in increasing the level of superoxide dismutase. . .. SOD has anti-inflammatory qualities which arthritis sufferers desperately need, so adding manganese back into the body to increase synthesis and function of SOD has been connected with a decrease in symptoms . . ..”\u003Cbr>\n• “Manganese has also exhibited efficiency in controlling the level of sugar in human blood. This may further prevent the occurrence of certain diseases like diabetes. To control the level of sugar in the blood, manganese normalizes insulin synthesis and secretion, and the unpredictable drops in blood sugar can be better regulated, providing a more normal and functional life for diabetics.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Molybdenum product page\u003C\u002Fstrong>\u003Cbr>\n• “Fights Inflammatory and Autoimmune Disease: Tetrathiomolybdate, a form of molybdenum with four sulfur atoms, lowers copper levels in the body, which makes it effective in the treatment of fibrotic, inflammatory and autoimmune diseases. . . . [I]n animal studies tetrathiomolybdate dramatically inhibits pulmonary and liver fibrosis, which is thickening and scarring of tissue, helps prevent liver damage from acetaminophen and reduces heart damage from doxorubicin, a bacterial antibiotic. Tetrathiomolybdate also shows a partially protective effect against diabetes.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Palladium product page\u003C\u002Fstrong>\u003Cbr>\n• “Palladium …is an anticoagulant…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Vanadium product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Inhibits the formation of cholesterol.”\u003Cbr>\n• “Vanadium may also help in treating or preventing osteoporosis…”\u003Cbr>\n• “Diabetes: . . . One clinical trial tested the use of vanadium in treatment of diabetes and showed that vanadium had beneficial effects on patients with type 2 diabetes. Vanadium may also improve insulin sensitivity, as well as lower total and LDL, or ‘bad cholesterol,’ levels in people with type 2 diabetes . . ..”\u003Cbr>\n• “Cholesterol: Studies have shown that vanadium helps reduce the cholesterol in the liver cells and decreases blood lipid content . . .. Adequate vanadium content in the brain . . . prevents the development of sclerosis, prevents the risk of cardiovascular disease, hypertension.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net MSM (methylsulfonylmethane) product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Anti-inflammatory”\u003Cbr>\n• “Anti-inflammatory: MSM is a powerful anti-inflammatory”\u003Cbr>\n• \"Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial… Assessment of methylsulfonylmethane (MSM) on the development of osteoarthritis (OA): An animal study\".\u003Cbr>\n• “It cleans the bloodstream so allergies to food and pollens go away in about three to four days”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Relieve Progesterone Cream product page\u003C\u002Fstrong>\u003Cbr>\n• “Relieve is a combination of natural ingredients that work in harmony with the body to restore low progesterone levels. . .. Dr. John Lee of Oregon states that balancing the hormones by introducing progesterone through the skin is the first step to curbing osteoporosis. . .. Potential benefits to health: headaches\u002Fmigraines, depression, PMS prevention relief, mood swings, hot flashes, &amp; osteoporosis.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Silver Gel product page\u003C\u002Fstrong>\u003Cbr>\n• Product label: “Use for skin irritations such as . . . cuts, fungus, eczema, psoriasis, and insect bites”\u003Cbr>\n• “Silver Gel aids and promotes natural healing for your skin. . .. The antimicrobial nature of silver makes Silver Gel the perfect solution for all skin irritations. . .. Try Silver Gel for: Eczema, Psoriasis, Razor Burn, Dermatitis, Rosacea, Poison Oak &amp; Ivy, Dry skin, Sunburn, Rashes, Itching, Scrapes, Sunburn, and Acne.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Organa.net Blog:\u003C\u002Fstrong>\u003Cbr>\n\u003Cem>\u003Cstrong>Evaluating the Health Benefits of Colloidal Minerals, November 17, 2020\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr>\n• “Silver has been used for centuries to treat arthritis, cancer, tuberculosis, herpes, and practically anything and everything. Even as medical science has evolved, alternative practitioners worldwide credit colloidal silver for . . . preventing or treating mild to severe infections.”\u003Cbr>\n• “Though there is no evidential proof, Colloidal Silver is thought to help the body heal itself. Other benefits can include:\u003Cbr>\n&nbsp; o “Treat herpes, flue, pneumonia, certain eye infections.”\u003Cbr>\n&nbsp; o “Treatment of cancer and AIDS”\u003Cbr>\n&nbsp; o “Healing wounds: … It is seen when wounds or ulcers are dressed with silver-containing products; the silver particles exhibit antibacterial properties. . .. [C]olloidal silver was also put through scientific test-tube experiments. These studies exhibit antiviral, antifungal, antibacterial, and anti-inflammatory properties.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tell Me About Zinc, December 17, 2020\u003C\u002Fstrong>\u003Cbr>\n• “Zinc…reduces the risk, severity, and duration of infectious diseases.”\u003Cbr>\n• “Zinc…is needed for natural killer cells which help fight off infections.”\u003Cbr>\n• “A zinc deficiency…causes inflammation.”\u003Cbr>\n• “There have been many articles published recently about zinc and it’s [sic] ability to raise anti-viral resistance.”\u003C\u002Fp>\n\n\u003Cp>In addition, the “Reviews” portion of your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such testimonials include:\u003Cbr>\n• Mechel Wall: “I use the nano silver, zinc and minerals daily and have stayed healthy in spite of being exposed to the current virus several times.”\u003Cbr>\n• Lila Turnbull: “I order Essiac tea from Organa after surviving Colon [sic] cancer. It was recommended from a relative whose husband had great results from it after researching its use with cancer and its prevention.”\u003Cbr>\n• Rachel Folkman: “I’ve been using Uplift for two year [sic]. . .. Anytime I start to feel sick I take a capful for a couple of days and it helps kick my sickness.”\u003Cbr>\n• Tracy Mills: “I take the mineral drink everyday along with magnesium &amp; iron. Since doing that I rarely get headaches . . ..”\u003Cbr>\n• Maribel Lopez: “[I]t has helped me for infections, pain, nausea, bleeding, for infected eyes . . ..”\u003Cbr>\n• Maria Lopez: “The colloidal silver of this company is excellent and I am recommending it to everyone I know for how well it has worked for my daughters and my grandson since [sic] for cold or throat infection, skin infection, infection of the eyes . . ..”\u003Cbr>\n• Karina: “I bought it for a friend taht [sic] is undergoing chemotherapy . She is been dringing [sic] Essiac Tea 4 months and she is toleratong [sic] the chemo treatments and her tumors have reduced and some disappeared.”\u003Cbr>\n• A. Perrone: “I had a tooth extraction scheduled because the tooth was badly decayed. 10 days before the surgery I developed an abscess at the tooth site in my palette. I knew the oral surgeon would give me antibiotics and postpone the surgery. I used…Organa 30ppm Colloidal Silver twice daily and after 5 days the abscess was gone. The extraction went off without complication.”\u003Cbr>\n• Courtlin (pertaining to your Magnesium product): “I drink the magnesium and mineral drink and it has greatly helped my gastroenteritis issues. I have been to several doctors that have never seemed to be able to diminish the pain I used to feel in my stomach but to my surprise these have helped drastically.”\u003C\u002Fp>\n\n\u003Cp>In addition, your Facebook page contains evidence of intended use of your products as drugs, including evidence in the form of personal testimonials that you posted recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such evidence of intended use includes:\u003C\u002Fp>\n\n\u003Cp>• On June 15, 2020, Organa posted the following: “Rhodium is now being heavily researched as a means to treat cancer…”\u003Cbr>\n• On February 25, 2020, Organa posted the following testimonial from “Annie”: “The Silver has worked wonderfully on cuts, burns, and bugbites [sic]. We all came down with flu symptoms but since we’re all taking silver, it’s Ben [sic] going way [sic] before it can really get started. I began drinking it as soon as I felt the tickle in my thrust [sic] and I’m almost completely better belie [sic] the week is out. I’ve bought two bottles and am ordering one today because it really works and there are no crazy side effects as opposed to pharmesutical [sic] antibiotics.”\u003Cbr>\n• On January 22, 2020, Organa posted the following testimonial from an “Organa Customer”: “I started taking Copper one week ago because of swelling in my legs and pain from a torn ligament. I was taking products for joint support but still had pain and swelling. I RESEARCHED and read that Copper pulls nutrients into ligamints [sic]. I am moving my legs up and down the stairs and bending my legs 80% better after one week! I have suffered with this for 7 years after I had back surgery. I feel this was the missing link and very thankful this product is what they say it is”\u003Cbr>\n• On January 15, 2020, Organa posted the following: “Zinc deficiency may be contributing to the development or progression of chronic eye diseases such as macular degeneration, the major cause of vision loss among older people. In one study, vision loss was reduced by 10 percent in people taking supplements…of zinc . . .. In addition, there is a growing body of evidence that indicates that poor zinc intake is related to . . . cataract formation; and optic neuritis, the inflammation of the optic nerve. Zinc is still 15% off! Head to our website now and get yourself a bottle”\u003Cbr>\n• On December 10, 2019, Organa posted the following: “Many studies have shown that a zinc deficiency can impair a large variety of immune functions and defense mechanisms in animals, and some studies have shown similar effects in humans. These effects include abnormalities and eventual shrinking of the spleen, thymus, and lymph nodes; and impaired production of antibodies-have been found to be correctable with zinc supplementation. Zinc is on sale this month! Make sure you head over to our website to get some before the sale ends!”\u003C\u002Fp>\n\n\u003Cp>Your Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Silver, Relieve Progesterone Cream, and Silver Gel products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. No FDA-approved application pursuant to section 505 of the FD&amp;C Act [21 U.S.C. 355] is in effect for any of these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act [21 U.S.C. 355(a) and 331(d)].\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Dietary Supplement Misbranding Charges\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Even if your Copper, Rhodium, Ruthenium, Zinc, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, and Silver were not unapproved new drugs and\u002For misbranded drugs and described above, they would be misbranded foods under section 403 of the Act, as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 403(s)(2)(B)] in that the labels fail to identify your products using the term “dietary supplement” in accordance with 21 CFR 101.3(g), which requires that a dietary supplement be identified by the term “dietary supplement” as part of the product’s statement of identity, except the word “dietary” may be deleted and replaced by the name of the dietary ingredient in the product or an appropriate descriptive term. The product labels include a Supplements Facts label, which is evidence of your intent to market the products as Dietary Supplements.\u003C\u002Fp>\n\n\u003Cp>2. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size on the labels are incorrect. The terms “serving” or “serving size” for a dietary supplement are defined in 21 CFR 101.9(b) and 101.12, Table 2, as the maximum amount recommended on the label for consumption per eating occasion. The labels state the serving size is “1 tsp” while the directions indicate to “Take 2 tsp. once or twice daily as needed.” Furthermore, your “Silver” product is also misbranded because its label fails to include a serving size. The product labels fail to follow the listed “serving size” common measure with the equivalent metric quantity as required by 21 CFR 101.9(b)(7).\u003C\u002Fp>\n\n\u003Cp>3. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(B) [21 U.S.C. §343(q)(1)B] and 403(q)(5)(F) of the Act [21 U.S.C. §§ 343(q)(5)(F)] because the labels fail to declare the number of servings per container under the serving size on the left hand side of the nutrition label or fails to include this information as part of the net quantity of contents declaration in accordance with 21 CFR 101.36(b)(1)(ii).\u003C\u002Fp>\n\n\u003Cp>4. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. 343 § (q)(5)(F)] in that the presentation of the nutrition information on the labeling does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products fail to enclose the nutrition information (Supplement Facts label) in a box using hairlines and titled with bolded “Supplement Facts” (not “Supplemental Facts” as incorrectly noted on your product labels) set full width, as required by 21 CFR 101.36(e)(1) and (2). Furthermore, all nutrition information within the nutrition label (Supplement Facts label) must utilize all black or one color type, as required by 21 CFR 101.36(e)(3)(ii)\u003C\u002Fp>\n\n\u003Cp>b. The labels for your “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” and “Zinc” products list iron, magnesium, manganese, molybdenum, and zinc, respectively in the nutrition information label. Iron, magnesium, manganese, molybdenum, and zinc are (b)(2)-dietary ingredients (i.e., a dietary ingredient that has a Reference Daily Intake (RDI). Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\u003C\u002Fp>\n\n\u003Cp>c. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver”, “Vanadium,” “Zinc,” and “Essiac Tea” products fail to include the subheading “Servings Per Container” as required by 21 CFR 101.36(b)(ii) and 101.36(e)(6)(i). A heavy bar must be placed beneath the subheading “Servings Per Container” except that if “Servings Per Container” is not required and, as a result, not declared, the bar must be placed beneath the subheading “Serving Size”.\u003C\u002Fp>\n\n\u003Cp>d. The labels for your “Copper,” “Gold,” “Indium,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver”, and “Essiac Tea” products fail to include a heavy bar beneath the last (b)(3)-dietary ingredient (other dietary ingredient), as required by 21 CFR 101.36(e)(6)(iii).\u003C\u002Fp>\n\n\u003Cp>e. The following product labels are misbranded in that they fail to list “Other ingredients” in a separate “Other ingredients” list outside and immediately below the Supplement Facts label in accordance with 21 CFR 101.4(g):\u003Cbr>\n\u003Cbr>\ni. The product labels for Copper and Gold list “Purified Water” within the Supplement Facts label\u003C\u002Fp>\n\n\u003Cp>ii. The product labels for Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Rhodium, Ruthenium, Vanadium, and Zinc list “Distilled Water” within the Supplement Facts\u003C\u002Fp>\n\n\u003Cp>iii. The product label for Essiac Tea lists the “Other Ingredients: Distilled Water, Potassium Sorbate, Sodium Benzoate, and Phosphoric Acid” within the Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>f. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver,” and “Zinc” bear the following or similar statement: “Percent Daily Values based on a 2,000-calorie diet.” This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D).\u003C\u002Fp>\n\n\u003Cp>g. Several of your product labels are for persons within more than one group. If a product is for persons within more than one group, the percent of Daily Value for each group must be presented in separate columns, as required in 21 CFR 101.36(b)(2)(iii)(E).\u003C\u002Fp>\n\n\u003Cp>h. The Essiac Tea product label lacks a declaration of % Daily Value. Furthermore, on several of your product labels the statement *“Percentage Daily Value not established” is not linked to a symbol elsewhere in the nutrition information label, as required by 21 101.36 (b)(3)(iv).\u003C\u002Fp>\n\n\u003Cp>i. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to accurately declare the net quantity of contents on the principal display panel in accordance with 21 CFR 101.7 and 15 U.S.C.§ 1453(a)(2) of the Fair Packaging and Labeling Act.\u003C\u002Fp>\n\n\u003Cp>j. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343 (e)(1)] in that each label fails to list the name and place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5.\u003C\u002Fp>\n\n\u003Cp>k. Your Essiac Tea product is misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. § 343(r)(1)(A)] because the product label bears a nutrient content claim, but the product does not meet the requirements to make such claim. Under section 403(r)(1)(A) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of food must be made in accordance with a regulation authorizing the use of such a claim. Characterizing the level of a nutrient in the food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient misbrands the product under section 403(r)(l)(A) of the Act. Specifically, your Essiac Tea product label bears the claim, “Slippery Elm [an ingredient in your Essiac Tea product]: Rich in . . . antioxidants,” but use of this “antioxidant” nutrient content claim fails to comply with the requirements listed in 21 CFR 101.54(g). These requirements state, in part, that for a product to bear such a claim, a reference daily intake (RDI) must have been established for each of the nutrients that are the subject of the claim [21 CFR 101.54(g)(l)], and these nutrients must have recognized antioxidant activity [21 CPR 101.54(g)(2)]. The level of each nutrient that is the subject of the claim must also be sufficient to qualify for the claim under 21 CFR 101.54(b), (c), or (e), as required by 21 CFR 101.54(g)(3). Further, nutrient content claims using the term \"antioxidant\" must include the names of the nutrients that are the subject of the claim as part of the claim or, alternatively, the term \"antioxidant\" or \"antioxidants\" may be linked by a symbol (e.g., an asterisk) that refers to the same symbol that appears elsewhere on the same panel of the product label, followed by the name or names of the nutrients with recognized antioxidant activity [21 CFR 101.54(g)(4)]. Your claim \"[r]ich in antioxidants\" is a nutrient content claim, but Essiac Tea does not meet the requirements to bear such a claim because the claim does not include the names of the nutrients that are the subject of the claim or state them on the same panel and link them with an asterisk, as required by 21 CFR 101.54(g).\u003C\u002Fp>\n\n\u003Cp>l. The Essiac product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the product label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>We also offer the following comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>• Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products contain the statement, “This product is not intended to diagnose, treat, or prevent disease. Statements have not been evaluated by the FDA.” This disclaimer is not in accordance with the required text. Per 101.93, the required text should state: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Furthermore, this disclaimer is not linked to any specific structure function claim on the product label. The FDA disclaimer statement as noted on your product label must be bolded and set off in a box, and the symbol preceding the disclaimer statement must be linked to the same symbol placed at the end of each structure function statement on the label in accordance with 21 CFR 101.93(d) and (e).\u003C\u002Fp>\n\n\u003Cp>• For your product labels, there is no provision in the regulations for the listing of “Ingredients” as a heading in the Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>• Your Essiac Tea product label lists the chemical preservatives sodium benzoate, potassium sorbate and phosphoric acid but does not bear labeling stating that fact, in that the label fails to include a separate description of their function as a preservative in accordance with 21 CFR 101.22(j).\u003C\u002Fp>\n\n\u003Cp>• The directions for use statements on your product labels are placed before the nutrition information. Directions for use are considered intervening material. All information appearing on the information panel must appear in one place without other intervening material, as required by 21 CFR 101.2(e).\u003C\u002Fp>\n\n\u003Cp>• The Essiac Tea product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, “Turkish rhubarb” is not a standardized common name of a botanical dietary ingredient listed in the reference Herbs of Commerce.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303)236-3094 if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDenver District Director &amp; Program Division Director\u003Cbr>\nOffice of Human and Animal Food Operations Division West 4\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Even if certain of your products, such as your Indium and Palladium products, are marketed only for nonprescription indications, they would not meet the conditions under section 505G of the FD&amp;C Act [21 U.S.C. 355h] for lawful marketing without an approved application, including because indium and palladium were not active ingredients in any applicable final monograph or tentative final monograph issued under 21 CFR part 330, for purposes of section 505G(a), nor was marketing of these products permitted by an administrative order under section 505G(b). Additionally, these products would be misbranded under section 502(ee) of the FD&amp;C Act [21 U.S.C. 352(ee)] because they would be nonprescription drugs subject to section 505G of the FD&amp;C Act that do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act [21 U.S.C. 355].\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nLarry Mills\n\nRecipient Title\n\nPresident\n\nOrgana International Corp.\n\n533 N 1650 W\n\nSpringville, UT 84663\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations Division West 4\n\nUnited States\n\nOctober 13, 2021\n\nWARNING LETTER\n\nRef: CMS Case #613018\n\nDear Mr. Mills:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.organa.net and your social media website at www.facebook.com\u002Forganainternational in June 2021. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website at the Internet address www.organa.net in June 2021 and has determined that you take orders there for your products Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Relieve Progesterone Cream, and Silver Gel. We have also reviewed your social media website, www.facebook.com\u002Forganainternational, which directs consumers to your webpage at www.organa.net to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)] in that they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOrgana.net Copper product page\n\n• “Anemia…A copper deficiency can lead to anemia…”\n\n• “Heart Problems…Low intakes of copper may be associated with increased LDL ‘bad’ cholesterol and decreased HDL ‘good’ cholesterol. This may account for low copper levels being a potential contributing factor in heart and circulatory problems, which may lead to full blown heart disease.”\n\n• “Infections: A lack of copper in the diet may lower the body’s immune system. Normal intakes may help to reduce the risk of infection.”\n\n• “Osteoporosis: …[A] mild deficiency of copper may trigger, then worsen, osteoporotic lesions in bones. Boosting…intakes may help reduce the risk of osteoporosis.”\n\n• “Wound and Burn Treatment: …Colloidal copper promotes healing of skin burns and cuts. . .. [C]opper applied directly to the wound promotes faster healing and skin regeneration.”\n\n• “According to researchers…free radicals can offer a “pathway for cancer…and a variety of diseases.” Antioxidants, like those found in Colloidal copper, eliminate free radicals from the body.”\n\nOrgana.net Rhodium product page\n\n• Product label: “May be effective in treating HIV and cancer.”\n\n• “Early research has shown that rhodium has a positive effect on tumors in mice… Later research has determined that mismatched DNA is associated with carcinogenesis. Studies have shown that rhodium will bind with mismatched DNA and inhibit the damage associated with these cells.”\n\nOrgana.net Ruthenium product page\n\n• Product label: “Reported to neutralize cancer cells.”\n\n• “Antibacterial…Studies have shown that ruthenium particles have antibacterial properties. Studies have shown that ruthenium is more effective against Gram positive and Gram negative pathogenic bacteria.”\n\nOrgana.net Zinc product\n\n• Product label: “Essential in wound healing.”\n\n• “Zinc: . . .. Essential in wound healing.”\n\n• “…Zinc deficiency may be contributing to the development or progression of chronic eye diseases, such as macular degeneration . . ..”\n\n• “[T]here is a growing body of evidence that indicates that poor zinc intake is related to…cataract formation; and optic neuritis, the inflammation of the optic nerve.”\n\n• “Many patients who get frequent colds and sore throats have shown a marked decrease in these outbreaks with zinc supplementation.”\n\nOrgana.net Uplift product page\n\n• Product label:\n\no “Uplift is a product designed to target illness. Specific colloidal minerals are added to Organa Mineral Drink to … fight viruses and bacteria.”\n\no “Silver [an ingredient in Uplift]: A natural antibiotic\n\no “Zinc [an ingredient in Uplift]: Reduces the duration of colds and illnesses”\n\no “Gold [an ingredient in Uplift]: Has anti-inflammatory properties”\n\no “Essential Oil Blend [an ingredient in Uplift]: Antibacterial and antiviral properties…”\n\n• “Uplift is a product which targets the health and wellness of the body as well as the ability to fight off colds and viruses…”\n\n• “A special blend of pure essential oils is added [to Uplift]. These oils together all have anti-bacterial, anti-parasitic, anti-septic...properties.”\n\nOrgana.net Immune Boost product page\n\n• Product label:\n\no “Reduces Allergy Symptoms”\n\n• “… a tool to prevent illnesses from occurring.”\n\n• “sigA antibodies help by trapping bacteria before they cause harm.”\n\n• “When taken consistently, many have reported improvement in chronic allergy conditions, autoimmune problems...”\n\nOrgana.net Essiac Tea product page\n\n• Both the website and the images of your product label bear the following claims about ingredients in Essiac Tea:\n\no “Burdock…May help reduce inflammation.”\n\no “Slippery Elm…Soothes gastrointestinal … inflammation.”\n\no “Turkish Rhubarb…May help reduce inflammation...”\n\nOrgana.net Gold product page\n\n• “Anti-inflammatory properties: Research shows that colloidal gold can ease the swelling associated with inflammatory conditions like arthritis, bursitis, rheumatism, and tendinitis.”\n\n• “[G]old…may help individuals who are suffering from imbalanced emotional or mental states like anxiety, depression...”\n\n• “Neurological Improvements: Using colloidal gold may help improve neurological diseases in some patients, according to the Meridian Institute’s Health and Rejuvenation Research Center. The Institute followed the case of a woman with essential tremor, a neurological disorder, who found that her symptoms subsided when she took colloidal gold and came back when she stopped taking it.”\n\nOrgana.net Indium product page\n\n• “Indium manages the vital functions that are performed by the adrenals, pituitary gland and hypothalamus. These regulate many complex functions of the body, including…perception of pain…inflammations…”\n\nOrgana.net Iron product page\n\n• “Iron is an important component of hemoglobin, the substance in red blood cells . . .. A lack of red blood cells leads to anemia.”\n\n• “[I]ron is directly related to brain health and its functions. Proper flow of blood in the brain can … help to create new neural pathways to prevent cognitive disorders like dementia and Alzheimer’s disease . . ..”\n\nOrgana.net Magnesium product page\n\n• “[L]ack of magnesium…can result in serious deficiencies which cause illness and make you prone to infection and virus.”\n\n• “Blood Sugar: Magnesium allows your body to regulate blood sugar properly. Diabetes can occur when your body does not properly regulate the amount of sugar in your body.”\n\n• “Headaches: Magnesium has a surprisingly significant effect on migraines and headaches by helping to stop them from happening in the first place.”\n\n• “Depression”\n\nOrgana.net Manganese product page\n\n• “Although research has yet to consistently prove that manganese can prevent osteoporosis, it is believed to be one of the contributing factors that slow down the progress of that debilitating disease.”\n\n• “Manganese has been seen to alleviate anxiety…depression….”\n\n• Inflammation and Sprains: Manganese is a widely known remedy for sprains as well as inflammation as it helps in increasing the level of superoxide dismutase. . .. SOD has anti-inflammatory qualities which arthritis sufferers desperately need, so adding manganese back into the body to increase synthesis and function of SOD has been connected with a decrease in symptoms . . ..”\n\n• “Manganese has also exhibited efficiency in controlling the level of sugar in human blood. This may further prevent the occurrence of certain diseases like diabetes. To control the level of sugar in the blood, manganese normalizes insulin synthesis and secretion, and the unpredictable drops in blood sugar can be better regulated, providing a more normal and functional life for diabetics.”\n\nOrgana.net Molybdenum product page\n\n• “Fights Inflammatory and Autoimmune Disease: Tetrathiomolybdate, a form of molybdenum with four sulfur atoms, lowers copper levels in the body, which makes it effective in the treatment of fibrotic, inflammatory and autoimmune diseases. . . . [I]n animal studies tetrathiomolybdate dramatically inhibits pulmonary and liver fibrosis, which is thickening and scarring of tissue, helps prevent liver damage from acetaminophen and reduces heart damage from doxorubicin, a bacterial antibiotic. Tetrathiomolybdate also shows a partially protective effect against diabetes.”\n\nOrgana.net Palladium product page\n\n• “Palladium …is an anticoagulant…”\n\nOrgana.net Vanadium product page\n\n• Product label: “Inhibits the formation of cholesterol.”\n\n• “Vanadium may also help in treating or preventing osteoporosis…”\n\n• “Diabetes: . . . One clinical trial tested the use of vanadium in treatment of diabetes and showed that vanadium had beneficial effects on patients with type 2 diabetes. Vanadium may also improve insulin sensitivity, as well as lower total and LDL, or ‘bad cholesterol,’ levels in people with type 2 diabetes . . ..”\n\n• “Cholesterol: Studies have shown that vanadium helps reduce the cholesterol in the liver cells and decreases blood lipid content . . .. Adequate vanadium content in the brain . . . prevents the development of sclerosis, prevents the risk of cardiovascular disease, hypertension.”\n\nOrgana.net MSM (methylsulfonylmethane) product page\n\n• Product label: “Anti-inflammatory”\n\n• “Anti-inflammatory: MSM is a powerful anti-inflammatory”\n\n• \"Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial… Assessment of methylsulfonylmethane (MSM) on the development of osteoarthritis (OA): An animal study\".\n\n• “It cleans the bloodstream so allergies to food and pollens go away in about three to four days”\n\nOrgana.net Relieve Progesterone Cream product page\n\n• “Relieve is a combination of natural ingredients that work in harmony with the body to restore low progesterone levels. . .. Dr. John Lee of Oregon states that balancing the hormones by introducing progesterone through the skin is the first step to curbing osteoporosis. . .. Potential benefits to health: headaches\u002Fmigraines, depression, PMS prevention relief, mood swings, hot flashes, & osteoporosis.”\n\nOrgana.net Silver Gel product page\n\n• Product label: “Use for skin irritations such as . . . cuts, fungus, eczema, psoriasis, and insect bites”\n\n• “Silver Gel aids and promotes natural healing for your skin. . .. The antimicrobial nature of silver makes Silver Gel the perfect solution for all skin irritations. . .. Try Silver Gel for: Eczema, Psoriasis, Razor Burn, Dermatitis, Rosacea, Poison Oak & Ivy, Dry skin, Sunburn, Rashes, Itching, Scrapes, Sunburn, and Acne.”\n\nOrgana.net Blog:\n\nEvaluating the Health Benefits of Colloidal Minerals, November 17, 2020\n\n• “Silver has been used for centuries to treat arthritis, cancer, tuberculosis, herpes, and practically anything and everything. Even as medical science has evolved, alternative practitioners worldwide credit colloidal silver for . . . preventing or treating mild to severe infections.”\n\n• “Though there is no evidential proof, Colloidal Silver is thought to help the body heal itself. Other benefits can include:\n\no “Treat herpes, flue, pneumonia, certain eye infections.”\n\no “Treatment of cancer and AIDS”\n\no “Healing wounds: … It is seen when wounds or ulcers are dressed with silver-containing products; the silver particles exhibit antibacterial properties. . .. [C]olloidal silver was also put through scientific test-tube experiments. These studies exhibit antiviral, antifungal, antibacterial, and anti-inflammatory properties.”\n\nTell Me About Zinc, December 17, 2020\n\n• “Zinc…reduces the risk, severity, and duration of infectious diseases.”\n\n• “Zinc…is needed for natural killer cells which help fight off infections.”\n\n• “A zinc deficiency…causes inflammation.”\n\n• “There have been many articles published recently about zinc and it’s [sic] ability to raise anti-viral resistance.”\n\nIn addition, the “Reviews” portion of your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such testimonials include:\n\n• Mechel Wall: “I use the nano silver, zinc and minerals daily and have stayed healthy in spite of being exposed to the current virus several times.”\n\n• Lila Turnbull: “I order Essiac tea from Organa after surviving Colon [sic] cancer. It was recommended from a relative whose husband had great results from it after researching its use with cancer and its prevention.”\n\n• Rachel Folkman: “I’ve been using Uplift for two year [sic]. . .. Anytime I start to feel sick I take a capful for a couple of days and it helps kick my sickness.”\n\n• Tracy Mills: “I take the mineral drink everyday along with magnesium & iron. Since doing that I rarely get headaches . . ..”\n\n• Maribel Lopez: “[I]t has helped me for infections, pain, nausea, bleeding, for infected eyes . . ..”\n\n• Maria Lopez: “The colloidal silver of this company is excellent and I am recommending it to everyone I know for how well it has worked for my daughters and my grandson since [sic] for cold or throat infection, skin infection, infection of the eyes . . ..”\n\n• Karina: “I bought it for a friend taht [sic] is undergoing chemotherapy . She is been dringing [sic] Essiac Tea 4 months and she is toleratong [sic] the chemo treatments and her tumors have reduced and some disappeared.”\n\n• A. Perrone: “I had a tooth extraction scheduled because the tooth was badly decayed. 10 days before the surgery I developed an abscess at the tooth site in my palette. I knew the oral surgeon would give me antibiotics and postpone the surgery. I used…Organa 30ppm Colloidal Silver twice daily and after 5 days the abscess was gone. The extraction went off without complication.”\n\n• Courtlin (pertaining to your Magnesium product): “I drink the magnesium and mineral drink and it has greatly helped my gastroenteritis issues. I have been to several doctors that have never seemed to be able to diminish the pain I used to feel in my stomach but to my surprise these have helped drastically.”\n\nIn addition, your Facebook page contains evidence of intended use of your products as drugs, including evidence in the form of personal testimonials that you posted recommending or describing the use of your products for the cure, mitigation, treatment, or prevent of disease. Examples of such evidence of intended use includes:\n\n• On June 15, 2020, Organa posted the following: “Rhodium is now being heavily researched as a means to treat cancer…”\n\n• On February 25, 2020, Organa posted the following testimonial from “Annie”: “The Silver has worked wonderfully on cuts, burns, and bugbites [sic]. We all came down with flu symptoms but since we’re all taking silver, it’s Ben [sic] going way [sic] before it can really get started. I began drinking it as soon as I felt the tickle in my thrust [sic] and I’m almost completely better belie [sic] the week is out. I’ve bought two bottles and am ordering one today because it really works and there are no crazy side effects as opposed to pharmesutical [sic] antibiotics.”\n\n• On January 22, 2020, Organa posted the following testimonial from an “Organa Customer”: “I started taking Copper one week ago because of swelling in my legs and pain from a torn ligament. I was taking products for joint support but still had pain and swelling. I RESEARCHED and read that Copper pulls nutrients into ligamints [sic]. I am moving my legs up and down the stairs and bending my legs 80% better after one week! I have suffered with this for 7 years after I had back surgery. I feel this was the missing link and very thankful this product is what they say it is”\n\n• On January 15, 2020, Organa posted the following: “Zinc deficiency may be contributing to the development or progression of chronic eye diseases such as macular degeneration, the major cause of vision loss among older people. In one study, vision loss was reduced by 10 percent in people taking supplements…of zinc . . .. In addition, there is a growing body of evidence that indicates that poor zinc intake is related to . . . cataract formation; and optic neuritis, the inflammation of the optic nerve. Zinc is still 15% off! Head to our website now and get yourself a bottle”\n\n• On December 10, 2019, Organa posted the following: “Many studies have shown that a zinc deficiency can impair a large variety of immune functions and defense mechanisms in animals, and some studies have shown similar effects in humans. These effects include abnormalities and eventual shrinking of the spleen, thymus, and lymph nodes; and impaired production of antibodies-have been found to be correctable with zinc supplementation. Zinc is on sale this month! Make sure you head over to our website to get some before the sale ends!”\n\nYour Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, MSM (Methylsulfonylmethane), Silver, Relieve Progesterone Cream, and Silver Gel products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here1, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. No FDA-approved application pursuant to section 505 of the FD&C Act [21 U.S.C. 355] is in effect for any of these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act [21 U.S.C. 355(a) and 331(d)].\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Copper, Rhodium, Ruthenium, Zinc, Uplift, Immune Boost, Essiac Tea, Gold, Iron, Magnesium, Manganese, Molybdenum, MSM, Vanadium, Silver, Relieve Progesterone Cream, and Silver Gel products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nDietary Supplement Misbranding Charges\n\nEven if your Copper, Rhodium, Ruthenium, Zinc, Essiac Tea, Gold, Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Vanadium, and Silver were not unapproved new drugs and\u002For misbranded drugs and described above, they would be misbranded foods under section 403 of the Act, as follows:\n\n1. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 403(s)(2)(B)] in that the labels fail to identify your products using the term “dietary supplement” in accordance with 21 CFR 101.3(g), which requires that a dietary supplement be identified by the term “dietary supplement” as part of the product’s statement of identity, except the word “dietary” may be deleted and replaced by the name of the dietary ingredient in the product or an appropriate descriptive term. The product labels include a Supplements Facts label, which is evidence of your intent to market the products as Dietary Supplements.\n\n2. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size on the labels are incorrect. The terms “serving” or “serving size” for a dietary supplement are defined in 21 CFR 101.9(b) and 101.12, Table 2, as the maximum amount recommended on the label for consumption per eating occasion. The labels state the serving size is “1 tsp” while the directions indicate to “Take 2 tsp. once or twice daily as needed.” Furthermore, your “Silver” product is also misbranded because its label fails to include a serving size. The product labels fail to follow the listed “serving size” common measure with the equivalent metric quantity as required by 21 CFR 101.9(b)(7).\n\n3. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(1)(B) [21 U.S.C. §343(q)(1)B] and 403(q)(5)(F) of the Act [21 U.S.C. §§ 343(q)(5)(F)] because the labels fail to declare the number of servings per container under the serving size on the left hand side of the nutrition label or fails to include this information as part of the net quantity of contents declaration in accordance with 21 CFR 101.36(b)(1)(ii).\n\n4. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” and “Zinc” products are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. 343 § (q)(5)(F)] in that the presentation of the nutrition information on the labeling does not comply with 21 CFR 101.36. For example:\n\na. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products fail to enclose the nutrition information (Supplement Facts label) in a box using hairlines and titled with bolded “Supplement Facts” (not “Supplemental Facts” as incorrectly noted on your product labels) set full width, as required by 21 CFR 101.36(e)(1) and (2). Furthermore, all nutrition information within the nutrition label (Supplement Facts label) must utilize all black or one color type, as required by 21 CFR 101.36(e)(3)(ii)\n\nb. The labels for your “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” and “Zinc” products list iron, magnesium, manganese, molybdenum, and zinc, respectively in the nutrition information label. Iron, magnesium, manganese, molybdenum, and zinc are (b)(2)-dietary ingredients (i.e., a dietary ingredient that has a Reference Daily Intake (RDI). Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\n\nc. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver”, “Vanadium,” “Zinc,” and “Essiac Tea” products fail to include the subheading “Servings Per Container” as required by 21 CFR 101.36(b)(ii) and 101.36(e)(6)(i). A heavy bar must be placed beneath the subheading “Servings Per Container” except that if “Servings Per Container” is not required and, as a result, not declared, the bar must be placed beneath the subheading “Serving Size”.\n\nd. The labels for your “Copper,” “Gold,” “Indium,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver”, and “Essiac Tea” products fail to include a heavy bar beneath the last (b)(3)-dietary ingredient (other dietary ingredient), as required by 21 CFR 101.36(e)(6)(iii).\n\ne. The following product labels are misbranded in that they fail to list “Other ingredients” in a separate “Other ingredients” list outside and immediately below the Supplement Facts label in accordance with 21 CFR 101.4(g):\n\ni. The product labels for Copper and Gold list “Purified Water” within the Supplement Facts label\n\nii. The product labels for Indium, Iron, Magnesium, Manganese, Molybdenum, Palladium, Rhodium, Ruthenium, Vanadium, and Zinc list “Distilled Water” within the Supplement Facts\n\niii. The product label for Essiac Tea lists the “Other Ingredients: Distilled Water, Potassium Sorbate, Sodium Benzoate, and Phosphoric Acid” within the Supplement Facts label.\n\nf. The labels for your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Vanadium,” “Silver,” and “Zinc” bear the following or similar statement: “Percent Daily Values based on a 2,000-calorie diet.” This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D).\n\ng. Several of your product labels are for persons within more than one group. If a product is for persons within more than one group, the percent of Daily Value for each group must be presented in separate columns, as required in 21 CFR 101.36(b)(2)(iii)(E).\n\nh. The Essiac Tea product label lacks a declaration of % Daily Value. Furthermore, on several of your product labels the statement *“Percentage Daily Value not established” is not linked to a symbol elsewhere in the nutrition information label, as required by 21 101.36 (b)(3)(iv).\n\ni. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to accurately declare the net quantity of contents on the principal display panel in accordance with 21 CFR 101.7 and 15 U.S.C.§ 1453(a)(2) of the Fair Packaging and Labeling Act.\n\nj. Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” and “Zinc,” are misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343 (e)(1)] in that each label fails to list the name and place of business of the manufacturer, packer, or distributor in accordance with 21 CFR 101.5.\n\nk. Your Essiac Tea product is misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. § 343(r)(1)(A)] because the product label bears a nutrient content claim, but the product does not meet the requirements to make such claim. Under section 403(r)(1)(A) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of food must be made in accordance with a regulation authorizing the use of such a claim. Characterizing the level of a nutrient in the food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient misbrands the product under section 403(r)(l)(A) of the Act. Specifically, your Essiac Tea product label bears the claim, “Slippery Elm [an ingredient in your Essiac Tea product]: Rich in . . . antioxidants,” but use of this “antioxidant” nutrient content claim fails to comply with the requirements listed in 21 CFR 101.54(g). These requirements state, in part, that for a product to bear such a claim, a reference daily intake (RDI) must have been established for each of the nutrients that are the subject of the claim [21 CFR 101.54(g)(l)], and these nutrients must have recognized antioxidant activity [21 CPR 101.54(g)(2)]. The level of each nutrient that is the subject of the claim must also be sufficient to qualify for the claim under 21 CFR 101.54(b), (c), or (e), as required by 21 CFR 101.54(g)(3). Further, nutrient content claims using the term \"antioxidant\" must include the names of the nutrients that are the subject of the claim as part of the claim or, alternatively, the term \"antioxidant\" or \"antioxidants\" may be linked by a symbol (e.g., an asterisk) that refers to the same symbol that appears elsewhere on the same panel of the product label, followed by the name or names of the nutrients with recognized antioxidant activity [21 CFR 101.54(g)(4)]. Your claim \"[r]ich in antioxidants\" is a nutrient content claim, but Essiac Tea does not meet the requirements to bear such a claim because the claim does not include the names of the nutrients that are the subject of the claim or state them on the same panel and link them with an asterisk, as required by 21 CFR 101.54(g).\n\nl. The Essiac product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the product label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction.\n\nWe also offer the following comments:\n\n• Your “Copper,” “Gold,” “Indium,” “Iron,” “Magnesium,” “Manganese,” “Molybdenum,” “Palladium,” “Rhodium,” “Ruthenium,” “Silver,” “Vanadium,” “Zinc,” and “Essiac Tea” products contain the statement, “This product is not intended to diagnose, treat, or prevent disease. Statements have not been evaluated by the FDA.” This disclaimer is not in accordance with the required text. Per 101.93, the required text should state: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Furthermore, this disclaimer is not linked to any specific structure function claim on the product label. The FDA disclaimer statement as noted on your product label must be bolded and set off in a box, and the symbol preceding the disclaimer statement must be linked to the same symbol placed at the end of each structure function statement on the label in accordance with 21 CFR 101.93(d) and (e).\n\n• For your product labels, there is no provision in the regulations for the listing of “Ingredients” as a heading in the Supplement Facts label.\n\n• Your Essiac Tea product label lists the chemical preservatives sodium benzoate, potassium sorbate and phosphoric acid but does not bear labeling stating that fact, in that the label fails to include a separate description of their function as a preservative in accordance with 21 CFR 101.22(j).\n\n• The directions for use statements on your product labels are placed before the nutrition information. Directions for use are considered intervening material. All information appearing on the information panel must appear in one place without other intervening material, as required by 21 CFR 101.2(e).\n\n• The Essiac Tea product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, “Turkish rhubarb” is not a standardized common name of a botanical dietary ingredient listed in the reference Herbs of Commerce.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303)236-3094 if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDenver District Director & Program Division Director\n\nOffice of Human and Animal Food Operations Division West 4\n\n________________________\n\n1 Even if certain of your products, such as your Indium and Palladium products, are marketed only for nonprescription indications, they would not meet the conditions under section 505G of the FD&C Act [21 U.S.C. 355h] for lawful marketing without an approved application, including because indium and palladium were not active ingredients in any applicable final monograph or tentative final monograph issued under 21 CFR part 330, for purposes of section 505G(a), nor was marketing of these products permitted by an administrative order under section 505G(b). Additionally, these products would be misbranded under section 502(ee) of the FD&C Act [21 U.S.C. 352(ee)] because they would be nonprescription drugs subject to section 505G of the FD&C Act that do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act [21 U.S.C. 355].","Organa International Corp.","organa-international-corp-613018-10132021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forgana-international-corp-613018-10132021","2026-10-26T08:09:39.061065+00:00","2021-10-26","613018","2024-10-04","Larry Mills","2026-08-20T02:29:50.189+00:00","2021-10-13",46,{"510k":399,"classification":400,"enforcement":401,"event":402,"event_backfill":403,"pma":404,"warning_letter":405},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]